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Abstract 
Exercise is recommended for cancer patients due to its positive effects on 
treatment side effects and quality of life. Currently no structured exercise 
guidelines for prostate cancer patients exist and most advice is aimed at those 
receiving androgen deprivation therapy (ADT). The over-arching aim of this 
thesis is to develop an exercise programme to improve cardiometabolic health 
in patients treated for prostate cancer, particularly via robot-assisted radical 
prostatectomy, and assess its effectiveness through a randomised controlled 
trial.  
Resistance exercise training has shown via a systematic review and meta-
analysis, to be effective for inducing improvements in resting blood pressure, 
endothelial function, blood biomarkers and aerobic capacity and is a safe 
mode of exercise in both healthy and clinical populations (Chapter 3). This 
thesis also demonstrates that some men after robot-assisted radical 
prostatectomy are at increased risk of cardiovascular disease within ten years 
of surgery and suffer with clinically significant levels of fatigue (Chapter 4). 
Furthermore men after robot-assisted radical prostatectomy appear to meet 
the Government recommended guidelines for aerobic physical activity but not 
for resistance-based exercise. 
Patient and public involvement was integral to this thesis with the patients 
leading on the design and implementation of the exercise programme (Chapter 
5). The results of the  randomised controlled trial (Chapter 6), demonstrated 
that resistance exercise training had a clear effect on body composition, 
aerobic capacity, strength, functional wellbeing and prostate cancer specific 
quality of life and showed evidence of a favourable reductions in resting blood 
pressure and some blood biomarkers.  
Collectively, this thesis provides evidence that resistance exercise training is 
effective in improving multiple cardiometabolic health benefits in men who 
have undergone robot-assisted radical prostatectomy whilst being a safe and 
well-received mode of exercise. Therefore, resistance exercise training can 
generally be considered a useful adjunct therapy for this patient population.
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CHAPTER 1 
 
 
 
 
 
 
 
 
 
 
 
GENERAL INTRODUCTION  
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1.0 General Introduction 
The physiology of exercise is the study of how the body responds and adapts 
to exercise. The benefits of both acute and chronic exercise have been studied 
extensively in numerous populations. In recent years, exercise research has 
become more prevalent, with a focus on improving the outcomes of inactive 
populations and the effectiveness of varying exercise interventions in patient’s 
with chronic diseases.  
It is essential for exercise programmes to be individualised taking each 
person’s needs, abilities and health issues into consideration (Brown et al., 
2011; F. Campbell et al., 2015; Hardcastle et al., 2018; Vashistha, Singh, Kaur, 
Prokop, & Kaushik, 2016). Therefore, it is important to identify the most 
suitable exercise programmes for different populations, particularly those with 
chronic diseases. Clinical populations may benefit most from structured 
exercise programmes in addition to usual care due to the positive effects they 
can have on the illness, treatment side effects and patient quality of life.  
Exercise has been recommended for patients being treated for cancer 
(Meneses-Echavez, Gonzalez-Jimenez, & Ramirez-Velez, 2015; National 
Institute for Health and Care Excellence, 2014b). Cancer is a disease 
characterised by uncontrolled or abnormal cell proliferation. Prostate cancer is 
the most common malignancy in men aged 40-65 years and usually develops 
slowly with prostate cancer risk increasing with age, abdominal obesity and 
family history (Gann, 2002; Heidenreich et al., 2011) and the majority of cases 
being diagnosed in men over the age of 65 years (Smittenaar, Petersen, 
Stewart, & Moitt, 2016). Exercise is recommended for men being treated for 
prostate cancer by both the National Institute for Health and Care Excellence 
(NICE) and the American College of Sports Medicine (ACSM). This is due to 
the positive effects it can have on on physical and mental health, as well as its 
potential role in reducing disease progression and reoccurrence after 
treatment (Chodzko-Zajko, 2009; National Institute for Health and Care 
Excellence, 2013; Riebe, Ehrman, Liguori, Magal, & American College of 
Sports Medicine, 2017). However, there are currently no structured exercise 
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guidelines for prostate cancer patients and most advice is aimed at those who 
have received androgen deprivation therapy (ADT).  
Prostate cancer treatment, either through robot-assisted radical prostatectomy 
or ADT, carries numerous side effects, including urinary incontinence, negative 
mental state and erectile dysfunction (Lardas et al., 2017; Lehto, Tenhola, 
Taari, & Aromaa, 2017). The side effects of ADT are well documented and 
include increases in body fat, unfavourable changes in blood borne biomarkers 
of cardiometabolic health (e.g. high cholesterol levels, insulin resistance) and 
reduced bone mineral density (Bourke et al., 2011; Keilani et al., 2017). Robot-
assisted radical prostatectomy on the other hand often results in erectile 
dysfunction and urinary incontinence, alongside increased body mass, 
reduced skeletal mass and impaired physical functioning, potentially leading 
to unfavourable blood borne biomarkers of cardiometabolic health (Adam et 
al., 2017; Barocas et al., 2017; Joshu et al., 2011; Keilani et al., 2017; Santa 
Mina, Alibhai, et al., 2013). All the side effects of both treatments can 
consequently negatively impact a patient’s physical function and quality of life 
(Keilani et al., 2017; Keogh & MacLeod, 2012; Santa Mina et al., 2010; Smith 
et al., 2001). 
The effect of resistance exercise training (RET) on cardiovascular and 
metabolic health outcomes remains unclear. However, some studies have 
reported favourable improvements in body composition, blood glucose, fasting 
insulin and lipid profile as well as increases in muscle strength and aerobic 
capacity in healthy elderly adults and type 2 diabetes patients (De Salles, 
2010; Nikseresht, Agha-Alinejad, Azarbayjani, & Ebrahim, 2014; Romero-
Arenas et al., 2013; Sañudo et al., 2013; Sigal et al., 2007). In addition, RET 
may help to attenuate the age and treatment related loss of muscle mass often 
observed in men treated for prostate cancer through robot-assisted radical 
prostatectomy or ADT (Chodzko-Zajko, 2009; Keogh & MacLeod, 2012). Such 
benefits could improve health-related quality of life, reduce fatigue and improve 
overall physical functioning. The optimal RET programme for maintaining 
skeletal muscle mass and cardiometabolic health in prostate cancer patients 
is unknown and there is a need for more research. Given the treatment-
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associated health issues that prostate cancer patients face, it seems 
worthwhile to investigate how a RET programme, developed to maintain or 
enhance skeletal muscle mass and cardiometabolic health, might be 
incorporated into the patient care pathway to reduce treatment side effects and 
likelihood of developing cardiometabolic comorbidities (World Health 
Organisation, 2017). 
Chapter 2 provides an overview of the risk factors, pathophysiology and 
diagnosis of prostate cancer, the effect of treatments on cardiometabolic 
health and quality of life and how exercise could be incorporated into the 
pathway of care to attenuate the treatment side effects. Chapters 3 comprises 
a systematic review and meta-analysis of the effects of RET on 
cardiometabolic health outcomes in adults. Chapter 4 describes a survey of 
prostate cancer patients regarding their daily exercise levels and fatigue. 
Chapter 5 outlines the development of a RET programme to maintain or 
enhance skeletal muscle mass and cardiometabolic health in prostate cancer 
patients receiving robot-assisted radical prostatectomy and ADT. Chapter 6 
reports a clinical trial in which the primary aim was to investigate the effects of 
the RET programme on indices of cardiometabolic health in a group of robot-
assisted radical prostatectomy patients. Chapter 7 includes a general 
discussion, consideration of research limitations and overall conclusions. 
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CHAPTER 2 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
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2.0 Literature Review 
2.1 The Prostate Anatomy 
The prostate is located within the male pelvis and forms part of the male 
reproductive system (Figure 1). The function of the prostate is to secrete an 
alkaline fluid which contributes to the ejaculate. The base of the prostate is 
directly below the bladder neck, the gland surrounds the urethra. The seminal 
vesicles, which also contribute fluid towards the ejaculate, are attached to the 
base of the prostate next to the bladder.  
 
 
 
 
 
 
 
 
Figure 1. Location of the prostate in relation to other organs (Canadian Cancer 
Society, 2018). 
 
2.2 Pathophysiology of Prostate Cancer 
Prostate cancer is the most common malignancy in men aged 40-65 years and 
is often slow growing and, due to the location of the prostate, often affects 
urination (Cancer Research UK, 2015). The majority of prostate cancers are 
classified as an adenocarcinoma, being most common in the peripheral zone 
of the prostate. Over time, cancer cells multiply in an unregulated fashion to 
form a tumour that has the potential to invade nearby organs such as the 
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seminal vesicles or rectum, or the tumour cells may develop the ability to travel 
in the blood stream and lymphatic system – a condition referred to as 
metastasis. 
The majority of prostate cancers are initially highly dependent on androgens 
for growth. Androgens are naturally occurring hormones that regulate the 
development and maintenance of male characteristics. The activation of 
androgen receptors involves several co-regulators (proteins that interact with 
transcription factors) that respond to a changing microenvironment to regulate 
specific gene targets involved in cell growth and survival. In a normal prostate 
epithelium, there is a balance between the rate of cell proliferation and the rate 
of apoptosis, however, in prostate cancer this process is unbalanced, leading 
to tumour growth. 
All cells, including prostate cells, require a level of programming, known as 
epigenetics, to maintain their function, regenerate, and divide normally. 
Epigenetics involves heritable changes in gene function and expression, 
without changes to the base sequence of deoxyribose nucleic acid (DNA). 
These changes are influenced by environmental factors, such as diet (Choi, 
2010), smoking (Kanherkar, Bhatia-Dey, & Csoka, 2014) and physical activity 
(F. F. Zhang et al., 2011), and can exert significant influence on an individual’s 
phenotype via increased DNA methylation or decreased acetylation of 
associated histones. Such changes in the genes can cause cells to mutate and 
rapidly divide leading to cancer. Methylation is a normal and important part of 
development and transcription regulation however epigenetic dysregulation is 
associated with the development of cancer. Hypomethylation of DNA is 
common in cervical, prostate, stomach, lung, bladder, oesophageal, colorectal, 
breast and liver cancers in various cell and tumour types (Jin, Li, & Robertson, 
2011; Lu et al., 2006). In addition, hypermethylation of tumour suppressor 
genes can be altered with ageing and also promote oncogenesis, and is well 
established in many common human cancers (e.g. prostate cancer) (Lu et al., 
2006; Massie, Mills, & Lynch, 2017). Such genetic mutations in a given cancer 
can be reasonably heterogeneous between individuals, yet there are multiple 
epigenetic mutations that appear to be common in particular cancers, including 
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prostate cancer (Yegnasubramanian, 2016). Recently glutathione S-
transferase- (GSTP1) methylation has been detected in many types of cancer 
and has a prevalence of > 90% in prostate cancer (Henrique & Jeronimo, 
2004). As GSTP1 methylation has been detected in circulating DNA, it could 
be a promising future biomarker of prostate cancer detection and reoccurrence 
(Benedettini, Nguyen, & Loda, 2008; Henrique & Jeronimo, 2004).  
 
2.3 Prostate Cancer Prevalence and Incidence 
Cancer tends to be a disease of ageing with approximately a third (36%) of all 
cancer cases in the United Kingdom being diagnosed in patients 75 years and 
older each year. In 2015, more than half of all new cancers cases in the UK 
were either breast, prostate, lung or bowel cancer and the number of males 
diagnosed with cancer across the majority of sites in 2014 and 2015 was 
consistently higher than females (Cancer Research UK, 2017; Office Of 
National Statistics, 2017). 
Worldwide, more than 1.11 million men were estimated to have been 
diagnosed with prostate cancer in 2012, with the incidence varying across the 
world. Prostate cancer is a condition that, in the early stages, often does not 
present any symptoms (Heidenreich et al., 2011; Ngollo et al., 2014) and its 
incidence is increasing with 299,923 (corresponding to 822 per day) new cases 
being registered in England in 2015; an increase of 3060 from the same time 
point in 2014 (Office Of National Statistics, 2017). There is also some evidence 
of an association between prostate cancer incidence and deprivation in 
England. Prostate cancer is one of the few cancers where incidence rates, 
despite rising overall, are lower for males living in more deprived areas (Cancer 
Research UK, 2017). An ageing population, improved health awareness and 
screening for prostate cancer using the prostate specific androgen (PSA) 
blood test are thought to account for the increasing incidence of the disease in 
higher socioeconomic classes (Cancer Research UK, 2016; Siegel, Miller, & 
Jemal, 2017). The prevalence of prostate cancer in the UK is estimated to rise 
to 29% by 2035 which could be, at least partially, attributable to further 
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advances in screening and awareness of the disease (Cancer Research UK, 
2015; Smittenaar et al., 2016).   
 
2.4 Prostate Cancer Risk Factors 
Prostate cancer is linked to multiple non-modifiable risk factors such as family 
history of prostate cancer, age and ethnicity as well as modifiable risk factors 
including diet, physical activity and, overweight and obesity.  
The risk of being diagnosed with prostate cancer increases with age but with 
increasing age many patients also suffer from other comorbidities (Farmer, 
2008; Ng et al., 2017). The aetiology of prostate cancer is unknown, however, 
in the majority of cases, prostate cancer will have been present for a long 
indolent period suggesting that many prostate cancers are the result of genetic 
damage over a sustained period (Bostwick et al., 2004; Gann, 2002). Age-
specific incidence curves show that the number of new prostate cancer cases 
begins to rise sharply at 55 years of age and peaks at 75-79 years of age 
(Cancer Research UK, 2016; Gann, 2002). After 80 years of age there is a 
slight decline in prostate cancer diagnoses before a subsequent steady 
increase to over 90 years of age (Cancer Research UK, 2016). 
The inheritance of prostate cancer has been investigated in numerous ways, 
including case-control studies, cross-sectional studies, family studies and 
studies of twins, providing consistent evidence to support a level of genetic 
susceptibility. The risk of prostate cancer is increased by approximately 2-3-
fold if an individual has a first-degree relative (i.e. brother or father) with a 
history of prostate cancer (Gann, 2002; Heidenreich et al., 2011). Risk is 
further increased if prostate cancer is diagnosed at an early age in a relative 
or an individual has multiple relatives with the disease and, this risk appears 
to be constant across different ethnic groups (Farmer, 2008; Heidenreich et 
al., 2011). It has been estimated that gene alterations could explain 
approximately 10% of all prostate cancer cases, however it is not yet known 
the number of genes involved or the specific sequence changes in these genes 
(Gann, 2002; Lecarpentier et al., 2017).  
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Ethnicity is recognised as a risk factor for the development of prostate cancer 
disease. Several studies have noted higher incidence rates for prostate cancer 
among African-American men, who have a higher risk of prostate cancer than 
white men and also have a worse prognosis (Bostwick et al., 2004; Farmer, 
2008; Gann, 2002; Kheirandish & Chinegwundoh, 2011). It is thought that 
race-related discrepancies in prostate cancer risk may, in part, be due to 
factors including dietary differences, genetic mutations as well as differences 
in the detection of the disease and access to healthcare (Bostwick et al., 2004; 
Kheirandish & Chinegwundoh, 2011).  
Alongside non-modifiable risk factors there are some modifiable lifestyle 
factors that can potentially reduce the risk of prostate cancer development. 
Diet is associated with some types of cancer and, given that it can vary 
between social and ethnic groups, it is unsurprising that the effect of diet on 
prostate cancer has been investigated recently. It has been suggested that 
high amounts of animal fats in the diet, obesity (particularly abdominal obesity) 
and vitamin D deficiency can increase the risk of prostate cancer (Farmer, 
2008; Hori, Butler, & McLoughlin, 2011; Labbé et al., 2014; Mandair, Rossi, 
Pericleous, Whyand, & Caplin, 2014). These factors are thought to account for 
approximately 10% of the difference in incidence between black and white men 
(Farmer, 2008). Despite much research into the effects of diet on prostate 
cancer development, there remains no conclusive result. It does, however, 
remain a plausible risk factor as diet, excess weight and their related 
alterations in endogenous hormones such as androgens, insulin-like growth 
factor I (IGF-I), insulin and leptin, can result in an internal environment for 
prostate cancer to develop (Kaaks et al., 2003). Excess fat mass is known to 
reduce sex hormone–binding globulin levels, potentially leading to an increase 
in bioavailable testosterone, insulin and bioavailable IGF-1, which are possibly 
important in prostate cancer growth (Gann, 2002; Gill, Wilkens, Pollak, 
Stanczyk, & Kolonel, 2010; Kaaks et al., 2003). However there appears to be 
a lack of consistency amongst studies regarding the association between 
physiological levels of plasma androgens and prostate cancer risk. Such 
controversies exist despite strong indirect evidence of their tumour-stimulating 
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effects however, this may be due to the complex associations between 
androgens and IGF-I, insulin and leptin.  
In addition to diet, it has also been suggested that physical activity can, not 
only reduce body fat but also could potentially reduce prostate cancer risk, 
particularly the risk of being diagnosed with high-grade disease (Cosimo et al., 
2016; Friedenreich & Thune, 2001; Moore et al., 2009). Physical activity has 
previously been described as “any bodily movement produced by skeletal 
muscles that results in energy expenditure… that can be categorized into 
occupational, sports, conditioning, household, or other activities” (Caspersen, 
Powell, & Christenson, 1985, p. 126). With walking accounting for the majority 
of physical activity undertaken, it has previously been reported that men 
diagnosed with prostate cancer who engaged in ≥ 90 minutes of walking a 
week had a 61% (95% CI, 0.18 to 0.84) lower risk of prostate cancer mortality 
when compared to men who walked for much shorter durations (Kenfield, 
Stampfer, Giovannucci, & Chan, 2011; Richman et al., 2011). Exercise differs 
from physical activity in that it is “planned, structured, and repetitive and has 
as a final or an intermediate objective the improvement or maintenance of 
physical fitness” (Caspersen et al., 1985). Few studies have investigated the 
amount of exercise and its direct relationship with prostate cancer risk. 
However, findings from one study suggest that a moderate amount of 
structured exercise (3-8.9 metabolic equivalent task hours (METs) a week) 
may lead to a reduced risk of prostate cancer diagnosis, and in men with 
prostate cancer it may be associated with a lower risk of high grade disease 
(Antonelli et al., 2009; Cosimo et al., 2016). Further to exercise reducing the 
risk of prostate cancer, exercise post diagnosis can reduce overall prostate 
cancer mortality and improve quality of life therefore, exercise advice may 
become an important component of the treatment pathway for prostate cancer 
(Bourke et al., 2014; Kenfield et al., 2011; Lynch & Leitzmann, 2017), and 
especially as CVD is the leading cause of death among men with prostate 
cancer (Allott, Masko, & Freedland, 2013). However, more research is needed 
in the form of randomised controlled trials, to understand the benefits of 
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different exercise modes on prostate cancer risk and the effectiveness of 
exercise as part of the treatment pathway.   
 
2.5 Economic Burden of Prostate Cancer 
Driven by an increased incidence and prevalence, partly influenced by ageing 
populations, improved survival and improved care that has made cancer a 
chronic, controllable illness, cancer now accounts for an ever increasing 
proportion of global spending on healthcare (Bosanquet & Sikora, 2004). In 
2009, the UK spent approximately £12.8 billion on cancer related health care 
with prostate cancer initial treatment costs on average totalling £3300 per 
patient (Fourcade et al., 2010; Luengo-Fernandez, Leal, Gray, & Sullivan, 
2013). The total per patient costs are highly dependent upon cancer stage at 
diagnosis, survival and choice of treatment and, despite declining prostate 
cancer mortality rates, costs are expected to rise due to improved diagnosis, 
diagnosis at an earlier stage and increased survival, therefore increasing the 
economic burden (Cancer Research UK, 2015; Fourcade et al., 2010; 
Roehrborn & Black, 2011). Robot-assisted radical prostatectomy is a common 
method of treatment for patients with localised prostate cancer (see section 
2.8) rather than open surgery and a recent study has demonstrated that, 
although more costly in the first instance, it is more effective in maintaining 
function, reduced surgical margins and results in a reduced hospital length of 
stay (Close et al., 2013; Finkelstein et al., 2010). Cancer care results in 
medical, morbidity and mortality costs to the NHS and therefore the economic 
planning of cancer services in the UK requires detailed consideration. 
 
2.6 Detection and Diagnosis 
There is no national screening programme in place for prostate cancer. The 
vast majority of men will have no symptoms, however, prostate cancer can 
cause haematuria (blood in the urine), erectile dysfunction and urinary 
symptoms (Wilt & Thompson, 2006). To relieve some of the existing burden 
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on the health system and reduce invasive procedures on otherwise healthy 
men, a more effective way of diagnosing prostate cancer is needed. A major 
concern in the detection of prostate cancer is the need to differentiate between 
indolent and aggressive diseases to prevent over-diagnosis and over-
treatment of inactive or slow growing disease and to allow aggressive 
treatments to be suitably allocated (Massie et al., 2017). Currently, the main 
methods to diagnose prostate cancer include serum concentration of PSA 
followed by digital rectal examination (DRE), magnetic resonance imaging 
(MRI), and transrectal ultrasound (TRUS)–guided biopsies. 
 
2.6.1 NICE Pathway of Care  
Often men initially present to a General Practitioner (GP) with symptoms 
associated with prostate cancer (e.g. urinary frequency, haematuria, 
discomfort during urination) and/or undergo a PSA blood test whilst with the 
GP (J. Aning, 2018). If it is suspected that a man has possible prostate cancer, 
they are referred to local urology services for in-depth assessment. All men 
are offered individualised information in the form of leaflets, websites and 
support groups by a consultant or specialist nurse. The results of the PSA, 
DRE, comorbidities and family history are then used to inform prostate biopsy. 
The decision of undergoing a prostate biopsy is with the patient once the 
consultant or specialist nurse has provided all relevant information and 
support. There are two main types of prostate biopsy; (1) TRUS-guided and, 
(2) template (transperineal) biopsy. Biopsies are not usually offered to men if 
the suspicion of prostate cancer is high either due to high PSA and evidence 
of bone metastases unless it is a requirement of a clinical trial. Once all 
diagnostic tests are complete, specialists use the staging system described in 
section 2.7 (page 17) to inform the most appropriate treatment pathway for 
each individual. Figure 2 shows the NICE pathway of care for a male with 
suspected prostate cancer (National Institute for Health and Care Excellence, 
2014b).  
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Figure 2. Pathway of care for those suspected with prostate cancer. Adapted 
from NICE 2014 (National Institute for Health and Care Excellence, 2014b). 
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2.6.2 Prostate Specific Androgen 
PSA is a protein made in the prostate which can be measured in the blood of 
men (produced by prostate epithelial cells) and is currently used to aid prostate 
cancer diagnosis. Raised PSA concentrations may be associated with prostate 
cancer but also enlargement and inflammation of the prostate gland (Wilt & 
Thompson, 2006). PSA testing has increased over recent years, however, 
there is some controversy that surrounds the sensitivity and specificity of PSA 
testing (Kim & Andriole, 2015; Yegnasubramanian, 2016). Testing of PSA 
levels is often initiated by either the patient or physician and a PSA ≥ 3 ng/ml 
has been used as a biomarker to guide further investigation or biopsy (Aus et 
al., 2005; J. L. Donovan et al., 2018). However, there is concern that PSA 
testing is of limited benefit to men > 70 years of age or those with limited life 
expectancy (Wilt, Scardino, Carlsson, & Basch, 2014). The poor specificity of 
PSA testing can potentially lead to unnecessary prostate biopsies being 
carried out. It has therefore been recommended that biopsies should not be 
taken immediately after the initial PSA test, but rather the PSA test should be 
verified by a second test a few weeks later under the same conditions, except 
for initial tests that return high PSA values (> 20 ng/ml; (Heidenreich et al., 
2008)). 
 
2.6.3 Digital Rectal Examination 
During a DRE, a clinical physician palpates the prostate through the rectum 
with their finger. DRE accuracy can be highly user dependent (Wilt & Ahmed, 
2013). The majority of prostate cancers are located peripherally and so may 
be detected during a DRE, however a substantial proportion may either be 
organ confined or in the anterior prostate and thus not palpable at DRE. DRE 
also confers the opportunity to estimate the size of the prostate which may also 
be a causative factor for an elevated age specific PSA (European Association 
of Urology, 2016).  
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2.6.4 Biopsies 
A high PSA level and/or a suspicious DRE, as well as the patient’s age and 
potential comorbidities, are determinants for biopsies. TRUS-guided biopsy is 
the most common method of histopathological confirmation of suspected 
prostate cancer. The procedure involves passing an ultrasound probe into the 
rectum to image the prostate in real time and enabling the passage of a fine 
needle alongside the ultrasound probe to penetrate the prostate gland to 
retrieve biopsy samples. TRUS-guided biopsies are undertaken without prior 
knowledge of the area of the prostate in which the cancer could be located and 
therefore often leads to the over diagnosis of low-risk prostate cancer and the 
under-diagnosis of clinically important cancers (Ahmed et al., 2017; Grönberg 
et al.). Transperineal (template) prostate biopsy differ from TRUS-guided 
biopsies in that the needle samples the prostate through the perineum rather 
than the rectum. The procedure is carried out under either general or local 
anaesthetic and, using a grid template with holes 5 mm apart, the needle is 
inserted into each hole to sample the entire prostate gland. In the case of 
persistently increasing PSA values or an abnormal DRE, repeated biopsies 
may be performed (Heidenreich et al., 2011).  
The use of MRI over recent years has shifted from a staging tool to being used 
for detection and location purposes in prostate cancer patients (Figure 3). Due 
to the high soft-tissue contrast and image resolution, MRI is one of the best 
imaging tools available to clinicians allowing image-guided prostate biopsies, 
therefore overcoming the limitations of blind prostate sampling, avoiding 
unnecessary TRUS-guided biopsies and improving diagnostic accuracy 
(Ahmed et al., 2017; Futterer et al., 2015). Multiparametric-MRI (MP-MRI) is 
different to traditional MRI in that it combines up to three different types of scan 
and a contrast agent is injected to enhance the image produced. 
Multiparametric-MRI possess considerably better sensitivity and predictive 
value for clinically important prostate cancer when compared with TRUS-
guided biopsies and could be used as a triage test prior to biopsy, thereby 
decreasing unnecessary biopsies and over detection of clinically insignificant 
disease (Ahmed et al., 2017; Thompson et al., 2014). 
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Figure 3. MRI scan of a prostate with arrowheads marking extracapsular 
cancerous tumour extension (Bittencourt, Hausmann, Sabaneeff, Leandro 
Gasparetto, & Barentsz, 2014). 
 
2.7 Classification of Prostate Cancer 
Classifications of prostate cancer describe the extent and severity of the 
disease and are important when deciding on a patient’s treatment plan. The 
current histologic prostate cancer grading system was developed between 
1966 and 1974 by Donald Gleason and the Veterans Administration 
Cooperative Urologic Research Group (Gleason, 1992) and has since been 
the single most powerful predictor of prostate cancer risk. Since the original 
Gleason grading system, diagnosis and treatment has evolved leading to 
modifications to the grading system.  Epstein et al. (Epstein et al., 2016) 
described the histologic definitions of the five grade groups in the new grading 
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system (Table 1). Currently, the Gleason grade classification is combined with 
the tumour-node-metastasis (TNM) staging system (Table 2) to provide a 
comprehensive definition of a patient’s disease. 
 
 
Table 1. Gleason grading system. 
 
 
 
 
 
 
Grade Score Description 
1 Gleason score 3 + 3 = 6 Only individual discrete well-formed 
glands 
2 Gleason score 3 + 4 = 7 Predominantly well-formed glands with 
lesser component of poorly 
formed/fused/cribriform glands 
3 Gleason score 4 + 3 = 7 Predominantly poorly formed/ 
fused/cribriform glands with lesser 
component of well-formed glands 
4 Gleason score 8 Only poorly formed/fused/cribriform 
glands. Predominantly well-formed 
glands and lesser component lacking 
glands. Predominantly lacking glands 
and lesser component of well-formed 
glands 
5 Gleason scores 9–10 Lack of gland formation (or with necrosis) 
with or without poorly 
formed/fused/cribriform glands 
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Table 2. Tumour-node-metastasis staging system for prostate cancer. 
Adapted from the American Joint Committee on Cancer (Cancer, 2003).  
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T categories – size and spread of the tumour 
TX: Primary tumour cannot be 
assessed 
T0: No evidence of primary tumour 
 
T1: Cancer is within the prostate. It 
cannot be detected during a DRE 
and there are generally no symptoms 
T1a: Tumour in 5% or less of 
tissue resected 
 T1b: Tumour in more than 5% 
of tissue resected 
T1c: Tumour identified by 
biopsy 
T2: Cancer is confined to the 
prostate but is large enough to be felt 
during a DRE or apparent on a scan 
T2a: Cancer is only in one half 
of one of the two lobes of the 
prostate gland 
 ▪ T2b: Cancer is in more than 
one half of one of the lobes of 
the prostate 
▪ T2c: Cancer is in both lobes 
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d
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T3: Cancer has spread outside of the 
prostate 
▪ T3a: Cancer is not affecting 
the surrounding structures 
 ▪ T3b: Cancer has spread into 
seminal vesicles 
T4: Tumour is fixed or has invaded 
adjacent structures other than 
seminal vesicles 
 
L
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 N categories – spread of cancer to local lymph nodes  
NX: Nearby lymph nodes were not 
assessed 
 
N0: No regional lymph node 
metastasis 
N1: Metastasis in regional lymph 
nodes 
M
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 M Categories – spread of the cancer to other body parts 
M0: No distant metastasis  
M1: Distant metastasis ▪ M1a: Cancer has spread to 
distant lymph nodes 
 
▪ M1b: Cancer has spread to 
the bones 
M1c: Cancer has spread to 
other organs with or without 
spread to the bones 
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2.8 Treatment Options, Aims and Side Effects 
It is not possible to state that one therapy is superior over another when 
considering treatment for prostate cancer. This is due to numerous factors 
such as the patient characteristics and the stage of the disease and therefore 
treatment is individualised to each patients needs. However, the management 
of prostate cancer looks to reduce disease-specific and all-cause mortality 
and, prostate cancer progression whilst maintaining patient quality of life and 
improving prostate cancer cure rate (J. J. Aning, Wassersug, & Goldenberg, 
2012; Jayadevappa et al., 2017; Johnson, 2016). The treatment options 
considered for prostate cancer are detailed below.  
 
2.8.1 Active Surveillance 
Active surveillance, sometimes called active monitoring, is the recommended 
treatment option for monitoring prostate cancer that is low-risk and localised to 
the prostate. It involves regular monitoring of the disease through PSA and 
DRE checks approximately every 3-6 months. Active surveillance is offered to 
men who: (1) have localised prostate cancer and radiotherapy or robot-
assisted radical prostatectomy are suitable and the future risk has been 
assessed as low, or (2) have localised prostate cancer and the future risk has 
been assessed as intermediate and the patient does not wish to have active 
treatment straight away (National Institute for Health and Care Excellence, 
2014b). If there is concern about clinical or PSA changes at any time during 
active surveillance patients are usually reassessed with MP-MRI and/or re-
biopsy. The patient can elect to have curative active treatment at any time 
during active surveillance. The disadvantages of this treatment strategy 
include: (1) potentially having more biopsies can be uncomfortable, (2) over 
time, health may change, and the cancer could grow meaning some 
treatments would no longer be viable, and (3) the cancer may grow faster than 
expected and be more difficult to treat.  
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2.8.2 Watchful Waiting 
Watchful waiting is a method of monitoring prostate cancer that is not causing 
any symptoms or problems for the patient with the aim of monitoring it over the 
long term, and avoid treatment unless symptoms arise. Watchful waiting is 
often recommended to older men when it is unlikely that the cancer will shorten 
the life span or they possess other health problems in which active treatment 
would be deemed inappropriate (Mottet N.). In those who chose watchful 
waiting, PSA is measured once a year usually at a GP surgery rather than a 
hospital. If there are any signs that the cancer is progressing, the patient may 
be referred back to a hospital for further tests to be conducted. If the disease 
has progressed, treatment is usually given to relieve symptoms and improve 
quality of life rather than be curative.  
 
2.8.3 Radical Prostatectomy 
Robot-assisted radical prostatectomy involves surgical removal of the prostate 
and is now, in the majority of cases, the most common method of prostate 
removal (National Institute for Health and Care Excellence, 2014b). Performing 
the robot-assisted radical prostatectomy rather than open surgery in the 
treatment of prostate cancer often improves surgical margins and reduces 
blood loss, pain and results in a faster recovery time for patients (Tewari et al., 
2012). However robot-assisted surgery may not be suitable for all patients who 
have localised prostate cancer or locally advanced prostate cancer if they 
possess other conditions, such as  decreased cardiopulmonary reserve, 
vascular disease or are morbidly obese, which increase the risk of 
complications of major surgery (Maerz, Beck, Sim, & Gainsburg, 2017; Mottet 
et al., 2019). Patients are discharged from hospital approximately 1-3 days 
post laparoscopic surgery with a catheter that usually remains in place for 2 
days to two weeks. However, patients can expect to not attend work for a 
minimum of 8-12 weeks post-treatment. The side effects surgery include 
erectile dysfunction, urinary incontinence, potential muscle wastage and 
increased fat mass in the 8-12 weeks post-surgery and cancer related fatigue. 
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2.8.4 Radiotherapy and Brachytherapy 
Two types of radiotherapy are used for the treatment of prostate cancer; 
external and internal - with the type dependent on various factors such as the 
size, grade and stage of cancer. External beam radiotherapy involves radiation 
being targeted at the prostate cancer from a linear accelerator. External 
radiotherapy can also be used to shrink secondary tumours that have spread 
to bones and are causing pain. Internal radiotherapy, commonly known as 
brachytherapy, involves inserting small radioactive implants into or next to the 
cancerous tumour or placing radioactive seeds into the prostate (National 
Institute for Health and Care Excellence, 2014b). External beam radiotherapy 
uses beams (X-ray or gamma rays) of high-energy radiation focused on 
cancerous tissue and may be used as an alternative to surgery (National 
Institute for Health and Care Excellence, 2015). The aim of radiotherapy is to 
cure cancer when provided in cases of localised disease but to control the 
growth of the disease in cases of advanced disease. The side effects of 
radiotherapy and brachytherapy are for example, bowel and urinary problems, 
erectile dysfunction and cancer-related fatigue. 
 
2.8.5 Androgen Deprivation Therapy 
ADT refers to treatments that act by reducing the effects of testosterone and 
other androgens, thus inhibiting the growth and progression of prostate cancer 
and is available to men with localised, locally advanced and advanced prostate 
cancer (National Institute for Health and Care Excellence, 2014b). ADT is used 
to control the progression of cancer and can be achieved by either suppressing 
the secretion of testicular androgens or by inhibiting the action of androgens 
circulating in the body (Mottet et al., 2019). Luteinizing hormone-releasing 
hormone (LHRH) agonists are the most common type of injection or implant 
and include medications such as Zoladex® and Prostap®. Gonadotrophin 
releasing hormone (GnRH) antagonists are found in the drug degarelix 
(Firmagon®) for the treatment of prostate cancer that has spread to the bones, 
and as such, are used less often than LHRH agonists. Both LHRH and GnRH 
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work by supressing the release of testicular androgens. Conversely there are 
tablets that can be taken to block the effects of testosterone (anti-androgens) 
such as bicalutamide (Mottet et al., 2019). These two methods can also be 
combined to achieve what is known as maximal androgen blockade. Erectile 
dysfunction, unfavourable changes to body composition, reduction in bone 
mineral density and cancer-related fatigue are all side effects of ADT. 
 
2.8.6 Chemotherapy 
Chemotherapy is not a common treatment for prostate cancer however it is 
used for more advanced cases (i.e. metastatic prostate cancer). 
Chemotherapy utilises cytotoxic medicines to interrupt how the cells divide and 
multiply, therefore killing or stopping the growth of the cancer. Usually, 
chemotherapy drugs need to enter the bloodstream to travel to all areas of the 
body to reach the cancerous cells. The most common chemotherapy drug is 
docetaxel and side effects of this treatment include: (1) hair loss, (2) cancer-
related fatigue, (3) nausea and vomiting, and (4) bowel problems. 
 
2.9 Effect of Exercise Training on the Side Effects of Treatment 
The side effects of the multiple prostate cancer treatments are greatly diverse, 
therefore, in keeping with the focus of this PhD, only studies with relevance to 
patients who have been treated via robot-assisted radical prostatectomy or 
ADT will be discussed further. This section will discuss the impact of prostate 
cancer treatment on physical function and quality of life. 
 
2.9.1 Impact of Treatment on Physical Function 
In addition to the risk of CVD, ageing males suffer from a reduction in the levels 
of circulating testosterone, resulting in muscle atrophy, decreased sexual 
desire, viable sperm and prostate disorders, with prostate cancer treatments 
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accelerating and exacerbating some of these problems. Additionally, both 
surgical and ADT treatments for prostate cancer can result changes to body 
composition. Patients tend to be sedentary in the 8-12 weeks post-surgery, 
therefore potentially resulting in an increase in fat mass and a decrease in 
muscle mass and strength, but the extent of this is yet to be investigated. On 
the other hand, ADT results in female pattern weight gain (for example 
increased fat mass and a reduced muscle mass)  due to the hormonal changes 
induced to reduce the progression of prostate cancer (Galvao et al., 2006; 
Higano, 2003; Keilani et al., 2017). Those on ADT are reported to have 
approximately 24% less muscular strength, 7% less aerobic capacity, and 20-
27% less functional performance ability in repeated chair rise and walking tests 
(Galvao et al., 2009; Henwood & Taaffe, 2006; Keogh & MacLeod, 2012). Such 
changes can result in an increased risk of insulin resistance, fatigue and falls, 
particularly in older individuals (Fiuza-Luces et al., 2018; Walston, 2012). 
Furthermore, these changes can impact on self-confidence and result in 
premature fatigue and prevent patients from carrying out work and normal 
activities of daily living (Keogh & MacLeod, 2012; Storer, Miciek, & Travison, 
2012). If fatigue becomes persistent, it may prevent prostate cancer patients 
from engaging in physical activity and can lead to detrimental changes in blood 
pressure, blood lipid profile and other changes that are indicative of metabolic 
syndrome (Keogh & MacLeod, 2012; Wall et al., 2017). In addition, those on 
ADT can suffer a decrease in bone mineral density, resulting in a high risk of 
fractures and therefore further impacting physical function. A recent paper 
produced recommendations for exercise as part of the treatment and 
management of metastatic prostate cancer, to help reduce the impact on 
physical function (Figure 2) (National Institute for Health and Care Excellence, 
2014b). 
 
2.9.2 Impact of Treatment on Health-related Quality of Life 
While survival rates and improving surgical margins are critical goals in the 
treatment of prostate cancer, the impact of treatment on quality of life is 
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another consideration. Changes in body composition can negatively influence 
quality of life, but prostate cancer patients can also suffer from depressive 
symptoms, sexual dysfunction, urinary incontinence and gynecomastia, which 
all effect mental state and health-related quality of life.  
After surgery men often suffer with urinary incontinence and erectile 
dysfunction as a direct result of the operating procedure (Bang & Almallah, 
2016; Jones et al., 2014; Lardas et al., 2017; Lehto et al., 2017). It has been 
noted that exercise may reduce the risk of urinary incontinence by increasing 
muscle mass, thereby facilitating bladder and pelvic floor control, whereas 
being overweight/obese may increase the risk due to increased strain and 
pressure on the bladder (Wolin, Luly, Sutcliffe, Andriole, & Kibel, 2010). The 
robot-assisted radical prostatectomy procedure regularly results in impotence 
(75%), whereas this is much less (approximately 51-67%) in other treatments 
(i.e. radiotherapy, brachytherapy, ADT, active surveillance). Approximately 
32% of all surgical patients report permanent sexual dysfunction (Lehto et al., 
2017). It has been suggested that those receiving robot-assisted radical 
prostatectomy as a treatment option tend to be younger and more likely to 
have a sex life before treatment, therefore the impact of the surgery on sexual 
dysfunction has a far greater impact upon the patient and their partner’s quality 
of life (Lehto et al., 2017). The pathophysiology of erectile dysfunction post 
robot-assisted radical prostatectomy involves both neuronal and vascular 
endothelial cell dysfunction, which therefore lead to compromised penile tissue 
oxygenation and smooth muscle apoptosis, fibrosis, and veno-occlusion 
dysfunction (Jones et al., 2014; Watts, Chew, & Stuckey, 2007). ADT is also 
reported to induce sexual dysfunction and in some cases urinary incontinence, 
however, there is much less research into these issues with regard to health 
related quality of life (Cormie et al., 2015; Lehto et al., 2017).  
A recent longitudinal study explored quality of life and mood in patients treated 
with robot-assisted radical prostatectomy. The authors found that patients who 
reported being physically active, having low alcohol consumption and being 
non-smokers experienced lower risks of impaired quality of life, negative 
thoughts about the prostate cancer and depressed mood compared with 
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patients who were physically inactive, had high alcohol consumption and were 
current smokers (Bock et al., 2017). This therefore provides a rationale for 
more research into improving health behaviours before, during and after 
treatment through lifestyle changes whether that be diet, smoking cessation or 
exercise interventions.  
Additionally, in both surgical and ADT patients it is suggested that fatigue may 
act independently on quality of life but may also contribute to sexual 
dysfunction and a loss of self-esteem (Fosså et al., 2016). Due to a reduction 
in quality of life, alongside prostate cancer survivors experiencing a greater 
number of recurrent admissions and associated medical comorbidities, it is 
important to develop screening or preventive strategies such as exercise 
programmes as part of the treatment to reduce readmissions for this group of 
cancer survivors (Gnanaraj et al., 2017).  
 
2.9.3 The Role of Exercise Training for Prostate Cancer Patients  
There is a growing base of evidence that suggests engaging patients in 
exercise throughout the cancer continuum, leads to fewer symptoms and side 
effects, and reduces the rate at which physiologic systems are affected 
(Brown, Winters-Stone, Lee, & Schmitz, 2012). In this way, exercise can be 
used as an adjunct therapy to cancer treatments to help alleviate some of the 
side effects. Providing patient care however, produces many competing 
demands for clinicians and therefore it is unrealistic for clinicians to stay well-
informed of all the literature relating to cancer pathology, treatment modalities 
and exercise rehabilitation. 
Exercise after cancer treatment can benefit patients through both the 
physiological adaptations to exercise training and by reversing deconditioning 
that can begin at diagnosis and persist long into the recovery period. The 
majority of studies investigating exercise in cancer patients have used aerobic 
exercise to improve patient outcomes with few exploring the benefits of RET 
(Ashcraft, Peace, Betof, Dewhirst, & Jones, 2016; Courneya, McNeil, O'Reilly, 
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Morielli, & Friedenreich, 2017; Jones et al., 2014; Tian, Lu, Lin, & Hu, 2016; 
Windsor, Nicol, & Potter, 2004; Zopf et al., 2017). A systematic review 
conducted in 2016 suggested that those studies which do utilise RET are very 
generic and in a relatively heterogenous population and concluded that more 
interventions are required to apply the principles of RET, along with clear 
reporting of intervention characteristics (C M. Fairman, Hyde, & Focht, 2017). 
Specifically for prostate cancer patients after robot-assisted radical 
prostatectomy, preliminary evidence suggests that exercise training can 
improve quality of life, cancer-related fatigue, erectile function, 
cardiorespiratory fitness and strength, however there are limited studies that 
exist solely within this population (Bourke et al., 2016; Silva, Sousa, Azevedo, 
& Martins, 2017). 
 
2.10 Guidelines for Exercise Treatment 
NICE currently recommend exercise but have no published guidelines on 
exercise during or after cancer treatment despite several studies 
demonstrating that exercise is safe, enhances quality of life and can potentially 
reduce some of the side effects associated with treatment (National Institute 
for Health and Care Excellence, 2014a). Commonly, doctors recommend that 
patients try to meet general Government guidelines on physical activity (Sutton 
et al., 2017). These guidelines state that healthy adults aged 19-64 years 
should complete at least 150 minutes (2½ hours) of moderate intensity aerobic 
activity in bouts of 10 minutes or more over the course of a week alongside 
muscle strengthening activities on at least 2 days a week (Department of 
Health, 2011). Patients also often receive information produced by Prostate 
Cancer UK which offers brief advice, generally following Government 
guidelines regarding physical activity (Prostate Cancer UK, 2015). 
The ACSM has produced guidelines for exercise in cancer patients however 
these currently do not translate into UK healthcare practice. The ACSM 
recommends that cancer patients should avoid being inactive during and after 
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treatment and should undertake aerobic exercise such as walking, cycling and 
swimming as well as RET (e.g. weights, resistance bands and weight-bearing 
tasks) and flexibility exercise (Riebe et al., 2017). ACSM suggest that physical 
activity should be increased to 3-5 days a week over the course of one month, 
with RET being incorporated into a routine on 2-3 days a week. Despite a lack 
of clarity on the frequency, intensity and type of exercise that is safe and 
effective for cancer patients, numerous studies (Bloomquist et al., 2016; 
Cormie et al., 2016; Cunningham et al., 1986; C. M. Fairman, LaFountain, 
Lucas, & Focht, 2017) have explored these variables in multiple cancer 
populations.  
 
2.11 Exercise Advice Provided by Health Care Professionals 
There is currently a lack of research investigating exercise prescription and 
health care professionals’ opinions of exercise as part of the patient pathway 
of care. However, NICE recommends structured exercise programmes tailored 
to individual needs to manage, and for rehabilitation after, certain health 
conditions, such as myocardial infarction, stroke, chronic heart failure, chronic 
obstructive pulmonary disease, depression, lower back pain and chronic 
fatigue syndrome (National Institute for Health and Care Excellence, 2014a). 
Despite this, there are no published guidelines for exercise programmes in 
patients who have been diagnosed with, or treated for, prostate cancer despite 
it being recommended by NICE. A study in 1997 reported that a publicly funded 
programme of regular moderate intensity exercise for adults < 65 years old 
could achieve important health benefits at relatively low cost (Munro, Brazier, 
Davey, & Nicholl, 1997). Further studies in 2011 and 2012 suggested that 
exercise programmes are associated with modest benefits but are highly 
dependent on patient’s adherence (Anokye et al., 2011; Murphy et al., 2012).  
Prostate cancer patients have reported several barriers to taking part in 
exercise programmes such as lack of clinical advice, poor weather, lack of 
knowledge on the benefits of exercise, treatment side effects (i.e. urinary 
incontinence) and time pressures (Hackshaw-McGeagh et al., 2017). Despite 
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this, patients have expressed an interest in receiving exercise advice from 
health care professionals. A recent study indicated that whilst few health care 
professionals advise on exercise for prostate cancer patients, those who did 
only provided advice aligning with the Department of Health’s guidelines for 
adults (Sutton et al., 2017). Such recommendations may be inadequate as the 
guidelines are for adults who are assumed to be healthy and not tailored to the 
specific needs of prostate cancer patients. In spite of a lack of  evidence for 
prostate cancer specific exercise prescription, many health professionals 
agree that exercise should be tailored to individual patient’s pre-treatment level 
of fitness, current health, mobility problems, treatment received, and their 
stage in the treatment process (Sutton et al., 2017).  
A prostate cancer diagnosis has been previously described as a ‘teachable 
moment’ in which patients become motivated to reduce unhealthy behaviours, 
especially if the advice is delivered by a trusted source such as a health care 
professional (Horwood et al., 2014; McBride, Emmons, & Lipkus, 2003; Sutton 
et al., 2017). Therefore, the diagnosis of prostate cancer presents an 
opportunity to implement and engage patients in exercise interventions. 
Despite health care professionals being well-placed to deliver exercise advice, 
a survey commissioned by Macmillan Cancer Support in 2011 reported that 
72% of GPs and 60% of oncologists do not discuss exercise with patients 
(Macmillan Cancer Support, 2011). More recently it was reported that fewer 
than half of cancer specialists in the United Kingdom regularly discuss exercise 
with prostate cancer patients (Sutton et al., 2017). Furthermore, a study 
conducted in Australia reported few doctors recommend exercise and when 
they do the importance is on aerobic exercise (59%) rather than RET (13%) 
(Short et al., 2016). This data may demonstrate some naivety amongst health 
care professionals on the benefits of exercise in preventing, managing or 
reducing disease reoccurrence. Health care professionals have cited reasons 
including a lack of personal expertise, training and services to support 
exercise, with others simply reporting a lack of time (Cowan, 2016; Fortier, 
Guerin, & Segar, 2016; Sutton et al., 2017). 
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To reduce some of the side effects and long-term effects of the disease and 
treatment, exercise advice and prescription needs to be more readily available 
to patients. There also needs to more consistency across the country as 
currently exercise referral programmes are available in some NHS Trusts but 
not in others. Furthermore, health care professionals need more information 
and training on exercise advice and prescription to prostate cancer patients 
through better dissemination of research to governing bodies and societies 
(Macmillan Cancer Support, 2011). It is hoped that this may be improved 
through the 2015 launch of Exercise Medicine resources for use in teaching 
on medical degree programmes (Gates, 2015, 2016).  
 
2.12 Exercise for Alleviating the Effects of Prostate Cancer Treatment 
With both surgery and ADT causing side effects and functional decline, 
exercise can be used as a countermeasure to the side effects of treatment. It 
has been suggested that regular exercise can reduce disease symptoms, 
improve quality of life and side effects of the treatments and help to reduce 
disease reoccurrence (Hart, Galvao, & Newton, 2017). For example, erectile 
dysfunction, a major side effect of robot-assisted radical prostatectomy, is 
linked to reduced aerobic capacity and, in ADT patients, adverse 
cardiovascular risk profile (Jones et al., 2014; Watts et al., 2007). The use of 
exercise as part of the treatment pathway for prostate cancer has been 
explored in a recent systematic review (Moe et al., 2017). The review 
demonstrated that exercise should be considered an important component of 
prostate cancer care and that it is generally safe and well tolerated in such a 
population (Moe et al., 2017).  
The majority of research within clinical populations has focused on aerobic 
exercise. The benefits of aerobic exercise, with and without dietary advice, to 
prostate cancer patients has been studied extensively in recent years, with the 
most common benefits including improved peak oxygen uptake and physical 
functioning and, decreased levels of fatigue and depression (Eriksen et al., 
2017; Hvid et al., 2016; Jones et al., 2014; Martin, Battaglini, Hands, & 
31 
 
Naumann, 2015; Park et al., 2012; Segal et al., 2009; Shingler et al., 2017). 
The health benefits of RET in clinical populations, however, are far less 
extensively researched. The benefits of RET are becoming increasingly 
recognised with some including those that have traditionally been unique to 
aerobic training e.g. improved cardiorespiratory fitness (Steele et al., 2017). 
Some studies demonstrate that RET can result in longer-term health benefits 
compared to aerobic exercise when undertaken 2-3 days a week for 12 weeks 
(Baumann, Zopf, & Bloch, 2012; Champ, Francis, Klement, Dickerman, & 
Smith, 2016; Teleni et al., 2016). Many papers have attempted to use RET as 
a vehicle for improving strength, power and muscle mass in various different 
populations, including prostate cancer patients (Bechshoft et al., 2017; 
Lourenzi et al., 2017; Nilsen et al., 2015; Schoenfeld, Wilson, Lowery, & 
Krieger, 2016). Along with reducing feelings of depression and fatigue, regular 
RET can improve muscle strength and endurance, quality of life and even 
cardiorespiratory fitness, as well as reduce blood pressure and waist 
circumference after prostate cancer treatments (Baumann et al., 2012; Galvao 
et al., 2006; Hasenoehrl et al., 2015; Santa Mina, Connor, et al., 2013; Segal 
et al., 2009).  
 
2.12.1 Mechanisms for Benefits of RET for Prostate Cancer 
Mechanisms for the effects of RET on cardiovascular health and the side 
effects of those treated for prostate cancer via robot-assisted radical 
prostatectomy or ADT include endothelial function, microvascular changes 
affecting the skeletal muscle (i.e., angiogenesis) and macrovascular changes 
to the arterial tree (i.e., arteriogenesis). RET may also be used as a vehicle for 
improving other markers of cardiometabolic health, including central 
cardiovascular fitness, cardiometabolic health and skeletal muscle adaptions. 
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2.12.2 Endothelial Function 
An important factor related to both micro and microvascular adaptation to 
exercise is endothelial function. Dysfunction of the endothelium is not only a 
marker of the impairment due to risk factors of CVD acting on the arterial wall 
but is also a marker of the initiation and progression of atherosclerosis 
(Deanfield, Halcox, & Rabelink, 2007). Normal vascular endothelial function 
can be restored through both pharmaceutical treatment (e.g. statins) and 
exercise (Fiuza-Luces et al., 2018). A meta-analysis, conducted in adults, 
found that aerobic exercise improves vascular endothelial function in a dose-
dependent manner, with every 2 MET increase in intensity approximately 
associated with a 1% improvement in FMD (Ashor et al., 2015). Furthermore, 
the studies included in the review demonstrated that aerobic, resistance and 
combined exercise modalities increased FMD by approximately 2%, potentially 
leading to a reduction in CVD risk of about 20% (Ashor et al., 2015). Ultrasound 
assessment of endothelial function using flow mediated dilatation (FMD) is a 
safe, inexpensive, non-invasive methods of assessing vascular health and 
predicting the risk of future cardiovascular events (Deanfield et al., 2007; 
Thijssen, 2011). The term FMD simply describes arterial vasodilation following 
an increase in luminal blood flow and resulting internal-wall shear stress 
(Thijssen, 2011). It is important to note the importance of nitric oxide, released 
from vascular endothelium, as a potent vasodilator and the anti-atherogenic 
properties it possesses. Shear stress on the endothelial cells is a physiological 
stimulus to nitric oxide production and, although the role of endothelium-
derived nitric oxide in acute exercise is not fully understood, prolonged 
repetitive exercise training up-regulates endothelial nitric oxide bioactivity 
(Deanfield et al., 2007; Daniel J. Green et al., 2003; Maiorana, O'Driscoll, 
Taylor, & Green, 2003; Niebauer & Cooke, 1996; Thijssen, 2011). A meta-
analysis examining evidence from 14 studies demonstrated that for each 1% 
increase in FMD, the relative risk of suffering a cardiovascular event is reduced 
by 13% (Inaba, Chen, & Bergmann, 2010). Measurements of endothelial 
function via FMD are sensitive to changes in various cardiovascular risk factors 
such as plasma lipids, blood glucose and body composition, which can be 
altered favourably through exercise. Therefore, FMD might provide a suitable 
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method to evaluate changes in cardiovascular risk in men being treated for 
prostate cancer via robot-assisted radical prostatectomy or ADT. 
2.12.3 Angiogenesis 
Angiogenesis is stimulated through hypoxic and mechanical factors and is the 
process by which new blood vessels form from a pre-existing vascular bed and 
plays a critical role in tissue growth and repair (Heil, Eitenmuller, Schmitz-
Rixen, & Schaper, 2006; Rizzi, Benagiano, & Ribatti, 2017).  
There are multiple cytokines involved in angiogenesis but vascular endothelial 
growth factor (VEGF) appears to be central in the initiation of the process. 
VEGF is released from the small vessels involved in angiogenesis and 
stimulates endothelial cell proliferation and migration as well as being essential 
in the maintenance of muscle capillarity (Bloor, 2005). Interestingly, 
angiogenesis is also a fundamental part of the development of prostate cancer 
progression and metastasis (Russo, Mischi, Scheepens, De la Rosette, & 
Wijkstra, 2012). Tumour cells can induce new blood vessels by producing 
VEGF, which is expressed by most cancer types including prostate cancer 
(Russo et al., 2012; Yu & Rak, 2003). In patients with prostate cancer treated 
via ADT the progression of cancer and therefore angiogenesis is somewhat 
reduced or slowed down. However, with both ADT and surgery for prostate 
cancer muscle wastage is common and exercise can be used to induce 
angiogenesis in the affected musculature and thereby countering the adverse 
effects of these prostate cancer treatment. Exercise induces changes in 
skeletal muscle through hypoxia resulting in increased vascular cell 
proliferation, muscle capillarity and the diameter of large conduit arteries 
(Bloor, 2005). At the tissue level, exercise increases flow capacity and capillary 
surface area (Bloor, 2005).  
The degree to which hypoxia, initiated through exercise, stimulates capillary 
angiogenesis remains unclear however, hypoxia is known to promote the 
upregulation of VEGF. VEGF stimulates the proliferation and migration of 
endothelial cells by binding to VEGF receptors which are expressed on the 
endothelial cell surface thereby producing microvascular changes (Yu & Rak, 
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2003). Because the expression of VEGF is reduced with increasing age, 
exercise-induced angiogenesis is likely to be impaired in men of advanced age 
who suffer muscle wastage due to prostate cancer treatments. This being said, 
exercise training at high intensities may improve the age induced 
downregulation of VEGF (Iemitsu, Maeda, Jesmin, Otsuki, & Miyauchi, 2006; 
Korivi, 2010). Therefore, regular exercise may be an effective stimulus for 
angiogenesis in normal physiological and pathological conditions. 
 
2.12.4 Arteriogenesis 
Arteriogenesis is the remodelling of current collateral arteries and arterioles 
into arteries, resulting in an increased diameter, and is influenced by physical 
forces, most importantly shear stress combined with the upregulation of key 
enzymes such as nitric oxide and VEGF (Heil et al., 2006; Helisch & Schaper, 
2003; Rizzi et al., 2017).  
Despite extensive research on angiogenesis and its interactions as a result of 
tumour growth and exercise, there has been little on vascular remodelling 
upstream of active angiogenesis at a tumour site. It has been suggested that 
due to angiogenesis of the capillary bed during cancerous tumour growth, 
there is concurrent expansion of the upstream arterioles (Yu & Rak, 2003). 
Moreover, muscle loading through RET has been reported as increasing the 
number and length of distal arterioles with an extension of the arteriolar tree 
(Hansen-Smith, Egginton, Zhou, & Hudlicka, 2001). Therefore exercise, 
particularly RET, may play a key part in reducing the CVD risk in men with 
prostate cancer, treated via surgery or ADT, by increasing the rate of 
arteriogenesis. Prostate cancer patients are at increased risk of CVD (Allott et 
al., 2013) and exercise can improve the utilization and extraction of oxygen 
from erythrocytes, influence blood viscosity, and help inhibit the progression of 
atherosclerosis (van Royen et al., 2001). 
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2.12.5 Blood Borne Biomarkers of Cardiometabolic Health 
Unfavourable levels of blood lipids, glucose and insulin are associated with the 
development of CVD and metabolic syndrome. It is therefore important that 
these risk markers are managed through a combination of pharmaceutical 
interventions and lifestyle alterations. Due to the average age of men 
diagnosed with prostate cancer being > 65 years of age, it is common that they 
also present with comorbidities such as hyperlipidaemia or diabetes that put 
them at an increased risk of developing CVD. Furthermore, blood lipid levels 
may increase in the weeks post-surgery due to patients being sedentary. ADT 
may also cause increases in blood lipid profile due to the increase in fat mass 
which often accompanies this treatment approach. 
RET can improve body composition by increasing lean body mass and 
reducing fat mass. The resulting changes in body composition from RET are 
thought to have a positive impact upon insulin resistance and blood glucose 
levels. Glucose is an important fuel for contracting muscle, and normal glucose 
metabolism is vital for health. Glucose transporter type 4 (GLUT-4) is an 
insulin-regulating protein responsible for glucose transportation into skeletal 
muscle. Muscle glucose uptake relies on GLUT-4 and exercise is the most 
potent stimulator on GLUT-4 expression. This in turn can contribute to 
improved insulin control, glucose synthesis and enhanced muscle glycogen 
storage following RET (Azarbayjani, Abedi, Peeri, Rasaee, & Stannard, 2014; 
Richter & Hargreaves, 2013; Sañudo et al., 2013). An increase in skeletal 
muscle mass can also improve blood lipid profile by increasing the capacity of 
the muscles to utilise lipids as a fuel (rather than glycogen) and increasing 
lipoprotein lipase activity (Laaksonen et al., 2000; Mann, Beedie, & Jimenez, 
2014). 
 
2.12.6 Cardiorespiratory Fitness 
Cardiorespiratory fitness declines with age, physical inactivity and sedentary 
behaviour.  Individuals achieving moderate-to-high cardiorespiratory fitness 
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levels (i.e. ≥ 8 METs) have been associated with a reduced risk of CVD events 
(Kodama et al., 2009). Additionally, it has been suggested that an increase in 
cardiorespiratory fitness of only 1 MET could decrease the risk of CVD by 15% 
(Fiuza-Luces et al., 2018; Kodama et al., 2009). 
A limited body of evidence suggests that RET has the potential to improve 
cardiovascular risk markers, as well as attenuating age- and chronic-disease-
related skeletal muscle loss/sarcopenia, which could potentially impact peak 
rate of oxygen consumption (V̇O2Peak) by increasing oxygen utilisation 
capacity. Muscle oxidative capacity is reduced in ageing by a reduction in 
muscle mass and mitochondrial density, influencing the age-related decline in 
V̇O2Peak (Frank et al., 2016). This is of particular importance for those aged 
>50 years as age-related physiological changes, including increases in blood 
pressure, arterial stiffness and fat mass (with associated changes in systemic 
physiology) coupled with reductions in V̇O2Peak increase the risk of premature 
cardiovascular mortality, particularly in inactive older people (Cornelissen, 
Fagard, Coeckelberghs, & Vanhees, 2011; Hollings, Mavros, Freeston, & 
Fiatarone Singh, 2017; Moro et al., 2017; Otsuki, 2006).  
Contrary to traditional opinions, several papers have been recently reported 
an increase in V̇O2Peak after RET programmes in both healthy elderly and 
clinical populations (Frank et al., 2016; Hunter, McCarthy, & Bamman, 2004; 
Osteras, Helgerud, & Hoff, 2002). Frank and colleagues (Frank et al., 2016) 
suggested that RET is effective in reversing the age-related decline in 
cardiorespiratory capacity due to a shift in muscle fibre type composition and 
an increase in mitochondrial biogenesis and proteins. Such changes could be 
due to: (1) the high frequency of training sessions (3 sessions a week), (2) high 
intensity which increased progressively and, (3) an increase in work economy 
that can be partly explained by enhanced changes in the force-velocity 
relationship and improved mechanical power output (Frank et al., 2016; Hunter 
et al., 2004; Osteras et al., 2002). The use of RET has recently been explored 
in a systematic review of patients undergoing cardiac rehabilitation 
programmes and similar improvement in V̇O2Peak were apparent in RET and 
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aerobic exercise groups when compared to a non-exercise control group 
(Hollings et al., 2017). 
 
2.12.7 Skeletal Muscle Adaptation  
Sarcopenia is an often overlooked as a cardiometabolic risk factor that can be 
in the most-part reversed through RET (Fiuza-Luces et al., 2018). It is a 
common condition in cancer patients, regardless of disease stage, and is 
associated with higher mortality rates in both advanced stage (Tan, Birdsell, 
Martin, Baracos, & Fearon, 2009; van Vledder et al., 2012) and early-stage 
patients (Villasenor et al., 2012). RET constitutes an effective modulator of 
skeletal muscle function with a growing body of evidence supporting the safe 
and effective use in prostate cancer patients in whom it has much potential to 
improve muscle mass and function (Christensen et al., 2014; C. M. Fairman et 
al., 2017; Hasenoehrl et al., 2015; Keilani et al., 2017; Norris, Bell, North, & 
Courneya, 2015). 
Skeletal muscle produces and releases myokines into the blood, particularly 
during muscular contraction, where they function to elicit countless benefits, 
including decreased inflammation and insulin resistance (Fiuza-Luces, 
Garatachea, Berger, & Lucia, 2013). Interleukin-6 (IL-6) is a pro-inflammatory 
cytokine that when elevated is associated with type 2 diabetes mellitus and 
intima-media thickness (Chen et al., 2017; B. Zhang et al., 2015). However, 
when released by contracting muscles during exercise IL-6 can induce healthy 
metabolic effects such as increasing lipolysis and fat oxidation in adipose 
tissue and reducing skeletal muscle insulin resistance (Lambernd et al., 2012; 
Pedersen & Febbraio, 2008). 
In addition to micro- and macro-vascular adaptions following RET 
programmes, skeletal muscle adaptions include improvements in muscle 
strength, muscle mass and endurance. A recent study which assessed lean 
body mass, via a dual x-ray absorptiometry (DXA), showed that despite no 
changes in trunk lean body mass, both lower and upper extremity lean body 
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mass improved significantly after 16 weeks of RET (Nilsen et al., 2015). One 
particular study in 2013 which examined the effects of 12 weeks of RET in men 
on ADT reported significant increases in total body muscle mass (2.7%), power 
(17%), and strength (28%) as well as  significant increases in functional 
performance (20%) and muscle endurance (110%) (Hanson et al., 2013). 
Another study showed that prostate cancer patients improved upper and lower 
body strength by 22% and 24%, respectively, following 24 weeks of RET  
(Segal et al., 2009). Furthermore, skeletal muscle is the major site of dietary 
glucose utilisation and therefore increasing muscle mass can contribute to a 
reduced risk of insulin resistance (Fiuza-Luces et al., 2018). Such 
improvements in skeletal muscle not only help improve quality of life through 
increase ability to complete activities of daily living but also help to reduce the 
likelihood of falls and risk of metabolic syndrome (Fiuza-Luces et al., 2018; 
Frank et al., 2016).  
 
2.13 Supervised Versus Home-based Exercise 
The benefits of supervised RET have been extensively reported and include 
improvements in lean body mass, muscle strength, aerobic capacity and blood 
lipid profile (Andersen, Schmidt, Pedersen, Krustrup, & Bangsbo, 2016; 
DeVallance et al., 2016; Fahlman, Boardley, Lambert, & Flynn, 2002). 
However, such research has been largely investigated in supervised groups 
using gym equipment, which is resource- and time-intensive for both the 
patient and the NHS. The estimated cost per patient for supervised exercise 
referral programmes in the NHS is £229 per person, which is based on a health 
technology assessment and inflation indices from the Personal Social Services 
Research Unit (F. Campbell et al., 2015; Curtis, 2011; Isaacs et al., 2007). This 
figure rises each year and could incur extra costs depending upon the 
comorbidities of the patients and the geographical area of implementation (F. 
Campbell et al., 2015). Due to the associated costs of supervised exercise 
referral programmes, there is some uncertainty surrounding the cost 
effectiveness of the programmes.  
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However, studies have reported that exercise interventions reduce fatigue, 
improve immune function and improve quality of life in prostate cancer patients 
who have undergone robot-assisted radical prostatectomy or ADT (Courneya 
et al., 2004; Galvao et al., 2006; Hojman, 2017; Park et al., 2012). In addition, 
aerobic exercise has been reported to improve peak oxygen uptake and 
decrease fatigue, reduce depression and prevent deterioration in physical 
function during treatment for prostate cancer (Jones et al., 2014; Keogh & 
MacLeod, 2012; Park et al., 2012; Storer et al., 2012). RET interventions are 
also effective for reducing fatigue and depression and may bring about more 
beneficial effects compared to aerobic training in relation to outcomes such as 
muscle strength, quality of life and well-being, as well as reductions in blood 
pressure and waist circumference after prostate cancer treatments (Baumann 
et al., 2012; Mustian et al., 2009; Segal et al., 2009). This body of research 
suggests that more exercise studies which include cost-effectiveness analysis 
are warranted.  
Maintaining regular exercise can be difficult for cancer patients due to cancer-
related fatigue and lack of clear information about exercise and its benefits 
(Fernandez et al., 2015). Other challenges to regular exercise include financial 
and environmental factors. However, investigations into the barriers to 
exercise have mainly focused on breast cancer survivors, with much less 
known about the barriers in other cancer populations (Nock et al., 2015; 
Ottenbacher et al., 2011). Fatigue and deconditioning as a result of cancer 
treatment can present physical barriers which may lead to social isolation and 
lack of regular exercise (Fernandez et al., 2015). Other studies have reported 
lack of time, enjoyment and treatment side effects as barriers to exercise in 
cancer survivors (Craike, Livingston, & Botti, 2011; Fernandez et al., 2015; 
Hefferon, Murphy, McLeod, Mutrie, & Campbell, 2013; Ottenbacher et al., 
2011; Spector, Battaglini, & Groff, 2013). A study by Ottenbacher and 
colleagues (Ottenbacher et al., 2011) showed that lack of will power and the 
weather can be important barriers to exercise participation after prostate 
cancer treatment. Studies have explored behaviour change techniques to 
promote exercise in patients living with and after cancer. A recent systematic 
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review demonstrated that those exercise interventions with the better 
adherence levels share some common characteristics (Bourke et al., 2013; 
Turner et al., 2018). Such characteristics include setting goals, promoting self-
monitoring and, encouraging patients to attempt behaviour learnt in a 
supervised setting in a non-supervised/home setting (Bourke et al., 2013; 
Greaves et al., 2011; Turner et al., 2018). Clinical populations already studied 
in home-based programmes include those with heart failure, prostate and 
breast cancer patients, type 2 diabetics, and those with osteoarthritis and good 
adherence rates have been demonstrated (Bruce-Brand et al., 2012; Hvid et 
al., 2016; Mustian et al., 2009; Plotnikoff et al., 2010; Safiyari-Hafizi, Taunton, 
Ignaszewski, & Warburton, 2016). Therefore, home-based training 
incorporating goal setting whilst maintaining or tapering a level of supervision 
may be more appropriate and cost-effective than fully supervised exercise for 
both the NHS and the patient.   
Although supervised RET interventions have the potential to generate longer-
term improvements (~6 months) in health when compared to aerobic exercise 
or standard care (Ashton et al., 2018; Baumann et al., 2012; Segal et al., 
2009), it is unlikely to be feasible for the NHS to implement or the patient to 
adhere to over a long period (Park et al., 2012; Segal et al., 2009). However, 
the health benefits gained from supervised RET have been shown to be 
sustained by a subsequent a home-based exercise programme (Galvao et al., 
2014). Home-based RET programmes with continued support might help to 
overcome some of the barriers to exercise participation in prostate cancer 
survivors, as well as providing a low cost alternative to supervised RET 
programmes but to help to maintain adherence, the use of goal setting and 
self-monitoring should be incorporated (Bourke et al., 2013, 2014; Bruce-
Brand et al., 2012; Craike et al., 2011; Moe et al., 2017; Thiebaud, 2014).  
 
2.14 Conclusion 
In summary, progressive RET may facilitate improved cardiometabolic health 
and side effects of prostate cancer treatment, specifically robot-assisted 
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radical prostatectomy. Relevant beneficial physiological effects of RET include 
improved erectile dysfunction, cardiorespiratory fitness, muscle mass, blood 
biomarkers and attenuation of fatigue, fat mass, and arterial endothelial 
dysfunction. Appropriate RET programmes may be partially supervised but 
primarily take place in the home environment to help counteract some of the 
barriers to participation. Further research is clearly needed in the area of RET 
for patients treated for prostate cancer via robot-assisted radical 
prostatectomy. 
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CHAPTER 3 
 
 
 
 
 
 
 
 
 
 
 
SYSTEMATIC REVIEW 
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3.0 Effects of short-, medium- and long-term resistance 
training on measures of cardiometabolic health in adults: a 
systematic review and meta-analysis  
 
3.1 Introduction 
Cardiovascular disease is a substantial human and economic burden, 
responsible for 17.7 million deaths globally in 2015 (World Health 
Organisation, 2017). The positive impact of regular moderate to vigorous 
intensity aerobic exercise (e.g. brisk walking, jogging, cycling) on 
cardiometabolic health, including improvements in cardiopulmonary exercise 
capacity, blood pressure, glycaemic control, hypercholesterolemia and 
vascular endothelial function (Chodzko-Zajko, 2009; Otsuki, 2006), is well-
documented and recognised in current UK and global physical activity 
recommendations (UK Chief Medical Officers' Guidelines, 2011; World Health 
Organisation, 2010). However, while the health benefits of regular resistance 
exercise training (RET) in relation to maintaining skeletal muscle size and 
strength are also recognised in current physical activity recommendations, the 
role of RET in enhancing cardiometabolic health is less well defined.  
RET is characterised by muscular activities working against an external load 
and may be easier than aerobic exercise to implement and sustain in the home 
environment as it offers an alternative way to exercise for older adults who 
have limited space or access to equipment and time availability (Galvao et al., 
2014; King, Haskell, Taylor, Kraemer, & DeBusk, 1991; Thiebaud, 2014). Most 
studies of RET have focused on changes in skeletal muscle size and strength, 
with few investigating cardiometabolic health effects as primary outcomes 
although several have reported cardiometabolic variables as secondary 
outcomes (Liu & Latham, 2009; Raymond, Bramley-Tzerefos, Jeffs, Winter, & 
Holland, 2013; Thiebaud, 2014). 
There is preliminary evidence that RET may positively alter blood lipid profile, 
body composition, systolic blood pressure (Gerage et al., 2013; James et al., 
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2016; Moro et al., 2017), circulating inflammatory markers and 
cardiopulmonary exercise capacity (De Salles, 2010; Kelley & Kelley, 2010; 
Otsuki, 2006). RET may also generate longer-lasting improvements in body 
fat, fasted insulin, lipid profile and systolic blood pressure than aerobic 
exercise (Segal et al., 2009; Sigal et al., 2007). Finally, RET may have an 
important role in attenuating age-related physiological changes such as 
increases in systolic blood pressure and arterial stiffness, and the reduction of 
skeletal muscle mass (with associated changes in systemic physiology) 
(Chodzko-Zajko, 2009; Straight, 2016). 
Aside from the lack of RET intervention studies with a primary focus on 
cardiometabolic health outcomes, interpreting the impact of RET on 
cardiometabolic health is constrained by heterogeneity of methodology, 
including the duration of interventions and populations. High-quality systematic 
reviews and meta-analyses can help to overcome these challenges, while 
accounting for bias and heterogeneity, by providing more precise estimates of 
effect size changes. The aim of this systematic review was to assess the 
effects of short-, medium- and long-term RET programmes compared to 
control or usual care on cardiometabolic health outcomes in adults. 
 
3.2 Methods 
This systematic review was prospectively registered in an international 
database of systematic reviews in health and social care (registration number 
CRD42016037946; http://www.crd.york.ac.uk/PROSPERO/). The preferred 
reporting items for systematic review and meta-analyses (PRISMA) guidelines 
were followed to guide the reporting of this review (Moher, 2015). 
 
3.2.1 Eligibility Criteria 
We included randomised controlled trials (RCTs) published in English that 
compared any RET programme alone to a non-exercising control or usual care 
group. Participants must have been aged ≥ 18 years, non-athletic (World 
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Health Organisation, 2013), and recruited to a RET programme (e.g. elastic 
resistance band, weight machines, etc.) of at least 2 weeks duration, 
irrespective of intensity or frequency that was conducted in any setting (e.g. 
home, hospital). We included studies where isometric RET with whole body 
vibration was used. We excluded studies where RET interventions were 
combined with other lifestyle components or exercise modes (e.g. aerobic 
exercise, diet, etc.) to isolate the effects of RET. Studies that included at least 
one of the following cardiometabolic health outcomes or clinical end-points 
were eligible: V̇O2Peak; flow-mediated dilatation; C-reactive protein; total 
cholesterol; high-density lipoprotein cholesterol; low-density lipoprotein 
cholesterol; triglycerides; fasted glucose; fasted insulin; insulin resistance 
(HOMA-IR); resting blood pressure; mean arterial pressure; resting heart rate; 
cardiovascular mortality; all-cause mortality; non-fatal end-points (e.g. 
myocardial infarction, coronary artery bypass grafting; percutaneous 
transluminal coronary angioplasty; angina or angiographically-defined 
coronary heart disease; stroke; carotid endarterectomy; peripheral arterial 
disease.  
 
3.2.2 Search Strategy  
The MEDLINE Ovid and Cochrane Library databases were searched from 
inception to February 2018. The search strategy keywords and MeSH terms 
used included: progressive resistance, strength training, exercise and 
randomised controlled trial. Details of the full search strategy can be found in 
Appendix 2a. Reference lists of all relevant systematic reviews identified were 
searched for additional studies. All searches were conducted by the same 
author (RA), with search results collated using EndNote software (Thomson 
Reuters, New York), and duplicates removed. 
The first 10% of titles and abstracts were screened independently by two 
reviewers (RA and GT) and, due to good agreement, the remaining texts were 
screened by one reviewer only (RA, GT, JS or LL) (G. A. Tew, Brabyn, S., 
Cook, L., & Peckham, E. , 2016). Screening of full-texts was performed by two 
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independent reviewers (RA and GT) with disagreements resolved through 
consensus or a third reviewer being consulted (JS).  
 
3.2.3 Data Extraction  
Two authors (RA and SG) independently extracted data using Microsoft Excel. 
Any disagreements were resolved via consensus. When more than one 
publication was apparent for the same trial, data were collated (supplementary 
table 2). We extracted study design, participant demographics, intervention 
details and means and standard deviations for all outcomes. When necessary, 
published protocols and trial registries were searched for further 
methodological detail and risk of bias assessment. If there was insufficient 
information the authors (n = 40) were contacted via email. Resting blood 
pressure was expressed in millimetres of mercury (mmHg); resting heart rate 
in beats per minute (bpm), V̇O2Peak relative to body mass (ml/kg/min), flow-
mediated dilatation as percentage, fasted insulin in micro units per millilitre 
(µU/ml), C-reactive protein in milligrams per litre (mg/L) and glucose, lipid 
profile and HOMA-IR in milligrams per decilitre (mg/dL). Adverse events were 
also extracted.  
 
3.2.4 Risk of Bias 
Risk of bias was assessed by two authors independently (RA and SG) using 
the Cochrane Risk of Bias tool (J. P. Y. Higgins, Altman, D.G., Gøtzsche, P.C., 
Jüni, P., Moher, D., Oxman, A.D., Savović, J., Schulz, K.F., Weeks,L., Sterne, 
J.A.C., Cochrane Bias Methods Group & Cochrane Statistical Methods Group, 
2011). Any disagreements were resolved through consensus. We judged risk 
of bias on the study level as ‘low’, ‘unclear’ or ‘high’ risk (S. P. T. Higgins, & 
Green, S., 2011). We used funnel plots to assess publication bias when there 
were more than 10 studies contributing data for an analysis (S. P. T. Higgins, 
& Green, S., 2011; A. J. Sutton, Song, F., Gilbody, S.M., & Abrams, K.R. , 
2000). For all outcomes we conducted sensitivity analyses. For the sensitivity 
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analyses, we excluded studies that were judged as being at unclear risk of bias 
on the majority of domains on the Cochrane tool, or where at least 2 domains 
of the Cochrane tool were judged as being at high risk of bias before running 
the meta-analysis again.  
 
3.2.5 Data Synthesis 
Meta-analyses were undertaken using Review Manager (RevMan 5.3; 
Cochrane Collaboration, Oxford, UK) when more than two studies reported on 
the same outcome. In the pooled analysis of studies by duration, outcome data 
were organised into short-term (≤ 6 weeks), medium-term (7-23 weeks) and 
long-term (≥ 24 weeks) arbitrary categories. Where units of measurement 
could not be converted, standardised mean differences (SMD) were used. 
Data are presented as mean and 95% confidence intervals. The I² statistic was 
used to quantify statistical heterogeneity as follows: 0-40%: might not be 
important, 30-60%: moderate heterogeneity, 50-90%: substantial 
heterogeneity, 75-100%: considerable heterogeneity (S. P. T. Higgins, & 
Green, S., 2011). Fixed-effects models were used for analysis however, if 
statistical heterogeneity was noted (I2 > 40%), meta-analysis was performed 
using a random-effects model. The GRADE approach was used to assess the 
strength of evidence. Studies were downgraded if there were issues with risk 
of bias, consistency, precision or directness of the outcomes. The reasons for 
downgrading the evidence are outlined in Table 3. 
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Table 3. Criteria for downgrading the quality of outcomes using the GRADE 
approach. 
 
 
3.3 Results 
3.3.1 Search Results 
A total of 19,040 records were retrieved from database searches, of which 
5,669 records were duplicates. A further 11,696 were then eliminated following 
screening of titles and abstracts (Figure 4). Sixty-three potentially relevant 
papers were identified from screening of systematic review reference lists 
(Figure 4). After full-text screening of 1,738 articles, 194 manuscripts from 173 
RCTs were included in this review (Figure 4). Participants were individually 
randomised in all included trials (i.e. there were no cluster RCTs). 
 Reason to Downgrade the Level of Evidence 
Risk of Bias • Majority of studies rated as being at unclear risk of bias  
• Outcome includes studies that have been rated as 
being at high risk of bias in 2 or more categories 
Inconsistency • Large heterogeneity based on the similarity of point 
estimates, statistical heterogeneity and I2  50% 
Imprecision • Large confidence intervals when data are presented 
as standardised mean difference 
• Substantial heterogeneity (I2  50%) 
• If a recommendation or clinical course of action would 
differ if the upper versus the lower boundary of the 
confidence interval represented the truth 
• Sample size < 400 within the meta-analysis for each 
variable 
Indirectness • Use of surrogate outcomes 
Publication Bias • Asymmetric funnel plot 
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Figure 4. PRISMA flow diagram 
 
3.3.2 Studies Included 
The 173 RCTs comprised 6,169 participants (2,840 control and 3,329 RET 
participants), with sample sizes of 5-77 per group and 13-150 per study. One 
hundred studies involved healthy individuals and 73 studies involved clinical 
populations. All included studies were published between 1978 and February 
2018. Summary details of the included trials and populations are presented in 
Appendix 2b and 2c respectively.   
RET programmes mainly used weight machines (n = 90 studies; 52%), a mix 
of free weights, bodyweight and machine exercises (n = 43 studies; 25%), 
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elastic resistance bands (n = 13 studies; 8%), circuit exercises (n = 12 studies; 
7%), free weights (n = 10 studies; 6%), ankle/leg weights (n = 2 studies; 1%), 
isometric hand grip (n = 2 studies; 1%) and isometric exercise with whole body 
vibration (n = 1 study). 
The majority of interventions were supervised by an exercise professional (n = 
105 studies; 61%). One study reported data from an unsupervised 
intervention, and 13 (8%) used a combination of supervised and unsupervised 
programmes. Fifty-four studies (31%) did not report the level of supervision.  
The duration of the intervention varied from ≤ 6 weeks (n = 13), 7-23 weeks (n 
= 129) and ≥ 24 weeks (n = 31). The most common frequency of training was 
3 sessions per week (n = 110), followed by 2 sessions per week (n = 36), 
though some studies required participants to complete the programme in 1, 4 
or 5 sessions per week (n = 1, n = 7 and n = 5, respectively). The remaining 
studies stipulated either two-three sessions per week (n = 8), three-four 
sessions per week (n = 1) or did not report the frequency (n = 5).  
In the majority of studies, control participants were instructed to continue with 
their habitual activity (n = 115/173) or were allocated to usual care (n = 15). 
Three studies provided lifestyle advice to the control group and discussion 
about physical activity levels, but no structured/supervised exercise (n = 3). 
Forty studies did not report the requirements of the control group. The included 
studies did not report any clinical end-points. A summary of the quality of 
evidence, based on risk of bias, study design, confidence intervals and 
variability in results, has been collated using the GRADE approach (Table 4). 
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Figure 5. Risk of bias summary 
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3.3.3 Risk of Bias 
Figure 5 shows a summary of the risk of bias decisions made per category for 
the included studies. Appendix 2d describes risk of bias for each study in more 
detail. 
 
3.3.3.1 Selection Bias 
An acceptable method of random sequence generation (i.e. computer 
generated) was used in 36 studies, 8 studies were judged as being at high risk 
of bias and the remaining 129 studies were judged as being at unclear risk due 
to insufficient information to determine randomisation methods. The majority 
of studies (n = 156) did not report allocation concealment and were judged as 
unclear. Fourteen studies were judged as being at low risk of bias as allocation 
was blinded. In 3 studies, the researchers were not blinded to the allocation 
process and we judged these studies as being at high risk of bias. 
 
3.3.3.2 Performance and Detection Bias  
All trials were at high risk of performance bias (i.e. blinding of participants to 
the intervention and outcomes). Lack of investigator blinding could have 
influenced measures of resting blood pressure and flow-mediated dilatation 
but is more likely to have had an impact on the motivation provided to 
participants during V̇O2Peak tests. The majority of studies (n = 144) were rated 
as unclear for detection bias (i.e. blinding of outcome assessor) due to 
insufficient information provided in the studies. Two studies were at high risk 
of detection bias, with the remaining 27 studies at low risk.  
 
3.3.3.3 Attrition Bias 
The majority (n = 122) of studies were judged as being at low risk for 
incomplete outcome data. A further 37 studies were rated as unclear risk due 
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to attrition rates > 20% in one of the study groups (i.e. control or RET). Few 
studies were rated as high risk (n = 14) due to high dropout rates or some 
participants being excluded from the analysis. 
 
3.3.3.4 Reporting Bias 
The majority (n = 166) of studies were rated as low risk for selective reporting 
bias. A further 4 studies were classed as unclear due to a lack of description 
of outcome measures and 3 studies rated as high risk as data for some 
outcomes were not reported.  
 
3.3.3.5 Publication Bias 
Funnel plots were produced for all outcomes, except flow-mediated dilatation 
(Appendix 2e). All funnel plots were asymmetrical, indicating publication bias. 
 
3.3.4 Sensitivity Analysis 
Results from the sensitivity analysis are summarised in Appendix 2f. 
Heterogeneity was reduced in 16/33 outcomes.  The most considerable 
reductions were in those outcomes with fewer studies such as short-term 
systolic and diastolic blood pressure and long-term total and high-density 
lipoprotein cholesterol and these results could alter the main findings. 
However, in the outcomes with more studies (e.g. total cholesterol, high-
density lipoprotein cholesterol) it is unlikely that this sensitivity analysis will 
alter the main findings.  
 
3.3.5 GRADE Analysis 
All outcomes were rated as very low or, low quality evidence demonstrating 
that the estimate of effect for those outcomes is uncertain (Table 4). 
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Table 4. GRADE summary of findings. 
Outcome 
Anticipated absolute effects (95% CI) Number of 
participants 
(RCTs) 
Certainty Risk with 
control group 
Risk with resistance exercise training 
Cardiovascular morbidity/mortality Could not be calculated due to lack of reporting. 
Systolic blood pressure 
(mmHg) 
ST 115.45 mmHg MD 3.17 mmHg lower  (6.95 lower to 0.6 higher) 116 (4 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 122.8 mmHg MD 4.02 mmHg lower  (5.92 lower to 2.11 lower) 1456 (46 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 131.6 mmHg MD 4.88 mmHg lower  (10.55 lower to 0.78 higher) 346 (7 RCTs) ⊕⊕◯◯ LOW a,c 
Mean arterial pressure 
(mmHg) 
ST 86.5 mmHg MD 3.31 mmHg lower (6.86 lower to 0.78 higher) 67 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
MT 79.6 mmHg MD 1.57 mmHg lower (4.6 lower to 1.46 higher) 238 (10 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
Diastolic blood pressure 
(mmHg) 
ST 65.2 mmHg MD 1.44 mmHg lower (4.73 lower to 1.86 higher) 52 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 74.3 mmHg MD 1.73 mmHg lower (2.88 lower to 0.57 lower) 1418 (45 RCTs) ⊕⊕◯◯ LOW a,c 
LT 76 mmHg MD 4.93 mmHg lower (8.58 lower to 1.28 lower) 346 (7 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
Resting heart rate (bpm) ST 72 bpm MD 2.66 bpm lower (7.55 lower to 2.23 higher) 30 (2 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
MT 67.8 bpm  MD 0.35 bpm higher (1.44 lower to 2.13 higher) 977 (35 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 57.4 bpm MD 0.48 bpm lower (3.12 lower to 2.17 higher) 142 (5 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
Flow Mediated Dilatation (%) 7.8 % MD 1.69 % higher (0.97 higher to 2.41 higher) 138 (6 RCTs) ⊕⊕◯◯ LOW a,c 
Total Cholesterol 
(mg/dL)  
 
ST 179.3 mg/dL MD 5.55 mg/dL lower (9.62 lower to 5.47 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,c,e 
MT 180.9 mg/dL MD 0.57 mg/dL higher (5.63 lower to 6.77 higher) 882 (32 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 198.6 mg/dL MD 8.71 mg/dL lower (30.83 lower to 13.4 higher) 212 (8 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d,e 
High-density 
lipoprotein 
cholesterol (mg/dL)  
 
ST 53.8 mg/dL MD 0.82 mg/dL higher (5.4 lower to 7.03 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 53.3 mg/dL MD 2.35 mg/dL higher (0.66 lower to 5.35 higher) 1114 (38 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 53.5 mg/dL MD 2.79 mg/dL higher (0.69 lower to 6.82 higher) 339 (9 RCTs) ⊕⊕◯◯ LOW a,c 
Low-density 
lipoprotein 
cholesterol (mg/dL)  
 
ST 105.6 mg/dL MD 5.1 mg/dL lower (11.09 lower to 0.9 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 110.1 mg/dL MD 2.86 mg/dL lower (8.77 lower to 3.05 higher) 1000 (31 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 118.3 mg/dL MD 3.69 mg/dL lower (10.99 lower to 3.6 higher) 265 (6 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
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Table 4 cont. 
 
Triglycerides (mg/dL)  ST 115.2 mg/dL MD 3.63 mg/dL lower (17.45 lower to 10.2 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 91.8 mg/dL MD 3.99 mg/dL lower (8.78 lower to 0.8 higher) 1165 (37 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 102.7 mg/dL MD 2.82 mg/dL lower (14.98 lower to 9.33 higher) 265 (6 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
Fasted insulin (μU/ml) MT 16.2 μU/ml MD 1.11 μU/ml lower (1.74 lower to 0.49 lower) 590 (20 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 13.8 μU/ml MD 0.4 μU/ml lower (1.62 lower to 0.81 higher) 179 (4 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
HOMA-IR  
 MT 6.1 MD 1.22 lower (2.29 lower to 0.15 lower) 184 (9 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
LT 3.8 MD 0.18 lower (0.64 lower to 0.27 higher) 71 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
Fasted glucose 
(mg/dL)  
 
ST 87.3 mg/dL MD 3.39 mg/dL lower (6.9 lower to 0.11 higher) 122 (2 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 100.7 mg/dL MD 2.39 mg/dL lower (4.47 lower to 0.31 lower) 984 (34 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 92.3 mg/dL MD 0.7 mg/dL lower (2.8 lower to 2.67 higher) 271 (7 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
C-reactive protein 
(mg/L)  
 
ST 2.4 mg/L MD 0.13 mg/L lower (0.25 lower to 0.01 lower) 82 (2 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 3.2 mg/L MD 0.11 mg/L lower (0.6 lower to 0.38 higher) 394 (12 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
V̇O2Peak (ml/kg/min) 
ST 28.6 ml/kg/min 
MD 2.07 ml/kg/min higher (0.75 higher to 3.39 
higher) 
308 (9 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 28.9 ml/kg/min 
MD 1.07 ml/kg/min higher (0.38 higher to 1.76 
higher) 
1454 (48 RCTs) ⊕◯◯◯ VERY LOW a,c,d,e 
LT 23 ml/kg/min 
MD 1.22 ml/kg/min higher (0.44 higher to 2.0 
higher) 
399 (11 RCTs) ⊕◯◯◯ VERY LOW a,c,e 
CI - Confidence interval; RCTs – randomised controlled trials; MD – mean difference; ST – short term; MT – medium term; LT – long term;  V̇O2Peak – peak rate of 
oxygen consumption. 
a – Downgraded due to being a surrogate outcome. 
b – Downgraded due to potential for a recommendation or clinical course of action differing if the upper versus the lower boundary of the CI represented the truth 
and/or a sample size < 400. 
c – Publication bias suspected after inspection of funnel plots. 
d – Inconsistent due to high heterogeneity, non-overlap of CI and/or markedly dissimilar point estimates. 
e – Risk of bias was judged to be high. 
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3.3.6 Outcomes 
A summary of the change observed for each outcome at all durations is 
presented as mean difference and 95% CI in Figure 6. 
 
3.3.6.1 All-cause Mortality and Cardiovascular Events 
None of the included studies reported on cardiovascular mortality, all-cause 
mortality, non-fatal endpoints such as myocardial infarction, CABG, PTCA, 
angina or angiographically-defined coronary heart disease, stroke, carotid 
endarterectomy or peripheral arterial disease.  
Forest plots for each individual outcome are available in the supplementary 
documents (Appendix 2g). A summary of the change observed for each 
outcome at all time points is presented as mean difference and 95% CI in 
Figure 6. 
 
3.3.6.2 Blood Pressure, Mean Arterial Pressure and Heart Rate 
The effect of resistance training on systolic (SBP) and diastolic blood pressure 
(DBP) was investigated in 58 and 56 studies, respectively. Four studies 
investigated the effects of short-term resistance training on SBP (resistance 
arm n = 59, control arm n = 57). Figure 6 demonstrates a non-significant 
reduction in SBP following short-term resistance training interventions (mean 
diff, [95% CI]; -3.17 [-6.95, 0.6] mmHg P = 0.1; χ² = 5.76, I² = 48%, P = 0.12). 
Medium-term SBP included 46 studies (resistance arm n = 742, control arm n 
= 714) and demonstrated a significant reduction and considerable 
heterogeneity in SBP following medium-term resistance training interventions 
(-4.02 [-5.92, -2.11] mmHg, P < 0.0001; χ² = 325.48, I² = 86%, P < 0.00001). 
Long-term SBP included 8 studies (resistance arm n = 188, control arm n = 
178) and showed a significant reduction favouring resistance training and 
substantial heterogeneity (-5.08 [-10.04, -0.13] mmHg, P = 0.04; χ² = 19.46, I² 
= 64%, P = 0.007).  
57 
 
Four studies investigated the effects of resistance training on short-term DBP 
(resistance arm n = 59, control arm n = 57).  Figure 6 demonstrates a non-
significant reduction in DBP following short-term resistance training 
interventions (-0.72 [-3.66, 2.22] mmHg P = 0.63; χ² = 8.1, I² = 63%, P = 0.04). 
Medium-term DBP included 45 studies (resistance arm n = 721, control arm n 
= 697) and revealed a significant reduction in DBP (-1.73 [-2.88, -0.57] mmHg, 
P = 0.003; χ² = 263.07, I² = 83%, P < 0.00001). Long-term DBP included 7 
studies (resistance arm n = 177, control arm n = 169) and demonstrated a 
significant reduction favouring resistance training and considerable 
heterogeneity (-4.93 [-8.58, -1.28] mmHg, P = 0.008; χ² = 22.07, I² = 73%, P < 
0.001; Figure 6).  
MAP was reported in 13 studies. Three studies investigated the effects of 
short-term resistance training on MAP (resistance arm n = 35, control arm n = 
32) with Figure 6 demonstrating a non-significant reduction (-3.31 [-6.86, 0.25] 
mmHg, P = 0.07; χ² = 6.61, I² = 70%, P = 0.04). Medium-term MAP included 
10 studies (resistance arm n = 136, control arm n = 132) and demonstrated 
non-significant reduction in MAP over the course of a medium-term resistance 
training intervention (-1.57 [-4.6, 1.46], P = 0.31; χ² = 97.16, I² = 91%, P < 
0.00001).  
The effect of resistance training on resting heart rate was reported in 42 
studies. Studies (n = 2) investigating the effects of resistance training on short-
term resting heart rate (resistance arm n = 16, control arm n = 14) demonstrate 
no significant change (-2.66 [-7.55, 2.23] bpm, P = 0.7; χ² = 6.95, I² = 86%, P 
= 0.008; Figure 6). Medium-term resting heart rate included 35 studies 
(resistance arm n = 510, control arm n = 467) and Figure 6 shows no significant 
evidence of a change in resting heart rate over the course of a medium-term 
resistance training intervention (0.35 [-1.44, 2.13] bpm, P = 0.69; χ² = 266.11, 
I² = 87%, P < 0.00001). Long-term resting heart rate included 5 studies 
(resistance arm n = 74, control arm n = 68) and shows no evidence of change 
in long-term interventions (-0.48 [-3.12, 2.17] bpm, P = 0.72; χ² = 6.83, I² = 
41%, P = 0.15).  
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Figure 6. Effects of (A) Short-term, (B) medium-term, (C) long-term RET as 
standardised mean difference and 95% CI. SBP –systolic blood pressure, DBP 
- diastolic blood pressure, MAP – mean arterial pressure, V̇O2Peak – peak rate 
of oxygen consumption, FMD – flow mediated dilatation, HDL-Chol – high 
density lipoprotein cholesterol, LDL-Chol – low density lipoprotein cholesterol, 
HOMA-IR – insulin resistance, CRP – c-reactive protein. 
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3.3.6.3 V̇O2Peak  
The effect of RET on V̇O2Peak is presented in Appendix 2g. There was an 
improvement in V̇O2Peak with RET and moderate heterogeneity (mean 
difference 2.07 [95% confidence interval 0.75, 3.39] ml/kg/min, P = 0.002; χ² = 
11.35, I² = 30%, P = 0.18) in short-term studies (n=9; resistance arm: n = 177; 
control arm: n =131). In medium-term studies (n = 48; resistance arm: n = 767; 
control arm: n = 687) there was a significant improvement in V̇O2Peak with 
RET and substantial heterogeneity (mean difference 1.07 [95% confidence 
interval 0.38, 1.76] ml/kg/min, P = 0.002; χ² = 160.15, I² = 71%, P < 0.00001). 
In long-term studies (n = 11; resistance arm: n = 213; control arm: n = 186) 
there was a significant improvement in V̇O2Peak with RET (mean difference 
1.22 [95% confidence interval 0.44, 2.0] ml/kg/min, P = 0.002; χ² = 10.22, I² = 
2%, P = 0.42).  
 
3.3.6.4 Flow-Mediated Dilatation 
Eight studies reported flow-mediated dilatation, however due to missing data, 
only six studies (resistance arm: n = 68; control arm: n = 70), all medium-term, 
were included in the meta-analysis (Appendix 2g). There was a significant 
improvement in flow-mediated dilatation favouring RET (1.69 [0.97, 2.41], P < 
0.0001) with low heterogeneity (χ² = 0.72, I² = 0%, P = 0.98). One short-term 
study (Olson, Dengel, Leon, & Schmitz, 2006) and one long-term study (Vona 
et al., 2009) reported improvements in flow-mediated dilatation after RET.  
 
3.3.6.5 Blood Borne Biomarkers 
All blood outcomes are presented in Table 5 and Appendix 2g. Non-significant 
changes in total cholesterol are evident at all durations (short: -5.55 [-16.58, 
5.48], P = 0.32; medium: 0.57 [-5.63, 6.77], P = 0.86; long: -8.71 [-30.83, 
13.40], P = 0.44). Non-significant, but favourable changes were also evident 
in medium- and long-term HDL-chol and across all intervention durations for 
LDL-chiol and triglycerides. Significant reductions in fasted insulin and HOMA-
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IR was apparent in medium-term (-0.59 [-0.97, -0.21], P = 0.002 and -1.22 [-
2.29, -0.15], P = 0.02, respectively) but not long-term interventions. There was 
a significant reduction in fasted glucose in medium-term (-2.39 [-4.47, -0.31], 
P = 0.02) but not short- or long-term interventions. There was significant 
heterogeneity in the CRP analysis; however, reductions of borderline statistical 
significance after medium- and long-term RET interventions were present. 
 
3.3.7 Sub-group Analysis 
All data for the sub-groups are available in Appendix 2h.  
When comparing healthy young adults ≤ 40 years (n = 44) with healthy older 
adults ≥ 41 years (n = 50), there was a greater magnitude of cardiometabolic 
benefit from RET in the older populations. There were significant reductions in 
systolic blood pressure with medium-term RET interventions for healthy older 
adults compared to healthy younger adults (-4.36 [-5.73, -2.99] mmHg, P < 
0.00001, versus -0.56 [-1.57, 0.44] mmHg, P = 0.27, respectively). In the 
healthy older adults there were significant improvements in systolic blood 
pressure, diastolic blood pressure, mean arterial pressure, resting heart rate, 
total cholesterol, high-density lipoprotein cholesterol, triglycerides, fasted 
insulin, fasted glucose and C-reactive protein following medium-term 
interventions compared to younger adults for the same intervention duration. 
Significant improvements after long-term interventions were also apparent for 
diastolic blood pressure, V̇O2Peak, total cholesterol and fasted glucose in 
healthy older adults ≥ 41 years compared to younger adults.  
There were greatest improvements in medium-term LDL cholesterol, short- 
and medium-term V̇O2Peak, and short-term systolic and diastolic blood 
pressure among older adults (≥ 41 years) with elevated cardiometabolic risk 
or cardiometabolic disease (n = 42) after medium-term interventions, 
compared to healthy older adults. For example, the largest reduction in systolic 
blood pressure following medium-term RET interventions was observed in 
older adults ≥ 41 years with elevated cardiometabolic risk or disease (-8.80 [-
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9.90, -7.69] mmHg, P < 0.00001) compared to the healthy older adults (-4.36 
[-5.73, -2.99] mmHg, P < 0.00001).  
62 
 
Table 5. The short- (ST), medium- (MT) and long-term (LT) effects of resistance training on blood borne biomarkers
Blood marker 
Number 
of studies 
Number of participants Mean difference 
[95% CI] 
P values Heterogeneity 
RT CON 
Total 
Cholesterol 
(mg/dL) 
ST 3 80 66 -5.55 [-16.58, 5.48] † 0.32 χ² = 2.39, I² = 16%, P = 0.3 
MT 32 442 440 0.57 [-5.63, 6.77] 0.86 χ² = 190.82, I² = 84%, P < 0.00001 
LT 8 115 97 -8.71 [-30.83, 13.40] † 0.44 χ² = 71.91, I² = 90%, P < 0.00001 
HDL-chol 
(mg/dL) 
ST 3 80 66 0.82 [-5.40, 7.03] 0.56 χ² = 5.99, I² = 50%, P = 0.11 
MT 39 601 590 2.23 [-0.06, 4.51] † 0.06 χ² = 734.44, I² = 95%, P < 0.00001 
LT 9 179 160 2.79 [-0.69, 6.28] † 0.12 χ² = 12.33, I² = 35%, P = 0.14 
LDL-chol 
(mg/dL) 
ST 3 80 66 -5.10 [-11.09, 0.90] † 0.1 χ² = 0.32, I² = 0%, P = 0.85 
MT 31 503 497 -2.86 [-8.77, 3.05] † 0.34 χ² = 292.46, I² = 90%, P < 0.00001 
LT 6 135 130 -3.69 [-10.99, 3.60] † 0.32 χ² = 2.39, I² = 0%, P = 0.79 
Triglycerides 
(mg/dL) 
ST 3 80 66 -3.63 [-17.45, 10.2] † 0.61 χ² = 0.14, I² = 0%, P = 0.93 
MT 37 590 575 -3.99 [-8.78, 0.8] † 0.29 χ² = 250.54, I² = 86%, P < 0.00001 
LT 6 135 130 -2.82 [-14.98, 9.33] † 0.65 χ² = 7.99, I² = 37%, P = 0.16 
Fasted 
insulin 
(µU/ml) 
MT 20 304 286 -0.59 [-0.97, -0.21] † 0.002* χ² = 84.86, I² = 78%, P < 0.00001 
LT 4 89 90 -0.60 [-1.93, 0.72] † 0.37 χ² = 45.43, I² = 93%, P < 0.00001 
HOMA-IR  
MT 9 96 88 -1.22 [-2.29, -0.15] † 0.02* χ² = 94.62, I² = 92%, P < 0.00001 
LT 3 38 33 -0.18 [-0.64, 0.27] † 0.6 χ² = 1.45, I² = 0%, P = 0.48 
Fasted 
glucose 
(mg/dL) 
ST 2 64 58 -3.39 [-6.90, 0.11] † 0.06 χ² = 1.66, I² = 40%, P = 0.2 
MT 33 499 485 -2.39 [-4.47, -0.31] † 0.02* χ² = 318.33, I² = 90%, P < 0.00001 
LT 7 135 136 -0.07 [-2.80, 2.67] † 0.96 χ² = 46.09, I² = 87%, P < 0.00001 
CRP (mg/L) 
ST 2 41 41 -0.43 [-1.05, 0.19] † 0.07 χ² =1.58, I² = 37%, P = 0.21 
MT 12 199 195 -0.28 [-0.72, 0.15] † 0.20 χ² = 44.57, I² = 75%, P < 0.00001 
* Indicates statistical significance. † Indicates favouring resistance training. ST – short term, MT – medium term, LT – long term, 
HDL-chol – high density lipoprotein cholesterol, LDL-chol – low density lipoprotein cholesterol, HOMA-IR – insulin resistance, CRP 
– C-reactive protein. 
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3.3.8 Adverse Events 
One hundred and twenty-three RCTs (71%) did not report the occurrence of 
adverse events. Fifty studies (29%) reported information on adverse events 
and 17 of these reported that no adverse events occurred. Of the 50 studies 
reporting adverse events, 16 studies reported more than one adverse event 
occurring. Musculoskeletal injuries (e.g. lower back pain, knee pain) as a result 
of the intervention were reported in 20 studies (n = 20/50; 40%), with more 
than one adverse event being reported in 15 of the 20 studies. Two studies 
(4%) detailed discomfort and muscle soreness related to RET. Illness or injury 
unrelated to RET were reported in seven (14%) studies. Three studies (6%) 
reported that participants suffered injuries but the details and whether they 
were related to the intervention, was unclear. Syncope, possibly related to the 
intervention, was reported in three studies (6%). Cardiac issues (e.g. 
myocardial infarction, angina) thought to be unrelated to the RET were 
reported in four (8%) studies. Respiratory problems, unrelated to the 
intervention, were reported in two (4%) and hypoglycaemia in a further two 
(4%) studies. Four studies (8%) identified participants who underwent elective 
surgery unrelated to the study. Five studies (10%) reported a newly diagnosed 
condition or change in medication. Other adverse events reported only once 
included death (car crash), cerebral stroke, abdominal hernia and deep vein 
thrombosis; these were not associated with RET. Personal or professional 
issues resulting in withdrawal from the programme were reported in 5 (10%) 
studies. 
 
3.4 Discussion 
3.4.1 Summary of Evidence  
Resistance exercise training had a positive impact on cardiometabolic health, 
via improvements in resting blood pressure, V̇O2Peak and blood biomarkers 
of cardiometabolic risk. These improvements were most convincing for 
medium-term (7-23 weeks) interventions, which is likely to reflect the higher 
volume of published studies compared to short- (< 6 weeks) and long-term ( 
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24 weeks) intervention durations. Relatively few studies have primarily 
investigated the cardiometabolic health benefits of RET in clinical populations, 
particularly those at elevated risk of cardiovascular events. There is limited 
evidence of adverse events associated with RET with only 12% of studies 
included in the review reporting musculoskeletal injuries. Other studies 
reported transient levels of muscle soreness following RET, which is common 
after unaccustomed muscular exercise (Cheung, Hume, & Maxwell, 2003; 
McHugh, 2003; Nosaka, Sakamoto, Newton, & Sacco, 2001). Therefore, we 
suggest that RET is a safe exercise option for both healthy and clinical 
populations. 
There was a positive effect of RET on systolic and diastolic blood pressure. 
The reductions observed are of similar magnitude to those after aerobic 
exercise interventions (Arora, Shenoy, & Sandhu, 2009; Collier et al., 2009; 
Fenkci, Sarsan, Rota, & Ardic, 2006; Yavari, 2012), and could suggest a dose-
response relationship for interventions of varying durations. Furthermore, 
given that hypertension is a global cause of mortality (World Health 
Organisation, 2009), the pronounced effects of RET on blood pressure 
outcomes in older populations observed in our subgroup analyses suggest that 
RET could be an effective non-pharmacological strategy for the prevention 
and/or control of hypertension in older adults who are at elevated 
cardiometabolic risk. 
The effect of RET on mean arterial pressure and resting heart rate was not 
statistically significant. Although resting heart rate may be less sensitive to 
change after RET, the lack of effect on mean arterial pressure (particularly for 
medium-term studies) could be due to few studies reporting mean arterial 
pressure in comparison to systolic or diastolic blood pressure. Additionally, 
diastolic blood pressure has a greater influence on mean arterial pressure than 
systolic blood pressure and, due to the less pronounced effect of RET on 
diastolic blood pressure, this could have impacted upon the significance of 
mean arterial pressure.  
Low cardiopulmonary fitness has an indirect effect on cardiovascular disease 
risk and is partially (40-60%) mediated by cardiovascular risk factors including 
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hypertension, hypercholesterolemia, obesity and fasting glucose (Erez, 2015). 
Therefore, the beneficial effects of RET on V̇O2Peak is important. Traditionally, 
RET has not been used to provide a stimulus for improving cardiopulmonary 
exercise capacity, however our findings suggest that RET may be a 
reasonable choice for improving this health outcome. Improvements in 
V̇O2Peak after RET were modest (short-term: 2.38 [0.76, 4.00] ml/kg/min; 
medium-term: 1.13 [0.50, 1.76] ml/kg/min; long-term: 1.23 [0.6, 1.87] 
ml/kg/min). However, larger effects were observed for older adults at elevated 
cardiometabolic risk. This is clinically important since it suggests that RET may 
contribute to reducing the risk of cardiovascular morbidity and mortality in high 
risk populations (Kavanagh et al., 2003). On the other hand, it is also possible 
that those who participated in RET also increased their participation in aerobic 
activity. Exercise training outside of RET interventions was generally not 
monitored and may account for some of the change in V̇O2Peak after RET.  
Endothelial dysfunction is associated with cardiovascular disease and the 
ageing process. Endothelial dysfunction is linked to a decrease in nitric oxide 
availability, which can be improved through exercise (Seals, 2011). A 
deterioration in flow-mediated dilatation of approximately 1% is associated with 
a 13% increased risk of future cardiovascular events (D. J. Green, Jones, 
Thijssen, Cable, & Atkinson, 2011; Inaba et al., 2010). We found 
improvements in endothelial function (flow-mediated dilatation) with RET 
programmes that lasted 7-23 weeks. This is likely to result from shear stress-
induced adaptations in nitric oxide metabolism resulting from muscular 
contractions, resting heart rate and blood pressure changes during RET (Vona 
et al., 2009). Shear-stress induced adaptations may not be restricted to blood 
vessels within the active skeletal muscles, as exercise programmes that are 
performed predominantly with the legs induce improvements in brachial artery 
flow-mediated dilatation (Birk et al., 2012). Therefore, RET may be an effective 
stimulus for improving flow-mediated dilatation, potentially reducing the risk of 
cardiometabolic disease. 
The most favourable changes in blood biomarkers were apparent in short- and 
medium-term studies in the pooled analysis. The lower number of longer-term 
studies may have reduced the level of statistical power required to detect 
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significant changes. We found greater reductions in low-density lipoprotein 
cholesterol, triglycerides and fasted glucose among older adults. There were 
also significant reductions in C-reactive protein after short- and medium-term 
RET among older adults at elevated cardiometabolic risk (Table 5 and 
Supplementary Table 7). Reductions in C-reactive protein, fasted glucose and 
insulin, and HOMA-IR could have been mediated by the effect of RET on body 
composition, including an increase in skeletal muscle mass and reduction in 
fat mass, and the resulting impact on adipokine secretion (De Salles, 2010; 
Libardi, De Souza, Cavaglieri, Madruga, & Chacon-Mikahil, 2012), insulin 
sensitivity (Sañudo et al., 2013) and glucose transport (Azarbayjani et al., 
2014; Williams, 2007). These improvements in metabolic functioning following 
RET could have important clinical implications for the prevention and treatment 
of metabolic syndrome, type 2 diabetes mellitus and cardiovascular disease 
(Donges, Duffield, & Drinkwater, 2010; Fenkci et al., 2006; Libardi et al., 2012; 
Wojtaszewski, 2006). 
Future studies on RET interventions should monitor or control for the potential 
confounding influence of aerobic exercise outside of the intervention. It is 
unclear whether improvements in V̇O2Peak after RET are more attributable to 
the cardiopulmonary stimulus of RET leading to improved oxygen transport 
(via increased cardiac stroke volume) or metabolic adaptations resulting in 
improved utilisation of oxygen at the level of skeletal muscle. Improvements in 
V̇O2Peak following medium- to long-term programmes of aerobic exercise 
training tend to be greater and mainly reflect an increase in cardiac stroke 
volume in previously untrained individuals (O’Connor et al., 2017; Saltin et al., 
1968). The relative importance of, and potential to maximise central, systemic 
and peripheral adaptations, by altering the characteristics of RET (e.g. sets, 
repetitions, rest etc.) warrants further research. Furthermore, additional high-
quality research is also required to formulate the optimal design of a RET 
programme to promote cardiovascular health and risk factor management in 
middle-aged and clinical populations. 
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3.4.2 Limitations  
The main findings of this systematic review need to be considered in the 
context of some key limitations, including restricting the search to two 
electronic databases, language bias and unexplained statistical heterogeneity 
for some of the analyses. Publication bias was also evident, and is probably 
attributable to inadequate data analysis, poor methodological quality and/or 
varying sample sizes of included studies. It is unlikely that selective outcome 
reporting influenced the funnel plots as 90.6% of the studies were rated as low 
risk for this outcome. Additionally, poor methodological quality of some of the 
included studies could have affected the estimates of the outcomes. Although 
all the included studies were RCTs, few studies adequately reported the 
randomisation process (n = 36), allocation concealment (n = 14), or blinding of 
outcome assessment (n = 27). Therefore, many studies were rated as unclear 
bias in multiple categories, and this may have contributed to the lack of 
reduction in heterogeneity in the sensitivity analyses. Additionally, some data 
were not pooled due to lack of access to the mean (SD) scores.  
Reporting must improve, as many studies had incomplete descriptions of RET 
programmes and progression, small sample sizes, inadequate documentation 
of adherence and lacked detail regarding the timing of blood sampling in 
relation to the last bout of exercise (potentially influencing circulating levels of 
blood biomarkers). Improved reporting of trials may also improve the quality of 
evidence, as all outcomes in this review were graded as either very low or low 
quality, and higher-quality reporting of outcomes may alter the effect 
estimates. Authors should follow guidelines when reporting trials such as the 
TIDieR checklist and guide (Hoffmann et al., 2014).  
Studies of varying duration are needed, as the majority included in our 
systematic review involved medium-term interventions. In addition, data 
analyses were often based only on participants who successfully completed 
the training intervention, rather than applying an intention to treat analysis. This 
could have altered the study results (Akl et al., 2012; S. P. T. Higgins, & Green, 
S., 2011). Finally, cardiorespiratory fitness levels of participants prior to a RET 
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intervention is likely to influence training-induced adaptations and this should 
be considered in future research.  
 
3.5 Conclusions  
This systematic review provides quantitative estimates of the effects of RET 
on indices of cardiometabolic health in adults. RET appears a safe mode of 
exercise in both healthy and clinical populations and effective for inducing 
improvements in resting blood pressure, FMD, HOMA-IR, fasted glucose and 
insulin. There are also improvements in V̇O2Peak, which are less pronounced 
than those reported after programmes of aerobic exercise training. Future 
studies should aim to provide a detailed overview of the RET programme and 
progression methods in order for the optimal design of a RET programme for 
optimising improvements in cardiometabolic health to be explored. In addition, 
future research should investigate the effects of RET on cardiovascular health 
and risk factor management in healthy older and older clinical populations (> 
50 years of age) both in a supervised and home-based setting and include 
long-term clinical end-points.   
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CHAPTER 4 
 
 
 
 
 
 
 
 
 
 
 
CROSS-SECTIONAL STUDY OF PATIENT-REPORTED 
FATIGUE, PHYSICAL ACTIVITY AND CARDIOVASCULAR 
STATUS IN MEN AFTER ROBOTIC-ASSISTED RADICAL 
PROSTATECTOMY  
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4.0 Cross-sectional study of patient-reported fatigue, 
physical activity and cardiovascular status in men after 
robotic-assisted radical prostatectomy  
 
4.1 Introduction 
Radical prostatectomy is an accepted curative treatment option for men with 
clinically localised significant prostate cancer with greater than 10 years life 
expectancy and the ability to perform activities of daily living (National Institute 
for Health and Care Excellence, 2014b). Robotic-assisted radical 
prostatectomy is now the most prevalent modality for surgical removal of the 
prostate for prostate cancer in the UK (Khadhouri et al., 2018).  
Robot-assisted radical prostatectomy has been demonstrated to be associated 
with lower blood loss and decreased hospital stay when compared to open 
radical prostatectomy (Djavan et al., 2010). Although commonly assumed that 
men undergoing radical prostatectomy are fit and return to their pre-operative 
physical activity levels after surgery, there is little published data to 
substantiate this assumption. Additionally, few studies performed to date have 
explored cancer-related fatigue after robot-assisted radical prostatectomy. The 
limited data suggests that fatigue, which is often limited by treatment modality, 
is evident in prostate cancer patients and it has previously been reported that 
approximately 14% of patients who have undergone radical prostatectomy 
experience fatigue (Köhler et al., 2014; Storey et al., 2012). Therefore, the 
prevalence of fatigue and post-operative physical fitness in men who have 
undergone robot-assisted radical prostatectomy is largely unknown. Fatigue in 
cancer patients and survivors has been associated with reduced physical 
activity levels (Blaney, Lowe-Strong, Rankin-Watt, Campbell, & Gracey, 2013), 
potentially adversely affecting cardiovascular risk profile and recovery to full 
functional fitness after robot-assisted radical prostatectomy.  
To our knowledge, no study has explored the association between self-
reported physical activity, fatigue and comorbidities in men who have 
undergone robot-assisted radical prostatectomy. The aim of this pilot study 
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was to characterise fatigue, physical activity levels and cardiovascular status, 
over a two-week period, in men after robot-assisted radical prostatectomy and 
compare this with those on ADT to establish whether this is a substantial 
problem which future intervention studies should address. 
 
4.2 Methods 
4.2.1 Design 
A cross-sectional questionnaire study was administered to men who had 
undergone robot-assisted radical prostatectomy and men treated with ADT for 
prostate cancer. Ethics approval was granted by Northumbria University Ethics 
Committee. Approval was then obtained (ref: 202404) from the Health 
Research Authority (Appendix 1a). Ethics approval from NHS REC South 
Scotland was obtained on 8th September 2016 (ref: 16/SS/0143; Appendix 1b) 
and further approved by NUTH Research and Development on 11th October 
2016 (ref: 7832; Appendix 1c). The study was conducted according to the 
Helsinki Declaration (1964; revised 2001). Data from the ADT cohort of men is 
presented as a comparative control population.  
This study was conducted at Newcastle upon Tyne Hospitals NHS Foundation 
Trust which is a tertiary referral centre serving a population of 1.2 million 
people. Robot-assisted radical prostatectomy was performed by three 
experienced surgeons at the institution over the study period. 
 
4.2.2 Participants 
Men were eligible to participate in the study if they: (1) had histologically 
confirmed prostate cancer; (2) were at least 8 weeks after their treatment for 
prostate cancer with either robot-assisted radical prostatectomy or after 
initiation of ADT, and; (3) were able to provide consent and satisfactorily 
complete written questionnaires. All eligible patients attending outpatient 
clinics were approached. Men receiving any other treatment for prostate 
cancer were excluded from the study.  
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4.2.3 Study Outcome Data 
Consenting men were asked to provide demographic information including 
current health status via a questionnaire, average weekly alcohol intake and 
smoking status. Stature and body mass were measured. They were then 
invited to complete a questionnaire booklet containing validated 
questionnaires prospectively over a two-week period (see further details 
below) and return the booklet in a prepaid stamp addressed envelope. 
Questionnaire score calculations were performed in accordance with 
published questionnaire protocols. Likewise, missing data were treated in 
accordance with the questionnaire protocols. The questionnaires included are 
detailed below. 
 
4.2.3.1 Comorbidity and Cardiovascular Status 
Charlson Comorbidity Index was calculated using information provided on 
stature, body mass and information from patients medical records (Charlson, 
Pompei, Ales, & MacKenzie, 1987; MDCalc, 2018). The risk of suffering a heart 
attack or stroke within the next 10 years was calculated using Q-Risk2 
(Hippisley-Cox et al., 2008). Q-Risk2 score is calculated from patient-reported 
family history and smoking status, along with information from the patients’ 
medical records such as age, gender, ethnicity, and selected physiological 
measurements (e.g. diabetes, angina, atrial fibrillation, blood pressure, 
cholesterol levels).  Q-Risk 2 can be categorised as < 10% (low), 10-20% 
(medium) or > 20% (high) (Coghill, Garside, Montgomery, Feder, & Horwood, 
2018). 
 
4.2.3.2 Scottish Physical Activity Questionnaire  
The Scottish Physical Activity Questionnaire (SPAQ) was completed at the end 
of both weeks as a recall questionnaire and has good reliability (Cronbach’s 
alpha = 0.998) (Lowther, Mutrie, Loughlan, & McFarlane, 1999). This 
questionnaire assesses moderate to vigorous physical activity (MVPA) over 
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the previous 7 days. The questionnaire includes sections for both leisure time 
and occupational physical activity with each section containing questions on 
general activity such as walking, stair climbing and manual labour (Lowther et 
al., 1999). The average weekly total MVPA (mins) was calculated in addition 
to the mean total for each individual exercise component. 
 
4.2.3.3 Brief Fatigue Inventory 
The Brief Fatigue Inventory (BFI) was completed at the end of each day for all 
14 days of the data collection period to rapidly assess fatigue in cancer patients 
and is correlated with other validated fatigue questionnaires (Ahlberg, Ekman, 
Gaston-Johansson, & Mock, 2003; Mendoza et al., 1999; Sternberg et al., 
2013) and has good reliability (Cronbach’s alpha = 0.95) (Mendoza et al., 
1999). The BFI consists of three questions assessing fatigue severity and six 
questions assessing the interference of fatigue with the patient's mood and 
social/physical functioning with all answers being on a 0-10 scale. A global 
fatigue score was obtained for weeks 1 and 2 by averaging all the items on the 
BFI and as an average of the whole 2-week period (Mendoza et al., 1999). 
Clinically significant fatigue was defined as a global fatigue score > 3 (Shafqat 
et al., 2005; Storey et al., 2012). 
 
4.2.3.4 Stage of Change Questionnaire 
The Stage of Change Questionnaire was administered once at the start of the 
two-week study period to assess patient’s attitudes towards exercise 
behaviour change and has acceptable reliability (Cronbach’s alpha = 0.63) (R. 
J. Donovan, Jones, Holman, & Corti, 1998) . Participants answered ‘yes’ or 
‘no’ to four statements to assess each individual’s stage of behaviour change 
(Blaney et al., 2013). The stages are categorised as follows: stage 1 – pre-
contemplation, stage 2 – contemplation, stage 3 – preparation, stage 4 - action 
and, stage 5 – maintenance. 
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4.2.4 Statistical Analysis 
All returned surveys were included in the analysis, even if some sections were 
incomplete. Consequently, the number of total responses for each survey item 
varied because of missing data. Analyses were conducted using IBM SPSS 
Statistics Version 22 (IBM United Kingdom Limited, Hampshire, United 
Kingdom). 
Normality was assessed using the Shapiro-Wilk test and if data was not 
normally distributed, transformations were conducted using common 
logarithms or square root. To assess the associations of the outcomes with 
self-reported total physical activity levels (SPAQ), Pearson correlations and 
Spearman’s rank were employed. Independent samples t-tests were used to 
examine differences between the two treatment groups with P < 0.05 chosen 
as the accepted level of significance. 
 
4.3 Results  
4.3.1 Participants 
In total, 148 men were approached to take part in the study and 96 men 
consented to participate in the study, of these 62/96 (65%) participants 
returned postal questionnaires. Table 6 illustrates the demographic of the 
cohort. The patients approached were on average 11.7 months after robot-
assisted radical prostatectomy and 22.1 months after the initiation of ADT. The 
robot-assisted radical prostatectomy cohort comprised 42/62 responses, of 
these 57% and 14% were classified as overweight and obese respectively.  
 
4.3.2 Cardiovascular Status 
Charlson Comorbidity Index calculations indicated there was no significant 
difference in estimated 10-year survival after robot-assisted radical 
prostatectomy (87.3% ± 12.2%) or ADT (80.5% ± 18.7%), t(27.2) = 1.5, P = 
0.2. Q-Risk2 scores indicated that there was no significant difference in 10 
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year risk of suffering a heart attack or stroke between men after radical 
prostatectomy (18.1% ± 7.4%) and after initiation of ADT (22.4% ± 10.8%), 
t(28.4) = -1.6, P = 0.12.  
 
Table 6. Participant demographics.  
 
 
4.3.3 Physical Activity  
The levels of reported total physical activity did not differ over the 2-week 
period between the two treatment groups (robot-assisted radical 
prostatectomy total average mins = 658.1 ± 337.6 verses ADT total average 
mins = 631.9 ± 318.5, t(59) = 0.3, P = 0.8). Age, body mass, BMI and BFI 
scores were not associated with the total amount of physical activity performed 
in either treatment group (Table 7). Approximately 50% of all physical activity 
 RARP 
(n = 42) 
ADT 
(n = 20) 
Age (years) 63.8 ± 6.4 67.3 ± 9.0 
Body Mass (kg) 86.7 ± 13.4 86.4 ± 12.3 
Stature (cm) 180 ± 0.07 176 ± 0.07 
Body Mass Index (kg/m2) 27.0 ± 3.9 27.8 ± 12.3 
Drink Alcohol n (%) 38 (90.5) 18 (80.0) 
Months since treatment mean (range) 11.7 (2-115) 22.1 (2-120) 
Pre-RARP PSA 10.05 ± 6.3 
 
Pathological Gleason Score (n)  
GS 6 2 
GS 3 + 4 25 
GS 4+ 3 7 
GS ≥8 8 
Pathological Tumour Stage (n)  
PT2 24 
PT3a 13 
PT3b 5 
Data are presented as mean ± standard deviation unless stated otherwise. 
RARP – robot-assisted radical prostatectomy, ADT – androgen deprivation 
therapy, PSA – prostate specific androgen. 
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reported in both groups involved walking (e.g. walking to the shops/work, stair 
walking). Activities included in the ‘other’ category included yoga (1/42 post-
radical prostatectomy, 1/20 ADT), bowls (1/42 post-radical prostatectomy) and 
rambling (2/42 post-radical prostatectomy, 1/20 ADT). A breakdown of the 
amount of physical activity undertaken is illustrated in Table 8.  
 
Table 7. Correlation matrix between physical activity and demographic factors, 
stage of change and fatigue. 
 
 
Table 8. Self-reported MVPA over the 2-week period. 
 
Physical Activityª 
RARP ADT 
Age -0.1 -0.14 
Body Mass -0.02 -0.31 
Body Mass Index 0.1 -0.09 
Stage of Change 0.36 b 0.15 
Brief Fatigue Inventory -0.09 0.09 
ªTotal physical activity in minutes averaged over the two-week study 
period. 
b Spearman’s Rank correlation is significant at the 0.05 level. 
RARP - robot-assisted radical prostatectomy; ADT – androgen deprivation 
therapy 
 RARP ADT 
Total (mins) 658.1 ± 337.6 631.9 ± 318.5 
Walking (mins) 341.4 ± 245.5 319.5 ± 251.4 
Manual labour (mins) 125.4 ± 168.3 92.3 ± 158.2 
Active housework (mins) 57.6 ± 79.6 82.4 ± 89.4  
Dancing (mins) 3.2 ± 11.3 0.63 ± 2.8 
Sport/Leisure activities (mins) 92.3 ± 178.5 126.4 ± 209.4 
Other activities (mins) 40.4 ± 100.2 6.3 ± 22.3 
Data are presented as mean ± standard deviation. 
Two RARP participants did not provide physical activity data for week 1 or 
week 2.  
RARP - robot-assisted radical prostatectomy; ADT – androgen deprivation 
therapy 
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4.3.4 Fatigue 
All participants were experiencing fatigue over the two-week study period, the 
majority of fatigue reported was mild-moderate in severity and of borderline 
clinical significance. The mean severity of fatigue was significantly less over 
the two-week study period in the robot-assisted radical prostatectomy (1.6 ± 
1.7) than in the ADT group (2.6 ± 1.8), t(60) = -2.628, P = 0.011 (Figure 7). In 
addition, 9/42 (21.4%) participants post-radical prostatectomy and, 6/20 (30%) 
ADT participants, reported clinically significant fatigue. There was no 
association between fatigue and the amount of self-reported physical activity 
(Table 7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Reported fatigue severity over a 2-week period. RARP - robot-
assisted radical prostatectomy; ADT – androgen deprivation therapy.  
* represents statistical significance (P < 0.05) 
 
 
* 
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4.3.5 Stage of Change 
The majority of participants in both treatment groups reported being in the 
maintenance stage of change (Table 9). The maintenance phase is where 
individuals have made specific modifications to their exercise behaviour, 
however, it requires a conscious effort to maintain it. The stage of change 
outcomes positively correlated with the amount of physical activity undertaken 
in the robot-assisted radical prostatectomy treatment group, this is shown in 
Table 9. 
 
Table 9. Stage of change scores for both treatment groups.  
 
 
 
 
 
 
 
 
 
4.4 Discussion 
This is the first study to our knowledge to quantitatively explore cardiovascular 
risk, fatigue and physical activity, in men who have undergone robot-assisted 
radical prostatectomy as a prostate cancer treatment. This study found that a 
significant proportion of men post-radical prostatectomy are at an increased 
risk of suffering a cardiovascular related event within 10-15 years of their 
surgery and > 20% may suffer from clinically significant fatigue. Importantly 
this study suggested that these findings were present in men appearing to 
meet the UK public health guidance of undertaking at least 150 minutes a week 
of moderate to vigorous aerobic physical activity.   
Stage of change  
(number of patients) 
RARP 
(n = 42) 
ADT  
(n = 20) 
Stage 1 - Pre-contemplation 0 0 
Stage 2 - Contemplation 1 3 
Stage 3 - Preparation 0 1 
Stage 4 - Action 5 3 
Stage 5 - Maintenance 36 13 
RARP - robot-assisted radical prostatectomy; ADT – androgen 
deprivation therapy. 
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The present study identified that the Q-Risk2 score of the robot-assisted 
radical prostatectomy cohort indicated that they were at an 18% risk of 
suffering a heart attack or stroke within the next 10 years. Whilst 
cardiovascular risk status has been studied extensively in patients receiving 
ADT (Gilbert, Tew, Bourke, Winter, & Rosario, 2013; Keating, 2017; Voog et 
al., 2016; Wallis et al., 2016), there are no studies as far as the authors are 
aware to date which have characterised the cardiovascular risk status of robot-
assisted radical prostatectomy patients. The largest most contemporary study 
by Wilt et al. (2012), which gives a signal as to mortality risk from causes other 
than prostate cancer in a radical prostatectomy population. During a median 
follow-up period of 10 years, 171/281 of the radical prostatectomy group died 
and of these deaths 74% (127/171) were not due to prostate cancer (Wilt et 
al., 2012). Whilst it cannot be inferred that cardiovascular disease was the 
cause of all of these deaths due to other factors such as old age, this analysis 
combined with the findings from this study indicate potentially more can be 
done to improve the health of patients undergoing radical prostatectomy. The 
Q-Risk2 calculator predicts fatal and non-fatal cardiovascular disease, such as 
myocardial infarction, coronary heart disease, stroke and transient ischaemic 
attacks. The results of this study showed that our robot-assisted radical 
prostatectomy cohort were at a 3% elevated risk of cardiovascular disease 
when compared to moderately active males of a similar age (West, 2015). This 
finding, were it to be replicated in future larger-scale cohorts, supports the view 
that men after robot-assisted radical prostatectomy men should be offered 
lifestyle interventions to improve their cardiovascular health. 
Cancer-related fatigue has previously been reported as a side effect of 
prostate cancer treatment in up to 80% of men (Luo et al., 2016; Segal et al., 
2009; Stone et al., 2000; Taaffe et al., 2017). Few studies have investigated 
levels of fatigue in men who have exclusively undergone robot-assisted radical 
prostatectomy for prostate cancer however much work has been conducted in 
men receiving ADT and radiotherapy. Storey et al. (2012) performed a cross-
sectional questionnaire study in 2005 of recurrence free survivors who had 
undergone open radical prostatectomy utilising the BFI. Clinically relevant 
fatigue was identified in 22% (29/133) of men undergoing radical 
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prostatectomy, whereas in their control non-cancer population the incidence of 
clinically relevant fatigue was 16% (10/63) at a median follow up of 56 months 
after treatment. Within their radical prostatectomy cohort median age 72, 
coexisting depression had the strongest independent association with fatigue. 
Storey et al. (2012) did not examine physical activity levels within their cohort. 
Cancer-related fatigue has been acknowledged to be debilitating and to 
significantly impact on quality of life (Berger et al., 2015). We have shown that 
after robot-assisted radical prostatectomy in a contemporary younger 
population, similar to Storey et al. clinically relevant fatigue is reported by 20% 
of men at a mean follow up of 11.7 months.  This finding might be considered 
unexpected and highlights that post-treatment fatigue should be discussed 
with patients when they are counselled for robot-assisted radical 
prostatectomy. All patients included in this study underwent holistic needs 
assessment after treatment and received targeted support if required as part 
of routine care from a survivorship nurse specialist (J. J. Aning et al., 2018; 
Ferguson & Aning, 2015). It has previously been demonstrated that patients 
who undergo robot-assisted radical prostatectomy experience an unchanged 
overall quality of life (J. J. Aning et al., 2018). Therefore, it is possible that 
within our cohort the levels of clinically relevant fatigue identified are unlikely 
to result from psychological factors. 
This study found patient reported levels of physical activity after robot-assisted 
radical prostatectomy which met current UK public health guidelines within the 
robot-assisted radical prostatectomy cohort despite a high proportion of our 
patients having a high body mass index. We demonstrated that physical 
activity levels did not correlate with fatigue levels in our cohort suggesting that 
fatigue levels may not be a barrier to the amount of physical activity undertaken 
within this population. Although public health guideline levels of aerobic 
physical activity were met, we identified that after robot-assisted radical 
prostatectomy, patients did not achieve the recommended weekly amount of 
resistance exercise (Department of Health, 2011). None of the patients who 
took part in this study reported completing any resistance-based exercise. This 
important finding highlights a potential area of unmet need in the post-radical 
prostatectomy population. Resistance exercise has previously been examined 
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in other prostate cancer treatment groups, both epidemiologically and during 
interventional studies which found resistance exercise to be safe in the 
population, it can assist in mitigating fatigue and generated longer-term 
improvements in quality of life, strength, triglycerides, and body fat when 
compared to aerobic exercise (Cormie et al., 2013; Segal et al., 2003; Segal 
et al., 2009). As far as we are aware, this is the first time an examination of 
physical activity sub-classifications has been undertaken in a contemporary 
population of men who have undergone robot-assisted radical prostatectomy. 
The potential benefits of resistance exercise in relation to cardiometabolic risk 
profile were highlighted in a recent meta-analysis (Ashton et al., 2018). 
Although loss of skeletal muscle mass has been widely reported in prostate 
cancer patients undergoing ADT (Galvao et al., 2009; Owen et al., 2017; 
Winters-Stone, Dieckmann, et al., 2015) and many studies have investigated 
the impact of resistance exercise training programmes (Hasenoehrl et al., 
2015; Segal et al., 2003; Winters-Stone, Dieckmann, et al., 2015), much fewer 
studies have assessed changes in skeletal muscle characteristics after robot-
assisted radical prostatectomy. There is a need for future research to address 
this evidence gap and extending the provision of structured exercise 
interventions (including resistance exercise) to this population may be 
warranted. Such interventions could have a positive impact on fatigue in men 
recovering from robot-assisted radical prostatectomy, as demonstrated 
previously in fatigued prostate cancer patients receiving ADT (Taaffe et al., 
2017).  
This study’s findings add quantitative depth to recent qualitative work 
performed by Sutton et al. (2017) and Hackshaw-McGeagh et al. (2017) 
identifying patients’ priorities. These studies showed that men undergoing 
robot-assisted radical prostatectomy would value physical activity and dietary 
advice from their healthcare professional and would prefer to receive this at an 
early stage. In addition, they provided evidence that men undergoing robot-
assisted radical prostatectomy are willing to change their behaviour to improve 
their health, but they wish to be supported by their healthcare professional 
team to do so. The cohort of men in this study reported being in the 
maintenance phase derived from the stage of change questionnaire. This 
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demonstrates that they are aware that they are physically active and do not 
believe that they should be altering their current exercise regime. However, it 
is evident from the SPAQ that all patients within this cohort do not meet the 
UK guidelines for resistance-based exercise. Undergoing radical 
prostatectomy is potentially a ‘teachable moment’ to change exercise 
behaviour and we have demonstrated that this population is at risk of both 
cardiovascular events and fatigue. Qualitative research shows men are 
receptive to health behaviour change (Er et al., 2017; Hackshaw-McGeagh et 
al., 2017; Sutton et al., 2017) and such initiatives targeted at this population 
could have much potential to improve men’s overall health. This study supports 
consideration of further targeted research into strategies aimed at improving 
the health of men who have undergone robot-assisted radical prostatectomy. 
Feasibility to recruit patients and compliance with completing study 
questionnaires has been demonstrated, in addition to the ability to discriminate 
the health status and behaviours of the robot-assisted radical prostatectomy 
population.  
 
4.4.1 Limitations 
The present study has limitations. Whilst the patient reported questionnaire 
data showed that men appeared to meet UK guidance for aerobic physical 
activity levels, it is possible that poor accuracy of self-reported physical activity 
lead to an overestimation of the total amount and therefore there may be an 
opportunity to use activity trackers in parallel to the questionnaires to verify the 
findings of future studies. Additionally, the SPAQ does not allow for the 
separation of exercise at varying intensities and therefore potential over 
reporting of the amount of MVPA may have occured. For example, within the 
walking category some low-intensity physical activity may have been included 
despite the instructions stating otherwise. We believe that our findings would 
justify the inclusion of activity trackers used in parallel with patient-reported 
activity questionnaires in future study protocols to strengthen validity of such 
activity outcome results. The numbers included in this study were small 
meaning caution is needed when interpreting the results. However, this study 
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has identified the need for further research in this population of men and 
informed the sample size calculation required for further work in this area. In 
order to conduct a fully powered study using the reported fatigue effect size 
from this pilot study (Cohen’s d = 0.57) the minimum total sample size to 
achieve 80% power (α = 0.05) was determined as n = 100 patients (50 patients 
in each group). This would allow more precise estimates of fatigue prevalence 
as well as cardiometabolic risk and physical activity levels between the two 
groups to be detected (Cohen, 1977).  
 
4.5 Conclusion 
This study has shown that some men after robot-assisted radical 
prostatectomy are at increased risk of clinically significant consequences from 
cardiovascular disease within ten years of their surgery and do suffer with 
clinically significant levels of fatigue. Clinicians should consider including these 
factors in the discussion when counselling patients about robot-assisted 
radical prostatectomy. Additionally, this study has revealed that men after 
robot-assisted radical prostatectomy appear to meet the recommended 
guidelines for aerobic physical activity but do not meet them for resistance-
based exercise. Future research is needed to establish whether exercise 
interventions can improve health and fatigue levels in this population.  
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
 
 
INTERVENTION DEVELOPMENT 
  
85 
 
5.0 Intervention Development 
5.1 Introduction 
Patients who have been treated for prostate cancer are advised to be regularly 
active and undertake exercise however, there are no published guidelines for 
this within the United Kingdom despite a recommendation by NICE (National 
Institute for Health and Care Excellence, 2013). In order to develop an exercise 
programme that will benefit prostate cancer patients it is important to involve 
patients in the design of the intervention and in the feedback process (Bagley 
et al., 2016). Recently, patient and public involvement (PPI) has become an 
integral part of health care research ensuring that research is relevant, drawing 
on real-life experiences of patients  to inform every aspect of a project, from 
identification of the question to design, implementation and dissemination 
allowing researchers to understand what matters to prostate cancer patients 
(Gamble et al., 2014). PPI allows research to be developed with valuable 
insight into the best strategies to optimise patient health and experience 
(McKirdy, 2015).  
The role of physical activity in symptom management, reducing risk of 
reoccurrence and improving quality of life for cancer patients has been a 
growing topic of investigation in recent years. ACSM recommend that adults 
having received cancer treatment should complete aerobic exercise on 3-5 
days a week, resistance exercise 2-3 days a week and flexibility daily (Riebe 
et al., 2017). Although resistance exercise training is advised in conjunction 
with aerobic exercise, it is evident from the previous chapter that aerobic 
exercise is completed regularly with limited resistance exercise activities are 
undertaken in prostate cancer patients who have received either robot-
assisted radical prostatectomy or ADT. Resistance exercise has recently been 
demonstrated to be a safe mode of exercise for clinical populations with limited 
evidence of adverse events (Ashton et al., 2018). By increasing the amount of 
resistance exercise within this population it is possible to improve 
cardiometabolic risk factor profile, lower the risk of all-cause mortality and CVD 
events and improve the patient reported outcomes (Ashton et al., 2018; Garber 
et al., 2011). 
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Traditionally, resistance exercise has been used to improve muscular strength, 
mass and endurance with extensive research being conducted in this area. 
However, due to an increase in body fat, decrease in lean mass, perceived 
poor body image and a reduction in V̇O2Peak in the weeks post-surgery it is 
important that any exercise programme provided to this population also targets 
these issues (Institute of Medicine National Research Council, 2006; Schmitz, 
2010). Previous studies in prostate cancer patients have focused on quality of 
life, upper and lower body strength, and fatigue as the primary outcomes 
(Galvao et al., 2006; Norris et al., 2015; Santa Mina, Alibhai, et al., 2013; Segal 
et al., 2009; Winters-Stone, Dobek, et al., 2015) with few directly investigating 
cardiometabolic health, although several have reported cardiometabolic 
variables as secondary outcomes. It is possible for resistance exercise training 
to be manipulated to improve V̇O2Peak and cardiometabolic health whilst 
simultaneously achieving improvements in muscle strength. It has been 
suggested that resistance exercise performed in a circuit, with minimal rest 
between exercises, can maintain an elevated heart rate and improve V̇O2Peak 
whilst improving strength, body composition and cardiometabolic health 
(Ashton et al., 2018; Antonio Paoli et al., 2013; Romero-Arenas et al., 2013; 
Schmitz, 2010; Wilmore et al., 1978).  
Furthermore, previous studies in prostate cancer patients have involved either 
lifestyle interventions and/or supervised exercise (Bourke et al., 2011; Cormie 
et al., 2015; Owen et al., 2017; Taaffe et al., 2017; Winters-Stone, Dieckmann, 
et al., 2015), and whilst these programmes have shown that structured, class-
based exercise interventions are effective in improving physical fitness and 
health outcomes, they are often expensive to implement and sustain over the 
longer term (K. L. Fisher et al., 2017). Barriers also exist to participation in 
exercise interventions for older adults including cost, lack of transportation, or 
disinterest in structured, group-based exercise (K. L. Fisher et al., 2017). 
However, it has previously been suggested that home-based exercise 
programmes that promote self-managed exercise have the potential to 
improve exercise behaviour at a lower cost whilst being more convenient for 
the patient (G. A. Tew et al., 2015). Therefore, the aim of this chapter is to 
conduct intervention development sessions with robot-assisted radical 
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prostatectomy and ADT patients to develop and refine exercises that will be 
combined to form a home-based resistance training programme that optimises 
cardiovascular and cardiopulmonary health.  
 
5.2 Methods 
This section describes the development of the home-based resistance 
exercise intervention. Ethics approval was granted by Northumbria University 
Ethics Committee. Approval was then obtained (ref: 202404) from the Health 
Research Authority (Appendix 1a). Ethics approval from NHS REC South 
Scotland was obtained on 8th September 2016 (ref: 16/SS/0143; Appendix 1b) 
and further approved by NUTH Research and Development on 11th October 
2016 (ref: 7832; Appendix 1c). The study was conducted according to the 
Helsinki Declaration (1964; revised 2001). 
 
5.2.1 Patient and Public Involvement 
An initial patient and public involvement session at a local Prostate Cancer 
Support Group was attended. The session involved providing patients with an 
overview of the proposed trial and gaining their feedback on initial ideas 
surrounding research design, recruitment strategies, and suitable outcome 
measures. Twenty-eight prostate cancer patients at varying stages of different 
treatments were present along with a Consultant Surgeon and Nurse 
Specialist. 
 
5.2.2 Design 
To inform the development of the exercise intervention, intervention 
development sessions were conducted, a full description of which is presented 
in section 5.2.6. The intervention was developed over three sessions 
separated by a period of 1-2 weeks. All sessions took place in a designated 
room at The Freeman Hospital. The first two sessions began with discussion 
regarding current exercise levels, type of exercise currently undertaken and 
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opinions of exercise. Exercises were then performed with feedback provided 
during and at the end of the session. The full discussion schedule is available 
in Appendix 3a. A medical professional was present for both sessions. The 
third session allowed participants to provide feedback on the developed 
intervention and exercise manual. 
 
5.2.3 Participants 
The patients were identified from NUTH outpatient clinics. A Consultant 
Urological Surgeon or Prostate Cancer Specialist Nurse initially approached 
all participants before the researcher. Thirteen prostate cancer patients, 
treated via either surgery or ADT, were recruited to the study. All participants 
were informed of the design, requirements and possible risks of the study after 
which they provided informed consent. All participants were free to withdraw 
from the study at any time.  
 
5.2.4 Eligibility Criteria 
Patients were recruited if they had: (1) histologically-confirmed prostate 
cancer, (2) treated history of treatment for prostate cancer through robot-
assisted radical prostatectomy or ADT, (3) the ability to provide written 
informed consent and, (4) the ability to communicate to a group to provide 
feedback on the resistance exercise intervention. Patients were excluded from 
the study if they were receiving any other treatment for prostate cancer or 
participating in another clinical trial where concurrent participation was 
deemed inappropriate. 
 
5.2.5 Physical Activity Levels 
Over a 2-week period, participants completed the SPAQ at the end of each 
week as a recall questionnaire. The SPAQ has good reliability (Cronbach’s 
alpha = 0.998) (Lowther et al., 1999) and is used to assess MVPA over the 
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previous 7 days. The questionnaire includes sections for both leisure time and 
occupational physical activity, with each section containing questions on 
general activity such as walking, stair climbing and manual labour (Lowther et 
al., 1999). The mean total MVPA was calculated in addition to the mean total 
for each individual component. 
 
5.2.6 Intervention Development Session 
In sessions 1 and 2 the participants were then taken through a series of 
resistance exercises using Thera-bands (Table 10) with the researcher 
ensuring correct technique and providing teaching points for each exercise. 
The exercises were a combination of single- and multi-joint exercises to proke 
a strong cardiovascular stimulus whilst being acceptable for patients to 
perform. Participants were provided with heart rate monitors (Polar O.Y., 
Finland) to wear for the duration of the exercises. Ratings of perceived exertion 
(RPE) were measured using the OMNI-RES scale to assess the effort of 
participants during the exercises. After completing the exercises, the 
participants had the opportunity to provide feedback on the exercises, how 
they could be transferred into the home environment, the intervention as a 
whole and how they would feel about being prescribed such an intervention as 
part of their treatment. Once the intervention had been developed, a group of 
patients were invited back to the Freeman Hospital for session 3 to provide 
feedback on the developed exercise manual and the resistance training 
intervention. All intervention development sessions were audio-recorded using 
a Dictaphone.  
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Table 10. Exercises completed during sessions 1 and 2.  
Session 1 Session 2 
Wide stance squat Wide stance squat 
Lunge Singles leg press 
Reverse abdominal curl Abdominal curl 
Chest press Chest press 
Bicep curl Bicep curl 
Reverse flies Bent over row 
Upright row Lateral raise 
Elbow kick back Elbow extension 
  
5.2.6 Analysis 
Verbatim transcription was conducted by a medical secretary and checked by 
the researcher. The general inductive thematic analysis approach was used to 
identify themes in the text data relating to the study objectives (Cooper, 2012; 
Thomas, 2006). Once familiarised with the data, initial codes were generated 
in which themes arose from. The following themes were derived from the 
transcripts: (1) current exercise and perceptions of resistance exercise, (2) 
motivation for exercise and, (3) resistance exercise programme structure. 
 
5.3 Results and Discussion 
5.3.1 Participants 
A total of 13 participants (6 robot-assisted radical prostatectomy and 7 ADT) 
with a mean age of 63.4 ± 8.8 years (body mass 84.6 ± 12.5 kg) took part in 
the development sessions. All participants had all received treatment for 
prostate cancer within the previous 18 months. 
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5.3.2 Patient and Public Involvement 
Patient and public involvement within health research has steadily grown 
worldwide over the last few decades (Pii, Schou, Piil, & Jarden, 2019). As a 
result, INVOLVE was established in 1996 with the aim of advancing patient 
involvement in research. Patient and public involvement helps to make 
research projects more relevant, improve the patient research experience and 
to help define what is acceptable to potential participants (INVOLVE, 2016). In 
cancer research, patient and public involvement ensures that research to 
improve medicines, technologies, treatment and care corresponds with the 
needs and priorities of those affected by cancer.  
Initial patient and public involvement sessions were conducted with a group of 
prostate cancer pateints prior to the ethics application for this project. These 
early sessions allowed patients to provide input on the design of the project for 
example, length of intervention, frequency of testing sessions and type 
questionnaires used. Additionally the sessions highlighted patient concerns 
surrounding safety of maximal exercise testing after surgery and the relevance 
of maximal exercise in their daily lives. Unlike maximal testing, submaximal 
testing does not require medical supervision however does result in less 
accurate assessment of cardiopulmonary exercise capacity. As a result of the 
patient feedback, the protocol was changed to encorporate submaximal testing 
of strength and aerobic capacity. Furthermore, a patient representative was 
appointed who was consulted on all aspects of the project and any 
amendments made to the relevant ethics committees.  
 
5.3.3 Current Exercise and Perceptions of Resistance Exercise  
All participants reported being active on a weekly basis and this is evident from 
the SPAQ data (Table 11).  
 
 
92 
 
Table 11. Reported physical activity levels over a 2-week period using the 
SPAQ.  
 Average Minutes 
Total MVPA 651.7 ± 205.5 
Walking 309 ± 182.6 
Manual labour 113.2 ± 145.8 
Active housework 56.4 ± 80.1 
Dancing 0 ± 0 
Sport/Leisure activities 149.9 ± 219.8 
Other activities 23.2 ± 59.4 
All data presented as mean ± SD. 
MVPA – moderate to vigorous physical activity 
 
 
The most common sport/leisure activities reported included walking football, 
cycling and tennis. All participants reported that post-treatment they tried to 
increase the amount of walking they were completing on a daily basis however 
one participant commented on how tiring increasing walking mileage had been 
for him: 
“I was in agony… I don’t think I have to come to terms that I can’t do as much 
as I used to” (Participant 3, age 74 years) 
Another participant talked briefly about the barriers to exercise and stated 
that: 
“I hibernate during the winter” (Participant 1, age 60 years) 
Weather is a commonly reported barrier to exercise with it being reported in 
both colorectal and breast cancer patients (Courneya et al., 2005; L. Q. 
Rogers, Courneya, Shah, Dunnington, & Hopkins-Price, 2007; Laura Q. 
Rogers et al., 2006). In a previous study primarily examining the barriers to 
exercise, approximately 35% of prostate cancer patients reported bad weather 
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as a barrier to exercise behind being ‘too busy’ and ‘having no willpower’, 
therefore this finding is not surprising (Ottenbacher et al., 2011). These 
barriers may help in the development of future trials with potentially more 
home-based exercise interventions used to try to alleviate the effects of bad 
weather and being too busy as barriers to exercise participation.  
The participants were questioned by the researcher on their perceptions of 
resistance exercise and provided the following responses: 
“I tend to avoid weight training as I don’t really want to build muscle, but I 
believe now that it is potentially beneficial” (Participant 2, age 67 years) 
“I thought cardiovascular exercise I thought was more beneficial… didn’t 
realise resistance exercise could help burn fat” (Participant 2, age 67 years) 
“The exercise man at Maggie’s, because I tend to go to that on a Tuesday, told 
me that if you do more reps and a lighter weight it will help burn fat but less 
reps and a harder weight will build muscle, I don’t know if that is right?” 
(Participant 4, age 57 years) 
Such responses suggest a lack of understanding surrounding resistance 
exercise and its potential benefits. This could be due to a lack of information 
on this mode of exercise provided by health care professionals at the point of 
diagnosis and treatment (Smaradottir, Smith, Borgert, & Oettel, 2017). It is 
unknown how much exercise guidance is currently provided to patients by 
clinicians however a UK-based study by Daley and colleagues reported that 
approximately 56% of oncologists and surgeons did not routinely discuss 
exercise with their patients (Daley, Bowden, Rea, Billingham, & Carmicheal, 
2008). Additionally it has been stated that 58% of nurses are unaware of 
research surrounding exercise training for cancer rehabilitation and 33% 
reported receiving no training relating to exercise and health for cancer 
patients (Stevinson & Fox, 2005). Furthermore, only 31% of colorectal cancer 
patients could recall being provided with exercise advice during consultations 
(A. Fisher, Williams, Beeken, & Wardle, 2015). Despite this, exercise has been 
shown to be safe for cancer patients to perform over the course of the cancer 
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continuum and could improve the outcomes for some cancer survivors (A. 
Fisher et al., 2015; Institute of Medicine National Research Council, 2006). 
 
5.3.4 Motivation for Exercise 
All participants discussed the difficulties of exercising in the home and the self-
motivation required with one participant stating: 
“I used to run a lot… the hardest thing to do was to put my shoes on. Once 
you’ve got your shoes and your kit on, you’re out there then, doing it is not a 
problem, it’s just switching your mind on to do it basically. Making the time and 
do it when you decide to do it.” (Participant 1, age 60 years) 
Research into exercise adherence and motivation has previously been mixed 
in cancer populations. Some studies suggest that the strongest correlates of 
exercise adherence among women treated for breast cancer are not 
demographic, socioeconomic, or medical variables but rather social and 
cognitive variables such as attitudes, perceived behavioural control and 
subjective norms (Jones & Courneya, 2002; Ottenbacher et al., 2011). 
Courneya et al. (Courneya et al., 2008) argue that such social and cognitive 
variables are not predictors of exercise adherence and suggest that patients 
who enrol in exercise interventions are already motivated to engage in 
exercise, an observation reflected by the fact that although adherence to 
exercise trials is high, uptake into these trials is generally low (Courneya et al., 
2008; Maddocks, Mockett, & Wilcock, 2009). Knowledge of these barriers to 
exercise participation has been suggested to aid the optimal design of targeted 
physical activity interventions among prostate cancer survivors and should 
result in long-term exercise adherence within the population (Gho, Munro, 
Jones, & Steele, 2014; Ottenbacher et al., 2011). 
The researcher asked participants how the study could be designed in order 
to improve patient motivation and improve adherence to the exercise 
intervention. One participant responded with: 
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“Tick box, so when I’ve done the exercises, I know I’ve done them. So, if I 
haven’t done the exercises, I feel guilty” (Participant 7, age 60 years) 
Another participant suggested having some information surrounding goal 
setting within the exercise manual as it: 
“Keeps you focused, gives you a target” (Participant 6, age 57 years) 
After some discussion between the researcher and participants, it was 
concluded that a goal setting page should be included in the final exercise 
manual along with an exercise diary to allow patients to monitor their 
progression. It has been reported that tasks such as goal setting and self-
monitoring alongside some support increases adherence to exercise 
interventions and promotes long-term physical activity (Chao, Foy, & Farmer). 
Support would be given to patients in the exercise group in the form of a weekly 
telephone call. This would allow the researcher to monitor their progression 
and provide encouragement through the intervention alongside providing 
patients the opportunity to discuss any problems and barriers to maintaining 
the adherence to the intervention (Chao et al.; Room, Hannink, Dawes, & 
Barker, 2017).  
 
5.3.5 Resistance Exercise Programme Structure 
Exercise selection for the sessions was based on some of the resistance 
exercise interventions used in previous studies (Table 12). The ability for the 
exercises to be performed using Therabands within the home environment 
with minimal equipment also influenced the exercises selected.  
Discussion regarding the structure of the exercise intervention took place in 
both sessions 1 and 2. Whilst performing the exercises participants wore heart 
rate monitors which were checked by the researcher at multiple intervals. The 
exercises elicited heart rates between 100 bpm and 130 bpm, equating to 40-
70% heart rate reserve, for all participants but varied between the age of the 
participants and the different exercises. ACSM (Riebe et al., 2017) 
recommends beginning exercise interventions at heart rates between 40-60% 
96 
 
heart rate reserve for overweight individuals to assist with fat loss. Participants 
commented on what exercises they found difficult to perform: 
“The one where you did the lunge forward (Figure 8) I really struggle with that… 
I really struggle with balancing for that. The one where you sit down and push 
the leg out, I found it much easier.” (Participant 2, age 67 years) 
Another participant who reported existing back pain and mobility issues 
commented that: 
“The lower abdominal crunch (Figure 9) was hard for me… Truck curl (Figure 
10) up was easier” (Participant 10, age 71 years) 
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Table 12. A selection of studies employing resistance exercise interventions 
in prostate cancer patients. 
Paper 
Resistance Exercise 
Intervention 
Exercises 
Cormie et al. 
(2015) 
12 weeks 
2 days/week 
1-4 sets, 6–12 
Repetition 
Maximum (RM) 
60–85% of 1RM 
Leg press, leg extension, leg curl, 
calf raise, chest press, latissimus 
pull-down, biceps curl and triceps 
extension 
Courneya et al. 
(2004) 
12 weeks 
3 days/week 
2 sets, 8-12 reps 
60-70% 1RM 
Leg extension, leg curl, calf 
raises, chest press, latissimus 
pull-down, overhead press, 
triceps extension, biceps curls, 
and modified curl-ups 
Galvao et al. 
(2006) 
20 weeks 
2 days/week 
2-4 sets, 6-12 RM 
Chest press, seated row, 
shoulder press, latissimus pull-
down, triceps extension, biceps 
curl, leg press, squat, leg 
extension, leg curl, abdominal 
crunch and back extension 
Galvao et al. 
(2009) 
24 weeks 
2 days/week 
2-4 sets, 6-12 RM 
Chest press, seated row, 
shoulder press, leg press, leg 
extension, leg curl and 
abdominal crunches 
Norris et al. 
(2015) 
12 weeks 
3 days/week 
2 sets, 8-12 reps 
60-80% 1RM 
Chest press, leg press, 
latissimus pull-down, leg curl, 
shoulder press and leg 
extension 
Santa Mina, 
Alibhai, et al. 
(2013) 
24 weeks 
3-5 days/week 
2-3 sets, 8-12 reps 
60-80% 1RM 
Ball squats, hamstring curls, 
push-ups, upright rows, triceps 
extensions, bicep curls, seated 
row, lateral raises, ball 
abdominal crunches and hip 
extensions 
Segal et al. 
(2003) 
12 weeks 
3 days/week  
2 sets, 8-12 reps 
60–70% of 1RM 
Leg extension, calf raises, leg 
curl, chest press, latissimus pull-
down, overhead press, triceps 
extension, biceps curls, and 
modified curl-ups 
Segal et al. 
(2009) 
24 weeks 
3 days/week  
2 sets, 8-12 reps 
60–70% of 1RM 
Leg extension, leg curl, seated 
chest fly, latissimus pull-down, 
overhead press, triceps 
extension, biceps curls, calf 
raises, low back extension, and 
modified curl-ups 
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Figure 8. Lunge performed with a Theraband. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Lower abdominal crunch performed with a Theraband (A) starting 
position, (B) end position. 
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Figure 10. Truck curl up performed with a Theraband (A) starting position, 
(B) end position. 
 
As a result of this feedback it was decided by the research team that both 
balance and back pain could be common issues in the age group to be studies 
in the main trial. Due to this, the lunge was excluded, and a standing abdominal 
exercise was included.  
The structure was based on ACSM guidelines for cancer survivors alongside 
the design of the studies mentioned in Table 12. The ACSM recommends that 
cancer survivors after surgery should be allowed adequate time to heal before 
undertaking moderate to vigorous aerobic exercise 3-5 days a week and 
moderate intensity (60-70% 1RM) resistance exercise 2-3 days a week (Riebe 
et al., 2017). ACSM states that resistance exercise should consist of at least 1 
set of 8-12 repetitions and target all major muscle groups (Riebe et al., 2017). 
In addition, upon discussion of the intervention, participants had varying 
opinions as to the structure. Some participants commented that they would 
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prefer to be given a set programme to follow where as others stated that they 
would like to have some choice as to what exercises they wished to do.  
“Rather than doing the same thing day to day it is sometimes nice to change it 
about a bit… some core ones and to mix and match others in” (Participant 5, 
age 48 years) 
Due to such a variety of feedback, the research team suggested that every 
patient would receive an individualised exercise programme. They would also 
be provided with a bank of exercises to allow them to swap exercises within 
the same muscle group should they wish to have some flexibility within the 
intervention.  
As a result of the feedback from sessions 1 and 2, a manual was developed 
and in session 3, a group of patients were asked to provide feedback on the 
exercise manual. The final manual can be found in Appendix 3b. Below is a 
selection of the comments received: 
“Might be useful to have a little schematic showing you should feel tension in 
this muscle” (Participant 2, age 67 years) 
“Remind people to breathe… people do hold their breath” (Participant 8, age 
62 years) 
“Something that I don’t think you address in here is the different strengths of 
the bands” (Participant 13, age 71 years) 
A page within the manual had been dedicated to allowing patients to monitor 
their exercise intensity. The OMNI-RES (Colado et al., 2012) scale has been 
validated in older adults within the same range as the patients that would be 
recruited to the trial. When discussing the session intensity and OMNI-RES 
scale one participant said: 
“I found it easier as that told me you know, can you talk to someone, can you… 
I think a little bit more of a description, just what you mean, I would find useful” 
(Participant 13, age 71 years) 
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As a result of such feedback, comments were added onto the OMNI-RES 
scale to provide more description to the patients at each stage (appendix 3c). 
At the end of the session participants commented on the manual as a whole: 
“I think this is super” (Participant 13, age 71 years) 
“It is really good” (Participant 12, age 62 years) 
 
5.4 Conclusion 
The research team took on board all the feedback provided by the participants 
over the three sessions and have included general information on the benefits 
of resistance exercise, information on the different resistance bands and 
exercises within the particular muscle group categories. Furthermore, 
behaviour change techniques were included in the manual including goal 
setting and self monitoring via an exercise diary, as a result of patient 
feedback. The exercise intervention would be individualised to each patient 
from a bank of exercises at the back of the manual. The intervention involves 
patients completing 3 sessions a week of the resistance exercise programme 
completing 3 sets of 10-15 reps in accordance with and progressed 
accordingly following ACSM guidelines (Riebe et al., 2017). All exercises are 
to be completed back-to-back with little rest between in order to maintain an 
elevated heart rate and oxygen consumption to aid adaptations to the 
cardiovascular system alongside muscular adaptions (Romero-Arenas et al., 
2013; Schmitz, 2010; Wilmore et al., 1978). 
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6.0 Clinical Trial 
6.1 Introduction 
Robot-assisted radical prostatectomy is an established minimally-invasive 
treatment for localised or locally-advanced prostate cancer, but often has an 
impact on both physical and mental well-being (J. J. Aning et al., 2018; 
Ansmann et al., 2018). Often patients experience side effects of treatment 
such as erectile dysfunction and urinary incontinence along with reduced 
quality of life (Bang & Almallah, 2016; Jeldres et al., 2015). It has also been 
documented in Chapter 4 of this thesis that patients who have received robot-
assisted radical prostatectomy are at an increased risk of a heart attack or 
stroke within the next 10 years compared to the average male of the same 
age. Additionally, it is possible that due to limited physical activity after surgery, 
unfavourable changes in body composition occur further impacting upon the 
risk of cardiovascular disease.  
There is a lack of research investigating exercise prescription within the robot-
assisted radical prostatectomy patient group and therefore no exercise 
recommendations currently exist within this pathway of care. NICE however, 
does recommend structured exercise programmes tailored to individuals 
receiving ADT for prostate cancer and for other health conditions such as 
myocardial infarction, stroke, chronic heart failure, chronic obstructive 
pulmonary disease, depression, lower back pain and chronic fatigue syndrome 
(National Institute for Health and Care Excellence, 2014a, 2014b). Exercise 
after diagnosis may help to reduce overall prostate cancer mortality and 
improve quality of life, therefore, exercise advice as part of the treatment 
pathway could be vital (Bourke et al., 2014; Kenfield et al., 2011). A recent 
systematic review demonstrated that exercise is generally safe and well 
tolerated in prostate cancer patients and should be considered an important 
component of prostate cancer care due its positive effects on fitness and 
physical function, and reduction of fatigue (Moe et al., 2017).  
RET over a 6-month period has recently been shown to improve systolic and 
diastolic blood pressure, arterial function, V̇O2Peak, blood lipid profile and, 
fasted insulin and glucose levels in both healthy and those with an adverse 
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cardiometabolic risk profile (Ashton et al., 2018). Additionally, a recent study 
investigated 3 months of RET, in combination with walking, and demonstrated 
improved urinary incontinence, however, this study was conducted in elderly 
women (Talley, Wyman, Bronas, Olson-Kellogg, & McCarthy, 2017). The 
evidence base for RET in those treated via robot-assisted radical 
prostatectomy is currently limited, however it is possible to hypothesise 
improvements in cardiometabolic health and urinary incontinence may occur.  
The majority of studies examining the effects of RET comprise of supervised 
exercise programmes (Almenning et al., 2015; Greenwood et al., 2015; 
Kemmler, Wittke, Bebenek, Frohlich, & von Stengel, 2016; O’Connor et al., 
2017; Segal et al., 2009). However, these programmes involve participants 
travelling to the centre which can be costly and time consuming, and so home-
based programmes have been suggested as a method of combating this. 
Home-based exercise is convenient for participants, relatively low cost to 
implement and provide an alternative and flexible way to exercise for older 
adults who are unable to carry out traditional RET or have access to gym 
facilities (Chuter, de Jonge, Thompson, & Callister, 2015; Thiebaud, 2014). 
Despite the benefits of home-based exercise to the participants, there are 
concerns with this type of exercise with regards to adherence and sufficient 
exercise progression (Thiebaud, 2014).  
The aim of this study was to assess the effects of a home-based progressive 
resistance exercise programme following robot-assisted radical prostatectomy 
in prostate cancer patients to counteract the adverse side effects of treatment. 
 
6.2 Methods 
The development of this trial followed the Medical Research Council’s (MRC) 
published guidelines on ethical issues along with guidance on consent, policy 
on risk management, developing clinical trials and clinical trial regulations 
(Medical Research Council, 2018). The Consolidated Standards of Reporting 
Trials (CONSORT) guidelines were followed to guide the reporting of this study 
(Schulz, Altman, & Moher, 2010). 
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6.2.1 Ethical Approval 
University ethical approval was granted by Northumbria University Ethics 
Committee. Approval was then obtained (ref: 202404) from the Health 
Research Authority (Appendix 1a). NHS ethical approval from NHS REC South 
Scotland was obtained on 8th September 2016 (ref: 16/SS/0143; Appendix 1b) 
and further approved by NUTH Research and Development on 11th October 
2016 (ref: 7832; Appendix 1c). The trial was prospectively registered on the 
International Standard Randomised Controlled Trial Number (ISRCTN) 
database (ref: ISRCTN10490647).  
 
 6.2.2 Research Governance and Good Clinical Practice 
This research recruited participants with prostate cancer from one NHS site. 
To ensure participant safety and confidentiality, the researcher received Good 
Clinical Practice training with all research being conducted in accordance 
within these guidelines. The study was conducted according to the Helsinki 
Declaration (1964; revised 2001). 
 
6.2.3 Study Design 
This study was a single-site, two-arm randomised controlled trial. 
Randomisation was conducted after the screening and baseline assessment 
on a 1:1 basis by an external investigator not directly involved with the trial. 
Initial follow-up was conducted at 12 weeks and a further follow-up session at 
24 weeks. A schematic of the trial design is presented in Figure 11.  
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Figure 11. Schematic of the trial design. 
 
 
6.2.4 Recruitment 
The patients were identified from NUTH outpatient clinics. A Consultant 
Urological Surgeon or Prostate Cancer Specialist Nurse initially approached 
potentially eligible patients before the researcher provided the patient with an 
information sheet. All patients were recruited to the study 8-12 weeks after 
surgery. All patients who responded to the patient information sheets were fully 
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informed of the study protocol and requirements and, considered for eligibility 
through an initial screening visit to ensure that they met all inclusion criteria. 
Upon successfully meeting these criteria, participants signed an informed 
consent form as per the MRC guidelines (Medical Research Council, 2018) 
before being entered into the study and data collection schedule planned. All 
participants were free to withdraw from the study at any time. 
 
6.2.5 Participants 
Inclusion Criteria 
• Men having undergone the robot-assisted radical prostatectomy 
procedure in the last 8-12 weeks after being diagnosed with prostate 
cancer 
• Completed a cardio-pulmonary exercise test (CPET) within the 
previous 4 months 
• Able to provide consent 
• Able to read and speak English to a level allowing satisfactory 
completion of written consent and questionnaires 
Exclusion Criteria 
• Participation in another clinical trial where concurrent participation is 
deemed inappropriate by a clinical investigator 
• Receiving any other treatment for cancer 
• Planned further surgery within the first 3 months after being randomly 
assigned to a group 
• Unsuitable for resistance exercise training based on opinion of the 
clinical investigator 
All data were collected at The Freeman Hospital, Newcastle upon Tyne. Prior 
to any testing all participants underwent checks of resting heart rate and blood 
pressure, and a 12-lead echocardiogram (ECG) configuration was used to 
assess real-time cardiac function. The ECG was conducted at rest and was 
interpreted and checked for any abnormalities by a medical professional. 
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Participants with no contraindications to exercise were allowed to continue into 
the study.  
6.2.6 Intervention 
The intervention group were asked to complete three resistance exercise 
sessions each week for 24 weeks (Borde, Hortobagyi, & Granacher, 2015; 
Lachman, Neupert, Bertrand, & Jette, 2006). Participants completed 3 sets of 
12-15 reps on each exercise in a circuit manner (Chodzko-Zajko, 2009; 
Ratamess, 2009). All participants began performing 7 exercises targeting each 
major muscle group such as legs (squat, leg press, quick kicks), abdominals 
(trunk curl-up, lower abdominal crunch, side bend), back (bent-over row, 
reverse flies), chest (chest press), shoulders (upright row, lateral raise, front 
raise), and arms (bicep curl and either elbow extension or elbow kick back). 
Participants had the choice to add in additional exercises from those provided 
and were asked to document any changes and their adherence in an exercise 
diary. The exercises were performed in a circuit with 30-60 seconds rest at the 
end of each circuit until 3 full circuits had been performed. The exercise 
programme was progressed according to the ACSM guidelines and the OMNI-
RES Scale (Riebe et al., 2017). Participants were either instructed to alter the 
hand/foot position on the band to increase resistance or, to progress onto the 
next level of resistance band once 7-8 was reached on the OMNI-scale 
(Colado et al., 2012).  
Participants in the intervention group were invited to take part in 3 supervised 
exercise sessions in the first week. In week 2, participants were invited to 2 
supervised sessions and 1 in the home environment (i.e., unsupervised). 
During weeks 3 and 4, participants were invited to 1 supervised session and 2 
completed at home. All supervised sessions took place in a designated room 
at The Freeman Hospital. During weeks 5 to 12, all exercise sessions were 
unsupervised, but participants in the intervention group received weekly 
telephone contact from a member of the research team (Hackshaw-McGeagh 
et al., 2017). Those who did not take up the invite of supervised sessions were 
contacted weekly via telephone from week 1. During weeks 12 -24, all sessions 
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were unsupervised with no contact from the research team. An exercise diary 
was used to record their RET activity levels over the 24 weeks. 
The control group were instructed to continue with their usual activity levels; 
their usual care was not affected by this trial. 
 
6.2.7 Outcome Measures 
All outcome measures were assessed in all participants at baseline (0 weeks), 
mid-way (12 weeks) and on completion of the trial (24 weeks). All follow-up 
sessions were conducted within the week surrounding the final exercise 
session to allow for participants’ availability.  
 
6.2.7.1 FMD 
For FMD assessments, a manual sphygmomanometer was placed distal to the 
olecranon process, with arterial imaging of the brachial artery performed using 
an ultrasound machine (Zonare, z.one ultra, United States of America) on the 
upper arm. Resting measurement of vessel diameter was performed for 1 min 
before cuff inflation to a pressure 50 mmHg above SBP. Occlusion was 
maintained for 5 min. Recordings were restarted 30 secs before cuff release 
and continued for a further 3 min thereafter (Thijssen, 2011). FMD 
measurements were completed at each assessment visit. Measurements of 
the artery diameter were taken along with the shear rate. Analysis of FMD 
recordings was completed using Cardiovascular Suite software (Quipu v3.4, 
2018). Measurements of baseline diameter (mm), maximum diameter (mm), 
recovery diameter (mm), baseline shear rate (s-1), maximum shear rate (s-1), 
area, area to maximum, FMD (%) and FMD with respect to recovery diameter 
(FMDr %) were all recorded. 
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6.2.7.2 Blood Sampling 
A total of 13 ml of whole blood was collected using 3 vacutainers at baseline, 
3 months and 6 months. An SST tube containing spray-coated silica and a 
polymer gel was used for blood lipid analysis (5 ml). An EDTA tube was used 
for insulin analysis (6 ml) and a fluoride tube for glucose analysis (2 ml). Insulin 
resistance was calculated using the formula below (Matthews et al., 1985):  
 
 
All blood samples collected were analysed by the Pathology Department of 
The Freeman Hospital, Newcastle upon Tyne. 
 
6.2.7.3 Anthropometric Profile 
Body mass (Seca Ltd, Seca Scales 709, Birmingham, UK) and stature (Seca 
Ltd, Seca 220 Stadiometer, Birmingham, UK) were recorded at all assessment 
visits. All skinfold assessments were completed in accordance with ISAK 
guidelines (Marfell-Jones, 2012) with the researcher ISAK Level 1 qualified. 
Skinfold assessments took place in a private room maintained as close to 20°C 
as possible for the participants comfort. Participants were asked to wear shorts 
and if comfortable to remove clothing from the waist upwards. Participants 
were asked to stand in the anatomical position and breathe normally 
throughout. Skinfolds using callipers (British Indicators, Harpenden, Sussex, 
UK) were taken at seven sites: triceps, subscapular, biceps, iliac crest, 
supraspinale, abdominal, front thigh and medial calf. Four girths were also 
taken using a body composition tape measure (tape): arm relaxed, arm flexed 
and tensed, waist (minimum) and gluteal. Finally, two breadths were measured 
using small sliding callipers: biepicondylar humerus and biepicondylar femur. 
Each skinfold, girth and breadth measurement was taken at least twice at each 
assessment visit with body fat percentage, and the sum of 6 and 8 skinfolds 
being calculated (Australian Sports Commission, 2004). 
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6.2.7.4 Submaximal Aerobic Capacity 
Participants performed a submaximal incremental walking protocol in the form 
of the Bruce ramp protocol on a motorised treadmill (Life Fitness, Next Gen 
9500 Treadmill, Cambridge, UK). The protocol comprised of 1-minute intervals 
in which both the speed and gradient increased (Riebe et al., 2017). The 
exercise test was terminated when the participant reached 15 on Borg’s 6-20 
Rating of Perceived Exertion (RPE) Scale (Kaminsky & Whaley, 1998) or for 
safety if the participant demonstrated an abnormal response to exercise such 
as a very high heart rate, chest pain, light headedness and dyspnea. Clinical 
cover and an on-call physician were available during all testing procedures in 
the event of an adverse reaction to exercise. V̇O2Peak was estimated from the 
level reached by the participant and using the ACSM Guidelines for Exercise 
Testing and Prescription (Riebe et al., 2017).  
 
6.2.7.5 Strength 
Exercises from the senior fitness test were used to evaluate upper and lower 
body strength in the participants. The elements used from the senior fitness 
test is available in Appendix 4a. Lower body strength was assessed through 
the chair stand test. This required participants to sit on a chair with their feet 
flat on the floor and knees at a right angle. Participants were then required to 
repeatedly stand up from and sit down on a chair for 30 seconds. Upper body 
strength was assessed through the bicep curl test and requires men to 
repeatedly lift an 8 lb (3.63 kg) weight for 30 seconds. Both strength tests were 
completed at each assessment visit. 
 
6.2.7.6 Cardiovascular Health 
The risk of suffering a heart attack or stroke within the next 10 years was 
calculated using Q-Risk2 (Hippisley-Cox et al., 2008). Q-Risk2 score is 
calculated from patient-reported family history, age, gender, ethnicity, socio-
economic status, and physiological measurements (e.g. SBP, medication, total 
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cholesterol and HDL cholesterol ratio), and can be categorised as < 10% (low), 
10%-20% (medium) or > 20% (high) (Coghill et al., 2018). 
 
6.2.7.7 Questionnaires 
Questionnaire booklets (Appendix 4b) were administered to the participants at 
each assessment visit at baseline, 12 and 24 weeks after entering into the trial. 
Participants were provided with full instructions on how to complete the 
questionnaire booklet. The questionnaires used were the EQ-5D-5L quality of 
life, FACT-P prostate cancer specific quality of life, the Godin Leisure Time 
Exercise questionnaire (modified) and the BFI. All permissions were sought 
prior to questionnaire use.  
The EQ-5D-5L was used to assess health-related quality of life in participants 
and has previously been validated in both cancer and diabetic populations 
(Janssen, Lubetkin, Sekhobo, & Pickard, 2011; Pickard, Wilke, Lin, & Lloyd, 
2007). The questionnaire comprises of five dimensions: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. The five responses 
represent a ‘health state’, which is converted using a standard algorithm to 
produce a single health state index score (Reenen & Janssen, 2015). The 
additional EQ-VAS was used to record the participants’ self-rated health on a 
vertical visual analogue scale, providing quantitative data reflecting the 
participants’ own judgement. 
The FACT-P is part of the Functional Assessment of Chronic Illness Therapy 
(FACIT) Measurement System and has 39 items grouped into five subscales: 
Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-
Being (EWB), Functional Well-Being (FWB) and the Prostate Cancer Subscale 
(PCS). The PWB, FWB and PCS subscales are combined to yield the FACT-
P Trial Outcome Index (TOI). The sum of PWB, SWB, EWB and FWB subscale 
scores gives the overall FACT-G score with a range from 0 to 108. The PCS 
score is combined with the overall FACT-G score to form the overall FACT-P 
score with a range from 0 to 156. 
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The Godin Leisure Time Exercise Questionnaire (modified) is a short 
questionnaire that is often used to assess exercise levels in oncology research 
(Amireault, Godin, Lacombe, & Sabiston, 2015). It is a 4-item self-administered 
questionnaire with the first three questions seeking information on the number 
of times one engages in light, moderate or vigorous aerobic activity and the 
fourth item seeks information on the frequency and duration of resistance 
exercise.  
The BFI is a standard, reliable instrument used to rapidly assess fatigue in 
individuals with cancer and is significantly correlated with other validated 
fatigue questionnaires (Mendoza et al., 1999; Sternberg et al., 2013). The 
purpose of the BFI is to rapidly assess the severity of fatigue and the impact 
of fatigue on daily functioning over the previous 24 hours in cancer patients. It 
consists of three questions assessing fatigue severity and six questions 
assessing the interference of fatigue with the participants mood and 
social/physical functioning. Fatigue intensity was defined as the score of the 
current, average and worst levels of fatigue (weariness, tiredness) over the 
previous 24 hours on a 0–10 scale with 0 = ‘no fatigue’ and 10 = ‘as bad as 
you can imagine’. Fatigue interference was the average score of all items 
assessing interference of fatigue with several functional domains such as 
general activity, mood, walking ability, work, relationships, and enjoyment of 
life. Each of these six items measures fatigue interference on a 0–10 scale, 
with 0 = ‘does not interfere’ and 10 = ‘completely interferes’. 
 
6.2.8 Sample Size Estimation 
The trial was powered to detect a 2.2% absolute difference between groups in 
FMD at 12 weeks. Previous studies have indicated that this is a clinically-
meaningful difference (Atkinson & Batterham, 2013; Yeboah et al., 2009), and 
one that was realistic to expect in a parallel-group study in which one group 
receive a 3-month structured exercise programme (Gilbert et al., 2016). 
Assuming a standard deviation of 2.8% (Gilbert et al., 2013), the anticipated 
effect size was approximately 0.80. To observe a difference of this magnitude 
with 80% power and 5% two-sided significance, a total sample size of 52 
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participants was required. Allowing for 15% attrition (Bourke et al., 2014), 60 
participants were needed in total with 30 participants randomised to each 
group. 
 
6.2.9 Randomisation 
Participants were randomised (1:1) in blocks of 4 to either the RET intervention 
or control group. Randomisation was conducted by an independent individual 
not directly involved with the trial using an online random number generator 
(http://www.randomization.com) after completion of the baseline assessments. 
 
6.2.10 Blinding 
Assessments at weeks 12 and 24 that could be influenced by the researcher 
(e.g. aerobic capacity) were conducted by a trained research assistant who 
was blind to group allocation. 
 
6.2.11 Statistical Analysis 
Multiple imputation was used for any missing data prior to intention-to-treat 
analysis being conducted (Manly & Wells, 2015). Multiple imputation replicates 
the incomplete dataset multiple times and replaces any missing data in each 
replicate with plausible values drawn from an imputation model taking into 
account the uncertainty associated with the imputed values (Hayati Rezvan, 
Lee, & Simpson, 2015; Manly & Wells, 2015). Analyses run on the dataset 
were pooled according to Rubin’s (1987) rules (Rubin, 2009). Normality of 
distribution for outcome measures was tested using the Shapiro Wilks test and 
assumptions were tested prior to analysis. The effect of the intervention was 
evaluated using an analysis of covariance (ANCOVA) model. The 12- and 24-
week outcomes were the dependent variables and trial arm (RET intervention 
and usual care) were the independent variables. The baseline value of the 
outcome was included as a covariate (Vickers & Altman, 2001). The treatment 
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effect (intervention minus control) is presented with its 95% confidence interval 
(CI). All analyses were conducted using IBM SPSS Statistics Version 22 (IBM 
United Kingdom Limited, Hampshire, UK). 
 
6.3 Results 
6.3.1 Participants 
In total, 73 participants post-robot assisted radical prostatectomy were 
deemed eligible and were provided with information regarding the study. A 
flowchart of participant recruitment, randomisation, and completion is 
presented in Figure 12. Forty-two men post- robot assisted radical 
prostatectomy were recruited over a 10-month period to take part in the trial. 
Recruitment ended due to the funding period coming to an end. Participant 
demographic information is presented in Table 13. Reasons for not taking part 
in the trial were given by most patients with the hospital being too far to travel 
the most common (n = 16). Nine patients approached said that they were 
already very active and so did not think they would benefit from taking part in 
the trial with a further 2 patients stating they did not have enough time. Four 
patients could not be contacted after the participant information sheet had 
been provided.  
Participants often had multiple comorbidities in addition to prostate cancer 
(range 0 - 4) which included hypertension (52.4%, n = 22), 
hypercholesterolemia (35.7%, n = 15), type 2 diabetes mellitus (11.9%, n = 5), 
asthma (9.5% n = 4), atrial fibrillation (4.8%, n = 2), arthritis (4.8%, n = 2), and 
depression (4.8%, n = 2). Two participants dropped out prior to the 12 week 
follow up (RET n = 1, usual care n = 1) one due to an unrelated back injury 
and one due to a family bereavement. A further 3 dropped out of the study 
prior to the 24-week follow up session (RET n = 1, usual care n = 2); one  
reporting multiple hernias (usual care group) and the remaining 2 not attending 
the follow-up session and being uncontactable thereafter. 
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Figure 12. A flowchart of participant recruitment, randomisation, and 
completion.  
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Table 13. Patient demographics upon recruitment.  
 Exercise Group 
(n = 20) 
Usual Care 
(n = 22) 
Age (years) 64.6 ± 6.2 66.9 ± 6.8 
Stature (cm) 176.9 ± 7.8 175.8 ± 6.5 
Body Mass (kg) 88.0 ± 13.3 87.6 ± 13.9 
Body Mass Index (kg/m2) 28.1 ± 3.5 28.3 ± 4.1 
White British (n (%)) 19 (95%) 22 (100%) 
Weeks since surgery 10 ± 1 11 ± 2 
Pre-operative PSA (ng/ml) 12.1 ± 10.9 11.9 ± 11.3 
Data are presented as mean ± standard deviation unless stated 
otherwise. PSA – prostate specific androgen 
 
 
6.3.2 Missing Data 
Missing data was evident for some variables, particularly blood biomarkers and 
FMD with further detail presented in Appendix 4c. Some missing data was due 
to participants dropping out of the study at varying time points. All participants 
who attended follow-up sessions had blood taken, however, approximately 
15% of participants did not have some sample results returned from the 
laboratory or results were incomplete. Approximately 38% of participants had 
some missing data over the 24 weeks for FMD. This was primarily due to the 
unavailability of equipment, despite it being requested.  
 
6.3.3 Intervention Adherence 
Adherence to the RET intervention was generally high. In weeks 1-12 
adherence was 94.1% ± 10.5%. An average of 1.9 ± 3.8 sessions were missed 
in the first 12 weeks. During the first 12 weeks one participant suffered a 
pulmonary embolism which meant they could not complete 2 weeks of the 
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programme. More common reasons for missing sessions were a bad back, 
common cold and holidays. In weeks 13-24 adherence was slightly lower at 
77.7% ± 29.8%. An average of 8.0 ± 10.6 sessions were missed in weeks 13-
24. Reasons provided here included becoming a father, Christmas 
celebrations, a rotator cuff injury and holidays with a handful of participants 
simply not returning the diaries for analysis.  
 
6.3.4 Flow Mediated Dilatation 
FMD outcome data are presented in Table 14. No significant differences were 
observed between groups at 12 or 24 weeks however some variables, at both 
time points, were in favour of the RET programme. 
 
6.3.5 Blood Biomarkers 
There were no significant changes to any blood biomarkers although most 
demonstrate a trend towards a reduction such as fasted insulin, HOMA-IR, 
LDL cholesterol and non-HDL cholesterol at 12 weeks and all but HDL 
cholesterol at 24 weeks. The mean difference and 95% confidence intervals 
(CI) for all blood biomarkers are present in Table 15. 
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Table 14. FMD outcome data at 12 and 24 weeks. 
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Table 15. Blood biomarker data at 12 and 24 weeks. 
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6.3.6 Cardiovascular Heath 
At 12 weeks, the RET groups did not demonstrated any significant reductions 
in cardiovascular health variables when compared to the usual care group 
although SBP and MAP showed a reduction in favour of RET at 12 and 24 
weeks (Table 16). No changes were evident in DBP, heart rate or QRisk2 
score at either time point.  
 
6.3.7 Anthropometric Profile 
Changes to body composition were evident in the RET group both at 12 and 
24 weeks (Table 16). Significant reductions were observed in the RET group 
compared to usual care in the sum of 6 skinfolds (-1.9 [-3.4, -0.4] mm, P = 
0.014) at 12 weeks. At 24 weeks body mass (-3.1 [-6.0, -0.2] kg, P = 0.036), 
BMI (-1.0 [-1.9, -0.1] kg/m2, P = 0.034), fat percentage (-1.9 [-3.5, -0.4] %, P = 
0.017) and sum of 8 skinfold (-13.3 [-25.3, -1.4] mm, P = 0.029) variables 
showed significant reductions for those in the RET group when compared to 
usual care. 
 
6.3.8 Submaximal Aerobic Capacity 
The mean difference and 95% CI for the submaximal aerobic capacity test are 
presented in Table 17. When compared to usual care, RET demonstrated 
significant increases in all submaximal aerobic capacity variables apart from 
maximum heart rate at both 12 and 24 weeks. 
 
6.3.9 Strength 
Significant changes are observed in the RET group for upper body strength at 
12 (3.6 [1.7, 5.5] reps, P < 0.001) and 24 weeks (4.3 [1.2, 7.3] reps, P = 0.008; 
Table 17). Increases to lower body strength were also demonstrated at 12 (3.1 
[1.0, 5.2] reps, P = 0.004) and 24 (3.2 [0.6, 5.9] reps, P = 0.019) weeks for the 
RET group compared to usual care. 
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Table 16. Cardiovascular health data and anthropometric profile at 12 and 24 weeks. 
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Table 17. Submaximal aerobic capacity and strength data at 12 and 24 weeks. 
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6.3.10 Questionnaires 
All questionnaire data is presented in Table 18. No statistical differences were 
evident in EQ-5D index score or the VAS at 12 or 24 weeks.  
The RET group demonstrated significant changes to the functional wellbeing 
(1.9 [0.3, 3.5], P = 0.02), prostate cancer specific (2.3 [1.0, 3.7], P = 0.001, trial 
outcome index (5.0 [1.9, 9.1], P = 0.002) and the FACT-P total score (5.3 [0.7, 
9.8], P = 0.03) elements of the FACT-P at 12 weeks. At 24 weeks, significant 
changes were also present for functional wellbeing (1.9 [0.001, 3.8], P = 0.05), 
prostate cancer specific (3.1 [1.3, 5.0], P = 0.002) and the trial outcome index 
(5.0 [1.8, 8.3], P = 0.003).  
At 12 weeks there were significant differences observed for RET compared to 
usual care for moderate intensity aerobic activity duration (22.1 [4.1, 40.0] 
mins, P = 0.02) but not for the frequency of the activity (0.2 ([-1.2, 1.6], P = 
0.8). Expectedly, there was a significant difference in the frequency and 
duration of RET at both 12 and 14 weeks for the RET group compared to the 
usual care group. There were no differences in the other exercise intensities 
at 24 weeks.  
There were no changes observed in the BFI scores at either 12 or 24 weeks. 
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Table 18. Questionnaire data for 12 and 24 weeks. 
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Table 18. Continued. 
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6.3.11 Adverse Events 
Five non-serious adverse events (hernia, accident resulting in back pain, 
abdominal pain, increased fasted insulin level, rotator cuff injury) and one 
serious adverse event (pulmonary embolism) were reported throughout the 
trial duration. Only the report of a rotator cuff injury was related to the trial and 
was the result of a participant choosing to progress to a more difficult 
resistance band despite being told not to. This participant was referred for 
physiotherapy and continued with the exercise programme but did not 
complete any exercises which the physiotherapist deemed would aggravate 
the injury. 
 
6.4 Discussion 
This is the first study to our knowledge to explore the benefits of RET in men 
who have undergone robot-assisted radical prostatectomy in the previous 8-
12 weeks. This study demonstrates that RET after robot-assisted radical 
prostatectomy can positively impact upon some aspects of body composition, 
strength, V̇O2Peak and patient-reported side effects of the treatment in the 8 
months post-surgery. Additionally, due to the low number of adverse events 
and good adherence levels throughout the intervention, it is reasonable to 
suggest that RET is a safe and effective form of exercise in the months 
following robot-assisted radical prostatectomy.  
FMD is calculated as the greatest percent change in arterial diameter following 
arterial occlusion and some favourable changes were observed during this 
study for FMD in the RET group. A recent review of FMD analysis methods 
highlight some issues with using allometric scaling of FMD in clinical trials, 
such as the difficulties in using the method to establish clinically meaningful 
difference in FMD, therefore this was not performed (McLay, Nederveen, 
Koval, Paterson, & Murias, 2018). Albeit not significant, this study observed 
increases in maximum diameter and baseline shear rate in the RET group at 
12 weeks. Artery dilation during the FMD response is thought to be due to 
shear rate stimulating the release of vasoactive substances which go on to act 
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on vascular smooth muscle (Cangemi et al., 2018; Thijssen, 2011). 
Furthermore, at 24 weeks there were also non-significant improvements 
evident in FMD and FMDr. The chronic effects of aerobic exercise training 
have been shown to improve endothelial function in populations with high CVD 
risk and prevent the age-associated loss in endothelium dependent 
vasodilation in men (DeSouza et al., 2000) However, the majority of studies 
examining endothelial function after RET only investigate the acute effects of 
a single bout of RET (Francois, Durrer, Pistawka, Halperin, & Little, 2016; 
Morishima, Tsuchiya, Iemitsu, & Ochi, 2018).  
The differences observed here are not as great as expected for patients taking 
part in an RET programme. Other studies have reported a change in FMD from 
6.2-8.3% and 9.7-11.8% after resistance-based exercise programmes 
however these were in young (18-35 years old) prehypertensives and  healthy 
young (18 years old) adults respectively (Beck, Casey, Martin, Emerson, & 
Braith, 2013; Okamoto, Masuhara, & Ikuta, 2011). The lack of statistical 
significance here is likely to be due to the study being underpowered, as it was 
estimated 60 participants were needed to potentially observe significant 
differences in FMD. However, to our knowledge this is the first study to 
examine endothelial function after 24 weeks RET in prostate cancer patients 
treated with robot-assisted radical prostatectomy and therefore further studies 
are needed to explore this further. 
At baseline, resting heart rate was low and within normal limits in both the RET 
and usual care groups and so no change in this variable is not surprising. 
However, systolic blood pressure and mean arterial pressure demonstrated 
favourable reductions over 12 and 24 weeks for the RET group. This is a 
potentially important finding given that approximately half of all myocardial 
infarctions in the UK are attributed to hypertension and as cardiovascular 
disease has been identified as one of the leading causes of death in men 
following robot-assisted radical prostatectomy (Public Health England, 2017; 
Shikanov, Kocherginsky, Shalhav, & Eggener, 2011; World Health 
Organisation, 2009). Therefore, RET could be utilised in men after robot-
assisted radical prostatectomy as a non-pharmacological method of reducing 
arterial blood pressure. 
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Aerobic capacity is known to decline with increasing age and with diagnosed 
hypertension therefore older adults exert themselves more conducting 
activities of daily living compared to younger adults. Such decreases in 
V̇O2Peak can not only aggravate underlying cardiovascular conditions, but it 
can also reduce activities of daily living and increase the risk of depression and 
functional dependence (Chandrasekaran et al., 2010). Submaximal exercise 
testing is a means of predicting V̇O2Peak without performing maximal exercise 
and is often associated with fewer risks for clinical populations. Aerobic 
exercise has traditionally been employed to improve V̇O2Peak (Chodzko-
Zajko, 2009), however, the results in this study show that RET can improve 
submaximal exercise performance and therefore helping to combat the age-
related declines in V̇O2Peak. 
With the age of those recruited in this study being > 60 years of age, it is 
possible that some of those who took part were experiencing age related 
declines in muscle mass and function (i.e. sarcopenia) (Dodds & Sayer, 2016). 
However, as with the majority of RET programmes we observed a significant 
increase in upper and lower body strength in the RET group compared to usual 
care. Furthermore, there were significant changes in all body composition 
variables for the RET group over the 24 weeks. The observed changes in body 
composition and reduction in fat mass supports suggestions that RET is 
beneficial in promoting fat loss (A. Paoli, Gentil, Moro, Marcolin, & Bianco, 
2017; Antonio Paoli, Moro, & Bianco, 2015; Willis et al., 2012). The findings 
here are in agreement with other studies that have also reported favourable 
changes in body composition following periods of RET (Padilha et al., 2017; 
Shaw, Gouveia, McIntyre, & Shaw, 2016; Villanueva, Lane, & Schroeder, 
2015). Such effects are potentially attributable to training intensity since some 
studies have shown increases in basal metabolic rates and fat oxidation 
following RET (Alvehus, Boman, Söderlund, Svensson, & Burén, 2014; 
Lemmer et al., 2001).   
There was no beneficial effect observed for fatigue levels in the RET group. 
This could be due to the relatively low levels of fatigue reported by participants 
at baseline. However, other studies have found exercise to reduce the levels 
of fatigue in other cancer populations (Meneses-Echavez et al., 2015). 
130 
 
Furthermore, the study was underpowered to detect any potentially small but 
important differences in the questionnaire outcome. The beneficial effects of 
RET were evident in the improvement of elements of the FACT-P 
questionnaire. The results suggest that RET can improve patient-reported 
functional wellbeing and prostate cancer specific factors such as urinary 
incontinence and frequency, and erectile dysfunction. Such factors are known 
to improve over the months after surgery however, the significant difference 
between the two groups suggests that RET could be more beneficial than 
usual care (Ernstmann, Weissbach, Herden, Winter, & Ansmann, 2017). This 
potentially has clinical implications to the advice and recommendations 
clinicians make to patients at this stage of their recovery.  
 
6.4.1 Limitations 
It is important to interpret these results in the context of several limitations. 
Firstly, there are issues surrounding studies being underpowered. For 
example, the risk of false negatives is greater and inflated effects sizes are 
more common (Button et al., 2013).  However, significant beneficial effects 
were evident for some of the secondary outcomes (i.e. waist circumference, 
strength, V̇O2Peak and elements of the FACT-P). Furthermore, there are 
issues with imputing missing data despite missing data being common in 
clinical research. Missing data points can lead to a loss in statistical power and 
potentially biased results if not handled appropriately. However, multiple 
imputation was employed which is widely adopted in practice for dealing with 
missing data (Hayati Rezvan et al., 2015).  
It is possible that, due to patients being aware of their participation in an 
exercise trial, they undertook more daily exercise accounting for the increased 
duration of moderate intensity aerobic activity in the RET group at 12 weeks. 
This could have contributed to an increase in Bruce ramp scores, however as 
there are no differences at the 24-week time-point it is unlikely that this is a 
contributing factor. Moreover, diet may also have changed due to participation 
in the trial, which was not accounted for, this may have led to favourable 
reductions in body/fat mass. 
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6.5 Conclusions 
This study highlights that RET is a safe and effective mode of exercise that 
elicits numerous cardiometabolic health benefits in men who have undergone 
robot-assisted radical prostatectomy. RET had a clear effect on body 
composition, V̇O2Peak, strength, functional wellbeing and prostate cancer 
specific quality of life and showed evidence of a favourable reduction in MAP, 
SBP, HOMA-IR, LDL cholesterol. The RET programme was well received by 
patients with adherence to the programme over 90% in the initial 12 weeks. 
Clinicians should consider discussing the benefits of exercise, particularly 
RET, to patients in the weeks following robot-assisted radical prostatectomy. 
Future studies should expand on this trial and explore these variables in a 
larger multi-centre randomised controlled trial. 
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CHAPTER 7 
 
 
 
 
 
 
 
 
 
GENERAL DISCUSSION AND CONCLUSION 
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7.0 General Discussion and Conclusion 
 
7.1 Introduction 
The research presented in this thesis has systematically examined evidence 
for the benefits of RET in both healthy adults and those at elevated 
cardiometabolic risk. In addition, the relationship between self-reported 
physical activity and fatigue in men receiving treatment for prostate cancer was 
examined. The effects of a supported, home-based RET programme in men 
after robot-assisted radical prostatectomy was the investigated in a 
randomised controlled trial. This chapter will collate and consider the findings 
of chapters 3 to 6.  
 
7.2 Summary of Key Findings 
The systematic review described in Chapter 3 identified the effects of RET 
versus control conditions in adults, as well as the strengths and limitations of 
existing studies. This systematic review demonstrated that an RET programme 
can elicit improvements in resting blood pressure, FMD, HOMA-IR, fasted 
glucose, insulin and V̇O2Peak, with most of the evidence available for 
interventions 7-23 weeks in duration. It was concluded that RET is a safe and 
effective exercise modality for inducing improvements cardiometabolic risk 
factors and cardiopulmonary fitness, particularly in middle-aged to older adults 
(≥ 41 years) and those with elevated cardiometabolic risk or disease. However, 
there was some uncertainty regarding the risk of bias because very few studies 
adequately reported the randomisation process, allocation concealment or 
blinding of outcome assessment. Additionally, many studies did not follow the 
TIDieR checklist (Hoffmann et al., 2014) and so had incomplete descriptions 
of the RET interventions, progression and adherence. 
Moreover, a pilot study was conducted to characterise fatigue, physical activity 
levels and cardiovascular status, in men after robot-assisted radical 
prostatectomy (Chapter 4). This study demonstrated that some men following 
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robot-assisted radical prostatectomy are at increased risk of clinically 
significant consequences from cardiovascular disease within ten years of their 
surgery and a substantial proportaion do suffer with clinically significant levels 
of fatigue. This suggests that patients due to receive robot-assisted radical 
prostatectomy as a treatment for prostate cancer should be counselled by the 
clinician on these factors. The research has shown that men after robot-
assisted radical prostatectomy appear to meet the recommended guidelines 
for aerobic physical activity but do not meet them for resistance-based 
exercise. 
A randomised controlled trial was then conducted to assess the effects of 
supported home-based progressive RET on cardiometabolic health outcomes 
following robot-assisted radical prostatectomy (Chapter 6). The men in the 
RET group showed improvements in endothelial function, total cholesterol, 
SBP, body composition, strength, V̇O2Peak and patient-reported functional 
wellbeing and prostate cancer specific quality of life. The RET intervention was 
also safe for patients following radical prostatectomy, with only one non-
serious adverse event being related to the intervention itself. The RET 
programme was well accepted by patients with adherence levels greater than 
90% in the first 12 weeks.  
Exercise is generally recommended to men with prostate cancer (specifically 
men who receive ADT, radiotherapy or chemotherapy) however, there is a lack 
of evidence for robot-assisted radical prostatectomy population. As discussed 
in Chapter 6, aside from its positive impact on cardiometabolic health 
outcomes, RET potentially facilitates the reduction of robot-assisted radical 
prostatectomy specific side effects such as urinary incontinence and erectile 
dysfunction as assessed via the FACT-P. Although this thesis did not compare 
different modes of RET, it is evident, from the results presented in this thesis, 
that RET could be a beneficial adjunct treatment for men who receive surgical 
treatment for prostate cancer. Furthermore, the behaviour change techniques 
employed, i.e. goal setting and self-monitoring, resulted in high adherence 
levels and low drop-out rates for an exercise intervention study. Supported 
home-based RET using Therabands is a cheap, accessible and practical mode 
of exercise. While more research is clearly needed in the area of exercise 
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training for prostate cancer patients on varying treatment pathways, this study 
is the first to demonstrate the benefits of RET in a robot-assisted radical 
prostatectomy cohort.  
 
7.3 Implications for Clinical Practice 
Recently NHS England published the NHS Long Term Plan for the next 10 
years. By 2028 the plan aims to improve early detection of cancer and improve 
survival rates (NHS England, 2019). This has the potential to increase the rates 
of men diagnosed with prostate cancer and improve survival from the disease, 
therefore meaning more men will suffer from the side effects of the treatment 
received. This thesis has demonstrated that men after robot-assisted radical 
prostatectomy who are supported through at least 12 weeks of a RET 
intervention report improved cardiometabolic health, functional well-being and 
prostate cancer specific factors (i.e. erectile dysfunction and urinary 
incontinence).  
The results from this thesis suggest that exercise, specifically RET, should be 
recommended to prostate cancer patients, regardless of the type of disease or 
treatment pathway, to improve cardiometabolic health and in robot-assisted 
radical prostatectomy patients specifically, prostate cancer specific quality of 
life. At present, NICE only recommends exercise to prostate cancer patients, 
regardless of the type of treatment they received, rather than providing specific 
guidelines for patients to adhere to. However, this thesis has highlighted the 
lack of RET undertaken in this population of prostate cancer patients and so 
clinicians and health care professionals should provide some exercise advice 
as part of the initial treatment for all patients being treated via robot-assisted 
radical prostatectomy.  
Cancer diagnosis has been described as a teachable moment in a pateints life 
where they are motivated to reduce unhealthy behaviours, especially when the 
advice is delivered by a trusted source such as a health care professional 
(Horwood et al., 2014; McBride et al., 2003; Sutton et al., 2017). Cumulative 
findings from exercise trials support the promotion of exercise principles to 
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gain and maintain physiological, functional, and quality of life benefits before, 
during and after treatment for cancer (Campbell, Stevinson, & Crank, 2012; 
Hayes, Spence, Galvão, & Newton, 2009; Schmitz, 2010). It is important that 
such programmes are tailored to individual patients taking into account their 
goals, strengths and weaknesses. Therefore a one-size-fits-all approach is not 
appropriate in this patient group or within the NHS setting. Evidence also 
supports using behaviour change strategies to improve exercise self-efficacy 
to empower people with cancer, to ensure that activity changes and 
subsequent benefits can be sustained (Bourke et al., 2013; Turner et al., 
2018). In addition to gaining the benefits from exercise during cancer 
treatment, there is also preliminary evidence that exercise performed post-
diagnosis may be associated with improved survival, however more research 
is needed (Campbell et al., 2012; Kenfield et al., 2011). Collectively, this 
evidence provides sound justification for including exercise as part of routine 
NHS cancer care. Due to resource constraints visible in the current NHS 
system, it is possible that remote support for home-based exercise 
interventions, similar to that which has been investigated in this thesis, may be 
a viable option for the NHS to employ.  
  
7.4 Limitations 
Specific limitations are addressed in respective chapters. The findings within 
this thesis are based upon a series of studies all involving a relatively small 
group of patients from one NHS Trust and, for this reason, the results require 
careful interpretation.  
A further limitation is that this thesis is based upon one mode of exercise. 
Specific health benefits in prostate cancer patients are likely to differ across 
exercise modalities and intensities, and it would therefore be inappropriate to 
generalise these findings to other exercise modalities. Nevertheless, these 
limitations should not detract from the potential clinical importance of these 
findings as clinicians can refine consultations based patient characteristics and 
exercise preferences. 
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There were issues with the use of the SPAQ questionnaire in Chapter 4. Many 
patients did not fully understand the format of the questionnaire (e.g. to only 
include MVPA), which possibly led to over-reporting of some items, particularly 
walking. Therefore, the Godin Leisure Time Questionnaire (modified) was 
used in the randomised controlled trial (Chapter 6) as this was much simpler 
in layout and quicker to complete.  
As with most clinical trials, recruitment was challenging, particularly for the 
randomised controlled trial (Chapter 6). This was in part due to time constraints 
but also attributable to the very large catchment area of the Trust. Many 
patients travelled > 2 hours to attend an outpatient appoint and did not feel that 
it would be beneficial for them to participate in a trial that required further trips 
to the hospital. However, many did comment that they would have taken part 
if it was ‘closer to home’.  
 
7.5 Areas for Future Research 
The next stage of research following this thesis should be extended to patient 
groups, urology specialists and physiotherapists/exercise physiologists to 
provide further guidance and refinement of the intervention components and 
the implementation within the care pathway. Moreover, it would be 
advantageous to follow on from this body of work by investigating the cost 
effectiveness to support the implementation of this within the NHS on a much 
larger scale through an appropriately design multi-centre randomised 
controlled trial.  
Although a relatively broad ranging and comprehensive assessment of the 
benefits of the RET intervention was conducted, due to financial resources, it 
was only possible to measure a limited number of blood-borne biomarkers 
(lipid profile, glucose and insulin). It would therefore be of interest, and 
potential importance to include further blood biomarkers such as CRP and 
HbA1c, as well as specific questionnaires directly assessing erectile 
dysfunction and urinary incontinence within this population. Longer-term 
follow-ups (> 6 months) could also be conducted to examine whether the 
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improvements made in the initial 6 months of the study are maintained over a 
longer duration. 
It is suggested that the recommendations generated from this thesis be 
advertised in outpatient clinics and promoted to patients who receive robot-
assisted radical prostatectomy. An assessment of patient uptake on the basis 
of recommendations may be beneficial to assess whether providing 
recommendations alone is effective in provoking change in exercise 
behaviours.  
 
7.6 Conclusions 
The findings in this thesis have demonstrated that: 
• RET of varying durations can positively impact cardiometabolic health 
in adults both with, and without, cardiometabolic risk factors. 
• Some men after robot-assisted radical prostatectomy are at increased 
risk of clinically significant consequences from CVD within ten years of 
their surgery and suffer clinically significant levels of fatigue. 
• Men using self-reported physical activity questionnaires after robot-
assisted radical prostatectomy report meeting UK guidelines for 
aerobic activity but not resistance-based exercise.  
• RET of 12-24 weeks in length elicits improvements in endothelial 
function, body composition, total cholesterol, SBP, V̇O2Peak, strength, 
functional wellbeing and prostate cancer specific quality of life. 
• RET is a safe and effective mode of exercise for men > 8 weeks post 
robot-assisted radical prostatectomy and is well received by patients 
with adherence to the programme over 90% in the initial 12 weeks. 
• Exercise should be integrated into the cancer care pathway for patients 
before, during and after treatment to gain and maintain physical, 
functional and quality of life benefits.  
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Appendix 2b. Trials Characteristics Included in the Systematic Review 
Author & year Country Population 
Duration & 
frequency 
Intervention Group 
Control 
Group 
Timing of 
outcomes 
Funding & conflicts of interest 
Ades et al. 
1996 
USA 
RT = 69.9 ± 4 yrs 
CON = 70.7 ± 5 yrs 
Male and female 
Healthy elderly 
12 weeks 
3 d per week 
Supervision not reported 
Free weights and weight 
machines 
3 sets of 8 reps at 50% 1RM 
with progression to 80% by 
week 9 
Continued 
with habitual 
activities 
Baseline and 
12 weeks 
Grants from National Institute of 
Health and General Clinical 
Research Centres. 
Afshar et al. 
2010 
Iran 
RT = 51 ± 16.4 yrs  
AT = 50.7 ± 21.1 yrs 
CON = 53 ± 19.4 
yrs 
Males  
Haemodialysis 
8 weeks Supervised by a physician 
Ankle weights 
2 sets of 8 reps progressed to 3 
sets 
 
Not reported Baseline and 
8 weeks 
Not reported 
Ahmadizad et 
al. 2007 
Iran 
RT = 40.9 ± 3.2 yrs  
AT = 41.3 ± 5.1 yrs  
CON = 38.6 ± 3.2 
yrs 
Male  
Sedentary obese 
12 weeks 
3 d per week 
 
Supervision not reported 
Circuit resistance training 
4 sets of 12 maximal reps at 11 
stations 
50–60% of 1RM in each station 
 
Not reported 
 
 
Baseline and 
12 weeks 
Tarbiat Moallem University of 
Sabzevar in Iran. 
Ahmadizad et 
al. 2014 
Iran 
Total cohort 23.4 ± 
0.6 yrs 
Male 
Sedentary 
overweight 
8 weeks 
3 d per week 
 
Supervised 
Free weights, weight machines 
and body weight 
1-2 weeks: 1 set of 10 reps  
3-8 weeks: 2–3 sets of 20–30 
reps 
NP: constant moderate intensity  
DUP: rotated loading 
LP: volume was decreased and 
the training intensity was 
increased each week 
Not reported Baseline and 
8 weeks 
Not reported 
Almenning et 
al. 2015 
Norway 
Total cohort 27.2 ± 
5.5 yrs 
Females  
10 weeks 
3 d per week 
Supervised by an exercise 
physiologist at least 1 session a 
week 
3 sets of 10 reps at 75% 1RM 
Not reported Baseline and 
10 weeks 
The Norwegian Fund for 
Research in Sports Medicine. 
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Polycystic ovary 
syndrome 
Anderson et 
al. 2004 
USA 
RT = 26.4 ± 7.5 yrs 
AT = 20.9 ± 2.4 yrs 
CON = 26.6 ± 6.5 
yrs 
Males  
Healthy sedentary  
6 weeks 
3 d per week 
 
Supervision not reported 
Free-weight and machine 
exercises 
2 sets of 10-15 reps 
 
Refrain from 
systematic 
physical 
activity 
Baseline and 
6 weeks 
Not reported 
Andersen et 
al. 2008 
Denmark 
RT = 44 ± 9 yrs  
Fitness Training = 
45 ± 9 yrs  
CON = 42 ± 8 yrs 
Females  
Trapezius myalgia 
10 weeks 
3 d per week 
 
Supervised 
Free-weight and machine 
exercises 
3 sets 
Intensity progressively increased 
from 12RM to 8RM  
Health 
advice 
Baseline and 
10 weeks 
Grants from Danish Medical 
Research Council and the Danish 
Rheumatism Association. 
Andersen et 
al. 2014 
Denmark 
Total cohort = 68.2 
± 3.2 yrs 
Males  
Healthy elderly 
16 weeks 
2 d per week 
Supervised 
Free-weight and machine 
exercises 
0-4 weeks: 3 sets of 16-20 reps  
5-8 weeks: 3 sets of 12 reps  
9-12 weeks: 3 sets of 10 reps  
13–16 weeks: 4 sets of 8 reps  
Not reported Baseline and 
16 weeks 
Supported by the FIFA Medical 
Assessment and Research 
Centre, The Danish Ministry of 
Culture, and Nordea-fonden, 
Denmark. 
Andersen et 
al. 2016 
USA 
Total cohort = 68.1 
± 2.1 yrs  
Healthy elderly 
36 weeks 
2 d per week 
Supervised 
Free weight, weight machines 
and body weight 
0-4 weeks: 3 sets of 16–20RM 
5-8 weeks: 3 sets of 12RM  
9-12 week: 3 sets of 10RM  
13-52 weeks: 4 sets of 8RM  
Continued 
with habitual 
activities 
Baseline and 
36 weeks 
Supported by the FIFA-Medical 
Assessment and Research Centre 
(Project 31964). The Danish 
Ministry of Culture 
(Kulturministeriets Udvalg for 
Idrætsforskning) (TKIF 2010-027), 
and Nordea-fonden (02-2011-
4360).  
Arora et al. 
2009 
India 
RT = 49.6 ± 5.2 yrs  
AT= 52.2 ± 9.3 yrs 
CON = 58.4 ± 1.8 
yrs 
Male and female  
Type 2 diabetes 
8 weeks 
2 d per week 
 
Supervised 
3 sets of 10 reps at 60-100% 
1RM 
Continued 
with habitual 
activities 
Baseline and 
8 weeks 
Grant from University Grants 
Commission, Delhi, India. 
Asad et al. 
2012 
Iran 
RT = 21 ± 1.6 yrs  
AT = 22 ± 0.9 yrs 
Concurrent = 21.4 ± 
2.1 yrs 
8 weeks 
3 d per week 
 
Supervision not reported 
Free weights and weight 
machines 
3 sets of 10-15 reps 
Not reported Baseline and 
8 weeks 
Not reported 
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CON = 21.4 ± 1.1 
yrs 
Male  
Healthy sedentary  
Weeks 2-8: first set for 10-12 
reps, 8-10 reps for second set 
and 4-8 reps for third set 
Augusto 
Libardi et al. 
2012 
Brazil 
RT males = 47 ± 4.5 
yrs 
RT females = 53.7 ± 
3.7 yrs 
CON males = 49.5 
± 5.6 yrs 
CON females = 
51.2 ± 6.4 yrs 
Males and females 
Healthy sedentary 
16 weeks 
3 d per week 
 
Supervision not reported 
Free-weight, machine exercises 
and body weight 
3 sets of 10 reps 
9-16 weeks: 8 reps 
Not reported Baseline and 
16 weeks 
Supported by Conselho Nacional 
de Desenvolvimento Científico e 
Tecnológico 
Azarbayjani et 
al. 2014 
Iran 
RT = 23.1 ± 1.4 yrs 
AT = 23.3 ± 1.3 yrs 
Concurrent = 22.9 ± 
1.7 yrs 
CON = 22.9 ± 1.7 
yrs  
Males 
Healthy sedentary 
12 weeks 
3 d per week 
 
Supervision not reported 
Free-weight and machine 
exercises 
3 sets of 10 reps at 70% 1RM 
 
Continued 
with habitual 
activities 
Baseline and 
12 weeks 
Grant (90084702) from the Islamic 
Azad University, Central Tehran 
Branch grants commission. 
Badrov et al. 
2013 
Canada 
IHG3 = 23 ±4 yrs  
IHG5 = 27 ±6 yrs  
CON = 24 ± 8 yrs 
Females 
Healthy sedentary 
8 weeks 
IHG3 - every 
other day  
IHG5 - five 
consecutive 
days 
Supervision for 2 sessions a 
week 
Isometric hand grip at 30% MVC 
Continued 
with habitual 
activities 
Baseline, 4 
and 8 weeks 
Supported by the University of 
Windsor (810043; 809264; 
808316; CLM), the Canadian 
Institutes of Health Research, 
Heart and Stroke/Richard Lewar 
Centre of Excellence Postdoctoral 
Fellowship, and an Ontario 
Graduate Scholarship. 
Baldi & 
Snowling 2013 
New Zealand 
RT= 46.5 ± 2.1 yrs  
CON = 50.1 ± 1.3 
yrs 
Females 
Type 2 diabetes 
10 weeks 
3 d per week 
Supervised 
1-2 circuits of 12 reps at 10RM 
(upper body) or 15RM (lower 
body) 
Continued 
with habitual 
activities 
Baseline and 
10 weeks 
Not reported 
DeBarros et al. 
2010 Brazil 
RT =  31.8 ± 4.9 yrs 
CON = 32.4 ± 5.4 
yrs 
24-34 weeks  
3 d per week 
 
Supervised by the researcher for 
1 session a week 
Elastic resistance band circuit 
Continued 
with habitual 
activities 
Baseline and 
24 weeks 
Supported by Coordenação de 
Aperfeiçoamento de Pessoal de 
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Female 
Type 2 diabetes 
Exercise intensity was controlled 
using a perceived exertion 
scale. Subjects advised to 
maintain an exercise intensity 
close to 5 or 6, which 
corresponds to a “somewhat 
heavy”.  
Nível Superior with master’s 
fellowship grant. 
Beck et al. 
2013 
 
Beck et al. 
2013 
USA 
RT = 21.1 ± 2.5 yrs  
AT = 20.1 ± 1.1 yrs  
CON = 21.6 ± 2.9 
yrs  
Normotensive CON 
= 21.6 ± 2.7 yrs  
Male and female 
young Pre-
hypertensives 
 
RT = 21.1 ± 0.6 yrs  
AT = 20.1 ± 0.9 yrs 
CON = 21.6 ± 0.8 
yrs  
Normotensive CON 
= 21.6 ± 0.7 yrs 
Male and female 
Pre-hypertensives 
8 weeks 
3 d per week 
 
Supervision not reported 
Weight machines 
2 sets of 8–12 reps to volitional 
fatigue 
 
Weight machines 
2 sets of 8–12 reps to volitional 
fatigue 
 
Continued 
with habitual 
activities 
Baseline and 
8 weeks 
Supported, in part, by a National 
Institutes of Health pre-doctoral 
training grant (NIH 5-T32-
HL083810-04) awarded by the 
University of Florida Hypertension 
Centre.  
 
Supported, in part, by a National 
Institutes of Health predoctoral 
training grant (NIH 5-T32-
HL083810-04) awarded to D.T.B. 
by the University of Florida 
Hypertension Centre. 
Bell et al. 2000 
Canada 
Total cohort = 22.3 
± 3.3 yrs 
Male and female 
Physically active 
12 weeks 
3 d per week 
Supervision not reported 
Free-weight and machine 
exercises 
2-6 sets of 4-12 reps  
Continued 
with habitual 
activities and 
asked to 
refrain from 
beginning 
any 
formal 
exercise 
training 
programme 
Baseline, 6 
and 12 
weeks 
Not reported 
Beltran Valls 
et al. 2014 Italy 
RT = 72 ± 1 yrs 
CON = 72 ± 1 yrs 
Male and female 
12 weeks 
2 d per week 
Supervised 
Weight machines 
Continued 
with habitual 
activities 
Baseline and 
12 weeks 
Grants from the University of 
Rome “Foro Italico” (Research 
2009) to D. C. The Lazio Regional 
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Healthy elderly 1-2 weeks:  4 sets of 15 reps at 
40–50 % 1RM  
3-12 weeks: 3–4 sets of 10–12 
reps at 70 % of baseline 1RM 
Municipality (Agreement CRUL-
Lazio n. 12650/2010) supported 
the post-doc scholarship to ID. 
Boardley et al. 
2007 
USA 
RT = 74.1 ± 6.2 yrs 
Combined = 75.3 ± 
6 yrs 
AT = 73.2 ± 6.6 yrs 
CON = 75.9 ± 7.7 
yrs 
Male and female 
Healthy elderly 
16 weeks 
3 d per week 
 
Supervised by project staff for 2 
sessions a week 
Elastic resistance bands 
1-2 weeks: 1 set of 10 reps 
3-16 weeks: 2 sets of 12 reps 
Theraband colour was changed 
so that it provided sufficient 
resistance to produce mild 
fatigue at the final rep 
Not reported Baseline, 8 
and 16 
weeks 
Funded by the National Institute 
for Nursing Research grant #R01 
NR04929. The Hygenic 
Corporation supplied the Thera-
Band but had no other role in the 
study. 
Borges & 
Carvalho 2014 
Brazil 
RT = 64.1 ± 12.5 
yrs 
CON = 67.8 ± 9 yrs 
Male and female 
COPD 
Completed a 
minimum of 
3 sessions 
Supervised 
Free weights and weight 
machines 
2 sets of 9 reps  
Initial load was 80% 1RM and 
adjusted in subsequent sessions 
based on symptoms, Borg 
Dyspnea Scale scores, and 
patient fatigue 
Normative 
daily care 
e.g. chest 
physiotherap
y, non-
invasive 
ventilation, 
and 
instructions 
to carry on 
with  
daily 
physical 
activities 
Evaluated on 
the second 
day in 
hospital, at 
discharge, 
and 30 days 
post 
discharge 
Not reported 
Brentano et al. 
2008 
Brazil 
Age not reported 
Female 
Post-menopausal 
24 weeks 
3 d per week 
 
Supervision not reported 
Free-weight and machine 
exercises 
RT circuit: 2-3 sets of 10-20 reps 
at 45-60% 1RM  
RT: 2-4 sets of 6-20 reps at 45-
80% 1RM 
Continued 
with habitual 
activities 
Baseline, 8, 
16 and 24 
weeks 
Not reported 
Brito et al. 
2013 
Brazil 
Age not reported. 
Male and female 
HIV/AIDS  
24 weeks. 
3 d per week 
Supervised 
Free-weight and machine 
exercises 
3 sets of 8-10 reps at 80% 1RM  
Continued 
with habitual 
activities and 
received 
Baseline and 
24 weeks  
Not reported 
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nutritional 
advice 
Broeder et 
al.1992 
USA 
Only report cohort 
18-35 years 
Males 
Physically active 
12 weeks 
4 d per week 
 
Supervised 
Free-weight and machine 
exercises 
1-2 weeks: 10-12 reps 
3-12 weeks: 10-12 reps on the 
first set, 8-10 reps on the 
second set, and 6-8 reps on the 
third set 
Continued 
with habitual 
activities 
Baseline and 
12 weeks 
Not reported 
Brooks et al. 
2007 
USA 
RT = 66 ± 2 yrs 
CON = 66 ± 1 yrs 
Males and females 
Type 2 diabetes 
16 weeks 
3 d per week 
 
Supervision not reported 
Weight machines 
3 sets of 8 reps  
1-9 weeks: 60% 1RM 
10-14 weeks: 70-80% 1RM 
Continued 
with habitual 
activities and 
medications 
Baseline and 
16 weeks 
Funded, in part, by the Brookdale 
Foundation, the USDA ARS 
agreement 58-1950-9-001, the 
NIH General Clinical Research 
Center M01 RR000054, and the 
International Life Sciences 
Institute North America. 
Buchner et al. 
1997 
USA 
RT = 74 yrs 
AT = 75 yrs 
AT + RT = 75 yrs 
CON = 75 yrs 
Male and female 
Healthy elderly 
24-26 weeks 
3 d per week 
Supervised 
Weight machines  
2 sets of 10 reps with the first 
set at 50-60% 1RM and the 
second set 75% 1RM 
Continued 
with habitual 
activities 
Baseline and 
24  weeks 
Follow up at 
28 weeks 
Grants from the National Institute 
on Aging (UO1 AG09095), 
Centres for Disease Control and 
Prevention (R48 CCR002181), 
and the Department of Veterans 
Affairs. 
Camargo et al. 
2008 
Brazil 
RT = 29 ± 3 yrs 
AT = 29 ± 4 yrs   
CON = 30 ± 4 yrs 
Males 
Healthy sedentary 
12 weeks 
3 d per week 
Supervised 
Weight machines 
3 sets of 15 reps at 60% of 1RM 
Continued 
with habitual 
activities 
Baseline and 
12 weeks 
Partially supported by a grant from 
FIPE-Hospital de Clinicas de 
Porto Alegre and FAPICC. 
Castaneda et 
al.  2002 
USA 
RT = 66 ± 2 yrs 
CON = 66 ± 1 yrs 
Male and female 
Type 2 diabetes  
16 weeks 
3 d per week 
 
Supervision not reported 
3 sets of 8 reps 
Weight machines 
1-8 weeks: 60-80% of baseline 
1RM 
10-14 weeks: 70-80% of mid-
study 1RM 
Continued 
with 
medications 
and received 
a weekly 
phone call  
Baseline and 
16 weeks 
Funded, in part, by Brookdale 
foundation in U.S. Department of 
Agriculture, the National Institutes 
of Health Clinical Research 
Centre and the International Life 
Sciences Institute, North America. 
Christensen et 
al. 2014  
Denmark 
RT = 34.4 ± 7.6 yrs 
CON= 35.8 ± 8.9 
yrs 
Male 
9 weeks 
3 d per week 
Supervised 
1-2 weeks: 3 sets of 15 reps at 
15RM 
Received 
standard 
care and 
continued 
Baseline and 
9 weeks 
Supported by Copenhagen 
University Hospital, the Beckett 
Foundation and the Centre for 
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Disseminated  
germ cell cancer 
3-9 weeks: 4 sets of 10 reps at 
10-12RM 
with 
medications 
Integrated Rehabilitation of 
Cancer Patients. 
Colado et al. 
2009 
Spain 
RT = 54 ± 2.8 yrs 
Aquatic = 54.7 ± 2 
yrs 
CON = 52.9 ± 1.9 
yrs 
Female 
Post-menopausal 
24 weeks Supervised 
Free-weight, machine and body 
weight exercises 
1-12 weeks: 8 exercise circuit, 1 
set of 20 reps with 30 sec active 
rest between sets, 1 set upper 
body, 2 sets lower body.          
12-24 weeks: 10 exercise circuit, 
1 set of 20 reps  
Not reported Baseline and 
24 weeks 
Funding (PMAFI-PI-01/1C/04) 
from the Research Funds 
Program of the Catholic University 
San Antonio in Murcia (Spain). 
Conceição et 
al. 2013 
Brazil 
RT = 53.4 ± 4 yrs 
CON = 53 ± 5.7 yrs 
Females 
Post-menopausal 
16 weeks 
3 d per week 
Supervision not reported 
Free-weight, machine and body 
weight exercises 
1-8 weeks: 3 sets of 10 reps at 
10RM with 60 s rest between 
sets 
9-16 weeks: 3 sets of 8 reps at 
8RM with 90 s rest between sets 
Continued 
with habitual 
activities 
Baseline and 
16 weeks 
Funding from the São Paulo 
Research Foundation (FAPESP) 
for financial support (2012/09709-
0). 
Courneya et 
al. 2007 
 
Courneya et 
al. 2010 
Canada 
RT= 49.5 yrs  
AT = 49 yrs 
Control = 49 yrs 
Females 
Breast cancer 
18 weeks  
Not reported 
Supervised 
Weight machines 
2 sets of 8-12 reps at 60% to 
70% 1RM 
Continued 
with habitual 
activity 
Baseline, 9 
(only for 
subjective 
measures) 
and 18 
weeks  
None reported  
 
Grant from the Canadian Breast 
Cancer Research Alliance. Also  
supported by a Doctoral Research 
Award from the Canadian 
Institutes of Health Research, the 
Canada Research Chairs 
Program, a Research Team Grant 
from the National Cancer Institute 
of Canada with funds from the 
Canadian Cancer Society and the 
National Cancer Institute of 
Canada Canadian Cancer Society 
Socio-behavioural Cancer 
Research Network and a New 
Investigator Award from the Heart 
and Stroke Foundation of Canada. 
Croymans et 
al. 2013 
USA 
RT = 21.5 yrs 
Control = 22 yrs 
12 weeks 
3 d per week 
Supervised Completed 
no 
Baseline and 
12 weeks 
Supported by the American Heart 
Association (BGIA no 0765139Y 
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Male 
Sedentary obese 
 Free-weight, machine and body 
weight exercises 
1-2 weeks: 2 sets of 12–15 reps 
at 100% of estimated 12–15RM 
3–7 weeks: 3 sets of 8–12 reps, 
at 100% of 8–12RM 
8–12: weeks: 6–8 reps at 6–
8RM 
resistance 
exercise for 
the duration 
of the 
intervention 
to CKR), the National Heart, Lung 
and Blood Institute (P50 
HL105188 to CKR) and the 
National Centre for Advancing 
Translational Sciences through 
UCLA CTSI Grant UL1TR000124 
RAH and the American Heart 
Association (10SDG305006). 
Davidson et al. 
2009 
USA 
FEMALES:  
RT = 67.6 ± 4.2 yrs 
AT = 69.1 ± 6.5 yrs 
Combined = 66.5 ±   
5.3 yrs 
CON = 66.7 ± 3.7 
yrs 
MALES:  
RT = 67.4 ± 6 yrs  
AT = 68.8 ± 6 yrs 
Combined = 67.1 ± 
5 yrs 
CON = 67.4 ± 3.8 
yrs 
Male and female 
Sedentary obese  
24 weeks 
3 d per week 
 
Supervision not reported 
Free-weight, machine and body 
weight exercises 
1 set 
Each exercise was performed 
until volitional fatigue 
Continued 
with habitual 
activities 
Baseline and 
24 weeks 
Supported by research grant MT 
13448 from the Canadian 
Institutes of Health Research. 
DeLima et al. 
2012 
Brazil 
RT linear 
periodization = 25.2 
± 4.4 yrs  
RT undulating 
periodization = 27.4 
± 2.8 yrs 
CON = 23.4 ± 1.3 
yrs 
Female 
Healthy sedentary 
12 weeks 
3 d per week 
Supervised 
Free-weight, machine and body 
weight exercises 
3 sets until failure 
RT linear: 3 sets of 30RM, in the 
second week 3 sets of 25RM, in 
the third week 3 sets of 20RM 
and in the fourth week 3 sets of 
15RM 
RT undulating: weeks 1, 3, 5, 7, 
9 and 11, participants trained on 
days 1 and 2 with 3 sets of 
30RM and on days 3 and 4 with 
3 sets of 25RM. Weeks 2, 4, 6, 
8, 10 and 12, participants 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
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trained on days 1 and 2 with 3 
sets of 20RM and on days 3 and 
4 with 3 sets of 15RM.  
DeSouza et al. 
2014 
Brazil 
RT = 25.9 ± 6.4 yrs 
Interval = 24 ± 7.5 
yrs 
Concurrent = 22.5 ± 
3.9 yrs 
CON = 22.1 ± 2.4 
yrs 
Male 
Physically active 
8 weeks 
2 d per week 
Supervision not reported 
3-5 sets of 6-12RM 
Not reported  Baseline and 
8 weeks 
Not reported 
Deibert et al. 
2011 
Germany 
RT = 55.5 ± 4.8 yrs  
RT + supplement = 
55.9 ± 3.5 yrs 
CON = 55.8 ± 5.5 
yrs 
Male 
Healthy sedentary 
12 weeks 
2 d per week 
 
Supervised 
Weight machines 
1–4 weeks: 25 reps  
5–9 weeks: 15 reps  
10-12 weeks: 10 reps  
Continued 
with habitual 
activity and 
received 
lifestyle 
advice 
Baseline and 
12 weeks  
Grants from Almased Wellness 
Corp. 
DeVallance et 
al. 2016 
USA 
RT = 51 ± 3 yrs 
CON = 44 ± 3 yrs 
Male and female 
Metabolic syndrome 
8 weeks 
3 d per week 
Supervision not reported 
Weight machines 
3 sets of 8-12 reps 
1–2 weeks: 60% of 1RM 
3–4 weeks: 70% of 1RM 
5–6 weeks: 80% of 1RM 
7–8 weeks: 85% of 1RM  
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Supported in part by the American 
Heart Association Grant 
11CRP7370056, National Heart, 
Lung, and Blood Institute Grant 
T32-HL-090610, and National 
Institute of General Medical 
Sciences of the National Institutes 
of Health under Award U54-GM-
104942 and 1P20 GM109098, 
STEM Mountains of Excellence 
Fellowship. 
Donges et al. 
2010 
Australia 
Age not reported. 
Male and female 
Healthy sedentary 
10 weeks 
3 d per week 
 
Supervised 
Weight machine exercises  
10RM that is reported to 
approximate with 75% of a 1RM 
Continued 
with habitual 
activity 
Baseline and 
10 weeks 
Funded by Charles Sturt 
University. 
Dunstan et al. 
1998 
Australia 
RT Circuit = 50.3 ± 
7.7 yrs 
CON = 51.1 ± 7.6 
yrs 
Male and female 
8 weeks 
3 d per week 
Supervised 
Free-weight, machine and body 
weight exercises 
1-2 weeks: 2 sets of 10-15 reps 
at 50–55% 1RM  
Continued 
with habitual 
activities 
Baseline and 
8 weeks 
Supported by a National Health 
and Medical Research Council 
program grant ‘Studies in 
hypertension and vascular 
disease’. 
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Type 2 diabetes 3-8 weeks: 3 sets of 10-15 reps 
at 50–55% 1RM  
Edge et al. 
2006 
Australia 
Total cohort = 18 ± 
1 yrs 
Female 
Physically active 
5 weeks Supervision not reported 
Free weights and machines 
1-2 weeks: 2-3 sets of 15-20 
reps 
3-5 weeks: 3-5 sets of 15-20 
reps 
Set 1 at 70% 3RM; set 2 at 60% 
3RM; sets 3–5 at 50% 3RM   
Not reported Baseline and 
5 weeks 
Not reported 
Egana et al. 
2010 
Ireland 
RT = 69 ± 5 yrs 
CON = 64 ± 4 yrs 
Female 
Healthy elderly 
12 weeks 
2 d per week 
 
Supervised 
Therabands 
2 sets at 100% 10RM  
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Elliott et al. 
2002 
UK 
RT = 58 ± 4 yrs 
CON = 53 ± 3 yrs 
Female 
Post-menopausal 
8 weeks 
3 d per week 
Supervision not reported 
3 sets of 8 reps at 80% 10RM  
Continued 
with habitual 
activity 
Baseline and 
8 weeks  
Follow-up at 
16 weeks 
Not reported 
Fahlman et al. 
2002 
USA 
RT = 73 ± 3 yrs 
AT = 76 ± 5 yrs  
CON = 74 ± 5 yrs 
Female 
Healthy elderly 
10 weeks 
3 d per week 
Supervision not reported 
Weight machines 
3 sets of 8 reps at 8RM 
Continued 
with habitual 
activity 
Baseline and 
10 weeks 
Not reported 
Fatouros et al. 
2005 
Greece 
RT low intensity = 
71.1 ± 3.6 yrs 
RT mod intensity = 
69.7 ± 3.8 yrs 
RT high intensity = 
70.8 ± 2.8 yrs 
CON = 69.8 ± 5.1 
yrs 
Male 
Sedentary obese 
24 weeks 
3 d per week 
 
Supervised 
Weight machines and body 
weight 
RT low intensity – 1-8 weeks: 2 
sets, 9-24 weeks: 3 sets, 45-
50% 1RM 
RT mod intensity – 1-8 weeks: 2 
sets, 9-24 weeks: 3 sets, 60-
65% 1RM 
RT high intensity – 1-8 weeks: 2 
sets, 9-24 weeks: 3 sets, 80-
85% 1RM 
 
Not reported Baseline and 
24 weeks 
Follow up at 
48 weeks 
Not reported 
Fenkci et al. 
2006 Turkey 
RT = 44 ± 10.2 yrs 
AT = 41.7 ± 6.9 yrs  
12 weeks 
3 d per week 
Supervision not reported 
Weight machines 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
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CON = 43.8 ± 7.4 
yrs 
Female 
Sedentary obese 
1 week: 1 set of 10 reps of 40-
60% 1RM 
2 weeks: 2 sets of 10 reps of 40-
60% 1RM 
3 weeks: 3 sets of 10 reps of 40-
60% 1RM 
4-12 weeks: 3 sets of 75-80% 
1RM 
Figueroa et al. 
2012 
 
Figueroa et al. 
2013 
 
Figueroa et al. 
2013 
USA 
Not reported. 
 
RT with WBV = 56 ± 
3 yrs 
CON = 56 ± 3 yrs 
 
RT with WBV = 55.5 
± 0.7 yrs 
CON = 56.4 ± 1 yrs  
Female 
Sedentary obese 
6 weeks  
12 weeks 
3 d per week 
Supervised 
Whole body vibration with free 
weights 
Vibration intensity was 
progressed by increasing the 
frequency (25–30Hz) and 
amplitude (1–2mm). The 
duration of the sets and rest 
periods was progressively 
increased (30–60 s) and 
decreased (60–30 s), 
respectively.  
Continued 
with habitual 
activity 
Baseline and 
6 weeks 
Not reported 
Franklin et al. 
2015 
USA 
RT = 30.3 ± 5.4 yrs 
CON = 30.8 ± 9.0 
yrs 
Female 
Sedentary obese 
8 weeks 
2 d per week 
Supervised 
Free weights and machines 
2-3 sets of 10 reps at 80–90% 
10RM 
Continued 
with habitual 
activity and 
offered 
educational 
material 
Baseline and 
8 weeks 
Supported by the National Heart, 
Lung, and Blood Institute grants 
lK23HL85614, RO1HL095701, 
and HL095701-01A2S, and the 
University of Illinois at Chicago, 
Centre for Clinical and 
Translational Science, award 
UL1RR029879 from the National 
Centre for Research Resources. 
Garcia-Lopez 
et al. 2007 
Finland 
RT = 54.9 ± 1.9 yrs 
AT = 53.6 ± 2.4 yrs  
CON = 53.3 ± 2.5 
yrs 
Male 
Healthy sedentary 
21 weeks 
2 d per week 
Supervised 
Weight machines 
1-7 weeks: 2-4 sets of 8-15 reps 
at 40–70% 1RM 
8–14 weeks: 2-5 sets of 5-12 
reps at 60–80% 1RM 
15-21 weeks:3-5 sets of 5-10 
reps at 60–85% 1RM  
Continued 
with habitual 
activity 
Baseline, 
10.5 (not 
control 
group) and 
21 weeks 
Funded, in part, by a grant from 
the Ministry of Education, Finland. 
Gater et al. 
1992 
USA 
Physically active 10 weeks Not reported  Baseline and 
10 weeks 
Grant from Ross Laboratories, the 
Achievement Reward for College 
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Scientists Foundation, and 
National Heart, Lung and Blood 
Institute Research Services Award 
HL-07249. 
Gelecek et al. 
2012 
Turkey 
RT = 54.3 ± 5.3 yrs 
CON = 51.8 ± 3.7 
yrs 
Female 
Post-menopausal 
12 weeks 
3 d per week 
 
Supervised 
Free weights and machines 
2 sets of 8-12 reps at 60% 1RM  
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Funded by the Department of 
Scientific Research Projects of 
Dokuz Eylül University. 
Gettman et al. 
1978 
USA 
Physically active 20 weeks 
3 d per week 
 
Supervision not reported 
Free weight, weight machines 
and body weight 
1-6 weeks: 10-20 reps per set at 
50% 1RM 
7-20 weeks: 15 reps per set at 
50% 1RM  
 Baseline and 
20 weeks 
Supported by the International 
Association of Chiefs of 
Police/Law Enforcement 
Assistance Administration, Grant 
No. 76-NI-99-001 
Gordon et al. 
2006 
UK 
RT = 67 ± 2 yrs  
CON = 67 ± 2 yrs 
Male and female 
Type 2 diabetes   
16 weeks 
3 d per week 
 
Supervision not reported 
Weight machines 
3 sets of 8 reps at 60-65% 1RM 
Continued 
with habitual 
activity and 
received 
weekly 
phone calls 
Baseline and 
16 weeks 
Supported by the Brookdale 
Foundation, USDA ARS 
Cooperative Agreement 58-1950-
9-00 I and NIH GCRC grant MOl 
RR000054. 
Greenwood et 
al. 2015 
USA 
RT = 54.6 ± 10.6 
yrs 
AT = 53.9 ± 10.7 yrs 
CON = 49.5 ± 10.6 
yrs 
Male and female  
Kidney transplant 
recipients 
12 weeks 
3 d per week 
 
Supervised 
Elastic resistance bands, ankle 
weights and free weights 
1-2 sets of 10 reps at 80% 1RM 
 
Usual care 
was followed 
and so seen 
routinely in 
the 
transplantati
on 
clinic 
Baseline and 
12 weeks 
Funded by an NIHR Doctoral 
Research Fellowship. The study 
was hosted in the King’s College 
Hospital NIHR clinical research 
facility. This article presents 
independent research funded by 
the NIHR. 
Gregory et al. 
2013 
USA 
Total cohort = 20.3 
± 0.3 yrs 
Female 
Physically active 
8 weeks 
3 d per week 
 
Supervised 
Free-weight, machine and body 
weight exercises 
3 sets of 3-12RM  
Continued 
with habitual 
activity 
Baseline, 4 
and 8 weeks 
Grant from the U.S. Army Medical 
Research and Materiel Command 
Bone Health and Military Medical 
Readiness Research Program to 
BCN. 
Hagberg et al. 
1989 
USA 
Total cohort = 72 ± 
3 yrs 
Male and female 
Healthy sedentary 
26 weeks 
3 d per week 
Supervised 
Weight machines 
8-12 reps 
Not reported Baseline, 13 
(not controls 
and 26 
weeks  
Funded, in part, by a grant from 
the Diabetes Treatment Centres 
of America Foundation. 
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Hagerman et 
al. 2000 
UK 
RT = 63.7 ± 5 yrs 
CON = 66.2 ± 6.5 
yrs 
Male 
Healthy elderly 
16 weeks 
2 d per week 
Supervision not reported 
Free-weight, machine and body 
weight exercises 
1 set of 10 reps at 85-90% 1RM 
followed by 3 sets to failure of 6-
8 reps at 85-90% 1RM  
Not reported Baseline and 
16 weeks 
Not reported 
Hagstrom et 
al. 2016 
Australia 
RT - 51.2 ± 8.5 yrs 
CON - 52.7 ± 9.4 
yrs 
Female 
Breast cancer 
16 weeks 
3 d per week 
Supervised 
Free weight and weight 
machines 
3 sets of 8-10 reps at 8RM 
 Baseline and 
16 weeks 
Supported by a grant from 
Western Sydney University, 
Australia. 
Hallsworth et 
al. 2011  
 
Jakovljevic et 
al. 
Finland 
RT = 52 ± 13.3 yrs 
CON = 62 ± 7.4 yrs  
RT = 49 ± 13 yrs 
CON= 62 ± 7 yrs 
Male and female 
Non-alcoholic fatty 
liver disease 
8 weeks 
3 d per week 
Supervision biweekly 
Free weights and weight 
machine 
2 sets at 50% 1RM  
Not reported 
 
Baseline and 
8 weeks 
Not reported 
Hautala et al. 
2006 
Canada 
RT = 42 ± 1 yrs  
CON = 41 ± 1 yrs 
Male and female 
Healthy sedentary 
2 weeks 
5 d per week 
Supervised 
1 set of 8-12 reps 
Continued 
with habitual 
activity 
Baseline and 
2 weeks 
Funding from the EU Seventh 
Framework Programme 
(FP7/2007-2013) under grant 
agreement no Health-F2-2009-
241762, for the project FLIP; the 
MRC; the UK NIHR Biomedical 
Research Centre on Ageing and 
Age-Related Diseases and 
Diabetes UK. 
Haykowsky et 
al. 2000 
Canada 
RT = 68 ± 3 yrs 
CON = 68 ± 4 yrs 
Male 
Healthy elderly 
16 weeks  
3 d per week 
Supervision not reported 
Free weights and weight 
machine 
3-10 reps at 60-80% 1RM 
Continued 
with habitual 
activity 
Baseline, 4, 
8, 12 and 16 
weeks 
Grants from the Ministry of 
Education (Helsinki, Finland) and 
the Medical Council of the 
Academy of Finland (Helsinki, 
Finland). 
Haykowsky et 
al. 2005 
Iran 
RT = 70 ± 4 yrs 
AT = 66 ± 3 yrs 
Combined = 68 ± 6 
yrs 
CON = 67 ± 4 yrs 
Female 
Healthy elderly 
12 weeks 
3 d per week 
Supervised 
2 sets of 10 reps at 50% 1RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
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Hedayati et al. 
2012 
USA 
RT 40% 1RM = 
23.2 ± 1 yrs  
RT 80% 1RM = 
21.9 ± 1.5 yrs 
CON = 20.8 ± 1 yrs 
Female 
Physically active 
4 weeks  
4 d per week 
Supervision not reported 
Free weights and machines  
3 sets of 8-11 reps 
Not reported Baseline and 
4 weeks 
Not reported 
Heffernan et 
al. 2013 
USA 
RT = 60 ± 2 yrs 
CON = 63 ± 2 yrs 
Sex not reported. 
Pre-hypertensive 
and newly 
diagnosed/never-
treated 
hypertensive 
12 weeks 
3 d per week 
Supervised 
Weight machines 
2 sets of 12-15 reps at 40% 
1RM for upper body and 60% 
1RM for lower body  
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Hendrickson et 
al. 2010 
USA 
RT = 21 ± 0.5 yrs 
AT = 21 ± 0.4 yrs 
Combined = 20 ± 
0.4 yrs 
CON = 20 ± 0.5 yrs 
Female 
Physically active 
12 weeks 
3 d per week 
Supervised 
Free weights, machine and body 
weight exercises 
3–6 weeks - ‘‘light’’ days at 
12RM, ‘‘moderate’’ days at 8–
10RM, and ‘‘heavy’’ days at 6–
8RM loads.  
8–11 weeks - ‘‘light’’ days at 
12RM, ‘‘moderate’’ days at 6–
8RM, and ‘‘heavy’’ days at 3–
5RM  
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Hiatt et al. 
1994 
 
Hiatt et al. 
1996 
Finland 
RT = 67 ± 6 yrs 
AT = 67 ± 7 yrs 
CON = 67 ± 5 yrs 
Male 
Peripheral artery 
disease 
12 weeks 
4 d per week 
3 d per week 
Supervised 
Cuff weight secured to the leg 
3 sets or 6RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Funded, in part, by a grant from 
the Medical Research and 
Material Command Bone Health 
Research Program to BCN. 
Hoff et al. 
2007 
Norway 
RT = 62.8 ± 1.4 yrs 
CON = 60.6 ± 3.0 
yrs 
Male and female 
Chronic obstructive 
pulmonary disease 
8 weeks 
3 d per week 
Supervision not reported 
4 sets of 5 reps at 85-90% 1RM  
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Grant H133G90114 from the 
National Institute on Disability and 
Rehabilitation Research. Dr Hiatt 
is the recipient of a National 
Institutes of Health Academic 
Award in Vascular Disease. 
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Holviala et al. 
2012 
Belgium 
RT = 56.5 ± 7.6 yrs 
AT = 55.5 ± 8.7 yrs   
Combined = 56.9 ± 
7.5 yrs 
CON = 56.7 ± 7.5 
yrs 
Male 
Healthy sedentary 
21 weeks 
2 d per week 
Supervised 
Weight machines 
1-7 weeks - 40–60% of 1RM 
8-14 weeks - 60–80% of 1RM 
15-21 weeks - 70–85% of the 
1RM 
Continued 
with habitual 
activity 
Baseline and 
21 weeks 
Not reported 
Hoof et al. 
1996 
Canada 
Age not reported. 
Male 
Healthy sedentary 
16 weeks 
3 d per week 
Supervised 
Weight machines 
1-4 weeks – 3 sets of 12 reps at 
70%1RM 5-16 weeks - 3 sets of 
10 reps at 70% 1RM followed by 
4 reps at 90% 1RM  
Continued 
with habitual 
activity 
Baseline and 
16 weeks 
Funded, in part, by the Norwegian 
Research Council by providing a 
Professor II position for Dr 
Richardson, grant HL-17731 from 
the National Heart, Lung, and 
Blood Institute and Tobacco 
Related Disease Research 
Program grant #15RT-0100. 
Horne et al. 
1996 
Finland 
Total cohort = 22.3 
± 3.3 yrs 
Male and female  
Physically active 
12 weeks 
3 d per week 
Supervision not reported 
Machines and free weights 
Not reported Baseline, 6 
and 12 
weeks 
Grants from the Belgian Ministry 
of Defence. 
Hu et al. 2009 
USA 
RT = 32.2 ± 7.2 yrs 
CON = 31 ± 7.5 yrs 
Males 
Healthy sedentary 
10 weeks 
2-3 d per 
week 
Supervised Continued 
with habitual 
activity 
Baseline and 
10 weeks 
Not reported 
Huffman et al. 
2014 
Norway 
Age not reported. 
Male and female 
Metabolic risk 
factors 
24 weeks 
3 d per week 
Supervised 
Weight machines 
3 sets of 8-12 reps 
 
Not reported Baseline and 
24 weeks 
Grants from the National 
Technology Agency of Finland, 
the Ministry of Education of 
Finland, Juho Vainio Foundation 
and partially funded by the 
National Science Foundation of 
Guangdong Province 
(815100760100004), China. 
Husby et al. 
2009 
 
Husby et al. 
2010 
USA 
RT = 58 ± 5 yrs 
CON = 56 ± 8 yrs 
Male and female 
Total hip 
arthroplasty 
4 weeks 
post-
operative 
5 d per week 
Supervised 
Weight machines 
4 sets of 5 reps at 85% 1RM 
Usual care 
involving 
conventional 
rehabilitation 
program 
following 
Pre-
operative, 1 
week post-
operative, 5 
week Follow 
up at 24 and 
52 weeks  
Supported by the National Heart, 
Lung, and Blood Institute, National 
Institute on Aging and National 
Institute of Arthritis and 
Musculoskeletal and Skin 
Diseases. 
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total hip 
arthroplasty 
Irving et al. 
2015 
Denmark 
Young: 
RT = 25 ± 1 yrs 
AT = 25 ± 1 yrs 
CON = 26 ± 1 yrs 
Combined = 26 ± 1 
yrs 
Old: 
RT = 70 ± 1 yrs  
AT = 70 ± 1 yrs 
CON = 71 ± 2 yrs 
Combined = 71 ± 2 
yrs 
Male and female 
Healthy sedentary 
8 weeks 
4 d per week 
Supervised 
4 sets of 8–10 reps  
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Supported by National Institute of 
Health grant R01-AG09531, RO1-
DK41973, National Centre for 
Advancing Translational Science 
grants UL1-RR024150 and KL2-
RR024151, CTSA Grant Number 
UL1- TR000135 from the National 
Centre for Advancing 
Translational Sciences a 
component of the National 
Institutes of Health. 
Jay et al. 2011 
Finland 
RT = 44 ± 8 yrs 
CON = 43 ± 10 yrs 
Male and female 
Healthy sedentary 
8 weeks 
3 d per week 
Supervised 
Kettlebells 
Not reported Baseline and 
8 weeks 
Funded by The National Research 
Centre for the Working 
Environment. 
Kaikkonen et 
al. 2000 
Brazil 
RT = 42.5 ± 7 yrs 
AT = 41.6 ± 6 yrs             
CON = 41.9 ± 7 yrs 
Male and female  
Healthy sedentary 
12 weeks 
3 d per week 
No supervision provided 
Weight machines 
3 circuits of 10 stations 
 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Kanegusuku et 
al. 2011 
Finland 
RT = 63 ± 1 yrs 
Power Training = 65 
± 1 yrs 
CON = 63 ± 1 yrs 
Male 
Healthy elderly 
16 weeks 
2 d per week 
Supervision not reported 
Weight machines 
RT: 2 sets, 10 reps at 70% to 4 
sets, 4-6 reps, 85-90% 
PT: 3 sets, 7 reps, 30% to 4 
sets, 4-6 reps, 45-50% 
Continued 
with habitual 
activity 
Baseline and 
16 weeks 
Supported by FAPESP 
(#07/56653-1 and #07/00788-6), 
CNPq (#471600/2008-3), CAPES, 
and Head of the 
Psychopharmacology Incentive 
Fund Association. 
Karavirta et al. 
2009 
 
Karavirta et al. 
2011 
Finland 
RT = 56 ± 6 yrs 
AT = 54 ± 8 yrs 
Combined = 56 ± 7 
yrs 
CON = 54 ± 8 yrs 
Male 
Healthy sedentary 
21 weeks  
2 d per week 
Supervised 
Weight machines and body 
weight  
1-7 weeks: 3 sets of 15-30 reps 
at 40–60% 1RM 
8-14 weeks: 2-4 sets of 6-12 
reps at 60–80% 1RM 
Continued 
with habitual 
activity 
Baseline, 
10.5 and 21 
weeks 
Partially supported by grants from 
the Ministry of Education, Finland, 
Central Finland Health Care 
District, Jyväskylä, Finland, and 
Polar Electro Oy. 
Partly supported by the Ministry of 
Education, Finland and the Juho 
Vainio Foundation, Finland. 
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15-21 weeks: 2-4 sets of 5-8 
reps at 70–85% 1RM 
Karavirta et al. 
2013 
Japan 
RT = 52 ± 8 yrs 
AT = 52 ± 7 yrs 
Combined = 49 ± 6 
yrs 
CON = 52 ± 8 yrs 
Female 
Healthy sedentary 
21 weeks 
2 d per week 
Supervised 
Weight machines and body 
weight  
1-7 weeks: 3 sets of 12-20 reps 
at 40–60% 1RM 
8-14 weeks: 2-4 sets of 5-12 
reps at 60–80% 1RM 
15-21 weeks: 2-4 sets of 5-8 
reps at 70–85% 1RM 
Not reported Baseline, 
10.5 and 21 
weeks 
Partly supported by the grants 
from the Ministry of Education and 
Culture, Central Finland Health 
Care District, Juho Vainio 
Foundation, Yrjo Jahnsson 
Foundation, the University of 
Jyväskylä, G. Harold and Leila Y. 
Mathers Charitable Foundation, 
James S. McDonnell Foundation, 
the National Institutes of Health-
sponsored Research Resource for 
Complex Physiologic Signals, and 
the National Institute on Aging. 
Karelis et al. 
2015 
Canada 
RT - 45. 3± 14 yrs 
CON - 39.4 ± 8 yrs 
Male and female 
Kidney transplant 
patients 
16 weeks 
3 d per week 
Supervised for 1 session a week 
Free weight, weight machines, 
body weight and elastic 
resistance 
3 sets of 10 reps at 80% 1RM 
Continued 
habitual 
activity 
Baseline and 
16 weeks 
 
Supported by funds from 
investigator-sponsored research 
by AstellasPharma Canada, Inc 
(SG112). RRL is supported by the 
Fonds de Recherche du Québec - 
Santé and holds the J-A De Sève 
research chair. MJH is supported 
by the Canadian Institutes of 
Health Research and Canadian 
National Transplant Research 
Program and holds the Shire chair 
in nephrology and renal 
transplantation and regeneration 
at the Université de Montréal. 
Kawano et al. 
2006 
Canada 
RT = 20 ± 1 yrs    
Combined = 21 ± 1 
yrs 
CON = 22 ± 1 yrs 
Male 
Healthy sedentary 
20 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3 sets at 50%1 RM 
Continued 
with habitual 
activity 
Baseline, 8 
and 12 
weeks 
Follow up at 
24 and 32 
weeks 
Grants from the Ministry of Health, 
Labour and Welfare (H18-J-W-
002), Japan Society for the 
Promotion of Science (17300226), 
and the National Institutes of 
Health in the US (AG20966). 
Kell & 
Asmundson 
2009 
UK 
RT = 40.1 ± 8.7 yrs 
AT = 36.7 ± 8.9 yrs 
CON = 35.3 ± 7.3 
yrs 
16 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
Continued 
with habitual 
activity 
Baseline, 8 
(not controls) 
and 16 
weeks 
Support from the Saskatchewan 
Health Research Foundation 
(New Investigator Grant) and the 
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Male and female 
Chronic lumbar pain 
4 sets of 10 reps at 53–72% 
1RM 
University of Alberta, Augustana 
Campus (travel grant). 
Kemi et al. 
2011 
Iran 
RT = 20.8 ± 2.4 yrs 
CON = 23 ± 2.9 yrs 
Female 
Healthy sedentary 
8 weeks 
3 d per week 
Supervised 
Free weights 
5 sets of 5 reps at 85% 1RM 
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Not reported 
Kemmler et al. 
2016 
Germany 
HIT = 42.9 ± 5.4 yrs 
CON = 42.5 ± 5.6 
yrs 
Male 
Healthy sedentary 
22 weeks 
2-3 d per 
week 
Supervised 
Weight machines 
Single set to failure of 6-8 reps 
Continued 
with habitual 
activity 
Baseline and 
22 weeks 
The authors are grateful for the 
support of the Staedtler-Stiftung 
(Nürnberg, Germany), Kieser 
Training (Erlangen, Germany), 
Post SV Nürnberg (Nürnberg, 
Germany), and Protein4you 
(Saarlouis, Germany).  
Khorvash et al. 
2012 
USA 
Total cohort = 25.1 
± 3.2 yrs 
Male 
Depression and 
anxiety 
10 weeks 
2 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
Not reported Baseline and 
10 weeks 
Not reported 
Kim et al. 2011 
Switzerland 
Traditional RT = 
20.8 ± 0.8 yrs 
Super slow RT = 
19.5 ± 0.3 yrs 
CON = 21.5 ± 0.8 
yrs 
Female 
Healthy sedentary 
4 weeks  Supervision not reported 
Weight machines 
Traditional RT: 3 sets of 8 reps 
at 80% 1RM 
Super slow RT: 1 set to fatigue 
at 50% 1RM 
Continued 
with habitual 
activity 
Baseline and 
4 weeks 
Not reported 
Ku et al. 2010 
Korea 
RT = 55.7 ± 6.2 yrs 
AT = 55.7 ± 7 yrs 
CON = 57.8 ± 8.1 
yrs 
Female 
Type 2 diabetes 
12 weeks 
4 d per week 
Supervised 
Elastic resistance bands  
3 sets of 15-20 reps 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Kwon et al. 
2010 
Korea 
RT = 55.7 ± 6.2 yrs 
CON = 57 ± 8 yrs 
Female 
Type 2 diabetes 
12 weeks 
3 d per week 
Supervision not reported 
Elastic resistance bands  
3 sets of 10-15 reps 
Continued 
with habitual 
activity 
 
Baseline and 
12 weeks 
Supported by Korean Diabetes 
Clinical Research Institution. 
Kwon et al. 
2011 Canada 
RT = 56.3 ± 6.1 yrs 
AT = 55.5 ± 8.6 yrs 
12 weeks 
3 d per week 
Supervision not reported 
Elastic resistance bands  
3 sets of 10-15 reps 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
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CON = 58.9 ± 5.7 
yrs 
Female 
Type 2 diabetes 
 
Larose et al. 
2010 
USA 
RT = 54.7 ± 7.5 yrs 
AT = 53.9 ± 6.6 yrs   
Combined = 53.5 ± 
7.3 yrs 
CON = 54.8 ± 7.2 
yrs 
Male and female 
Type 2 diabetes  
Run in of 4 
weeks 
followed by 
22 weeks 
intervention. 
2-3 d per 
week 
Supervised 
Biweekly supervision after week 
4 
Weight machines  
4 week run-in phase: 1-2 sets of 
10 reps 
5-22 weeks: 3 sets of 8 reps  
Continue 
with habitual 
activity 
Baseline and 
22 weeks 
Grants from the Canadian 
Institutes of Health Research 
(grant MCT-44155), Canadian 
Diabetes Association (The Lillian 
Hollefriend Grant), and the 
Interfaculty Grant program of the 
University of Ottawa. 
LeMura et al. 
2000 
Australia 
RT = 20 ± 1 yrs 
AT = 21 ± 2 yrs 
Cross training = 19 
± 2 yrs  
CON = 20 ± 1 yrs 
Female 
Healthy sedentary 
16 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
1-2 weeks: 1 set of 8-10 reps at 
60-70% 1RM 
3-14 weeks: 3 sets of 8-10 reps 
at 60-70% 1RM 
Continued 
with habitual 
activity and 
completed 
an activity 
log 
Baseline, 8 
and 16 
weeks 
Follow up  at 
20 weeks 
Not reported 
Levinger et al. 
2007 
 
Levinger et al. 
2008 
 
Levinger et al. 
2009 
Brazil 
LoMFC = 48.5 ± 7.7 
yrs 
LoMFT = 50.6 ± 5.1 
yrs 
HiMFC = 52.3 ± 5.8 
yrs 
HiMFT = 51.6  ± 7.1 
yrs 
 
LoMFC = 48.9 ± 7.4 
yrs 
LoMFT = 50.3 ± 4.1 
yrs 
HiMFC = 51.9 ± 5.8 
yrs 
HiMFT = 51  ± 7 yrs 
 
LoMFC = 48.5 ± 7.7 
yrs 
10 weeks 
3 d per week 
Supervised 
Weight machines 
Week 1: 2 sets of 15–20 reps at 
40–50% 1RM 
Week 2: 3 sets of 15–20 reps at 
50–60% 1RM 
3-6 weeks: 3 sets of 12–15 reps 
at 60–75% 1RM 
7-10 weeks: 3 sets 8 –12 reps at 
75–85% 1RM 
Continue 
with habitual 
activity 
Baseline and 
10 weeks 
Not reported 
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LoMFT = 50.6 ± 5.1 
yrs 
HiMFC = 52.3 ± 5.8 
yrs 
HiMFT = 51.6  ± 7.1 
yrs 
Male and female 
Metabolic risk 
factors 
Libardi et al. 
2011 
 
Libardi et al. 
2012 
Taiwan 
RT = 48.6 ± 5 yrs 
Concurrent = 48.5 ± 
5.3 yrs 
CON = 49.1 ± 5.5 
yrs  
Male 
Healthy sedentary 
 
RT = 49.3 ± 4.8 yrs 
AT = 49.3 ± 5.4 yrs 
Concurrent = 48.5 ± 
5.4 yrs 
CON = 49.1 ± 5.9 
yrs 
Male 
Healthy sedentary 
16 weeks 
3 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
3 sets at 8-10RM 
Not reported Baseline and 
16 weeks 
Supported by the National Council 
of Technological and Scientific 
Development, Brazil. 
Supported by the National 
Counsel of Technological and 
Scientific Development, Brazil. 
Lo et al. 2011 
Australia 
RT = 20.2 ± 1.4 yrs 
AT = 20 ± 0.7 yrs 
CON = 21.1 ± 1.7 
yrs 
Male 
Healthy sedentary  
24 weeks 
3 d per week 
Supervised 
Weight machines 
1-8 weeks: 1 set at 15RM 
9-16 weeks: 1 set of 10 reps at 
75% 1RM 
17-24 weeks: 2 sets of 4 reps at 
90% 1RM 
Not reported Baseline and 
24 weeks 
Follow- up at 
48 weeks 
Supported by the National 
Science Council, 95-2413-H-006-
010, Taiwan, ROC. 
Lovell et al. 
2009 
Lovell et al. 
2012 
USA 
RT = 74.1 ± 2.7 yrs 
CON = 73.5 ± 3.3 
yrs 
 
RT = 74.1 ± 2.7 yrs 
AT = 75.2 ± 3.0 yrs  
16 weeks 
3 d per week 
Supervised 
Weight machine 
3 sets of 6-10 reps at 50-
90%1RM 
Continued 
with habitual 
activity 
Baseline, 4, 
8, 12, and 16 
weeks 
Not reported 
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CON = 73.5 ± 3.3 
yrs 
Male 
Healthy elderly 
Madden et al. 
2006 
Iran 
RT = 69.8 ± 1.5 yrs 
AT = 70 ± 2.6 yrs 
CON = 71.8 ± 1.2 
yrs 
Female 
Healthy elderly 
24 weeks 
5 d per week 
Supervised 
Free weights 
3 sets of 8-12 reps at 85% 1RM 
Continued 
with habitual 
activity 
Baseline and 
24 weeks 
Supported by the AHA 
Washington Affiliate Grant-in-aid, 
the Medical research service of 
the department of veterans affairs 
Mahdirejei et 
al. 2014 
Australia 
RT = 47.6 ± 7.7 yrs 
CON = 49.6 ± 8.1 
yrs 
Male 
Type 2 diabetes 
8 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3 sets of 8-15 reps at 50-80% 
1RM 
Not reported Baseline and 
8 weeks 
Supported by Islamic Azad 
University Sari Branch, Sari, Iran. 
Maiorana et al. 
1997 
Australia 
RT = 61.2 ± 8.4 yrs 
CON = 59 ± 8.7 yrs 
Male 
Coronary bypass 
graft 
10 weeks Supervised 
Free weights, weight machines 
and body weight 
1-3 sets of 10-15 reps at 40-
60% MVC 
Continued 
with habitual 
activity 
Baseline and 
10 weeks 
Not reported 
Maiorana et al. 
2011 
USA 
RT = 58.8 ± 3.5 yrs 
AT = 61.3 ± 2.8 yrs 
CON = 64.4 ± 2.4 
yrs 
Male and female 
Stable chronic heart 
failure 
12 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
1-6 weeks: 3 sets of 60 secs at 
50-60% 1RM 
7-12 weeks: 3 sets of 60 secs at 
60-70% 1RM 
Continued 
with habitual 
activity 
Baseline, 6 
and 12 
weeks 
Supported by the National Heart 
Foundation (Australia), the Dutch 
Heart Foundation (E. Dekker, 
stipend) and the Australian 
Research Council. 
Malin et al. 
2013 
USA 
Normal body fat = 
21.9 ± 0.8 yrs 
High body fat = 21.0 
± 0.8 yrs 
CON = 20.9 ± 0.6 
yrs 
Female 
Healthy sedentary 
7 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3 sets of 10-12 reps at 60% 
1RM 
Not reported Baseline and 
7 weeks 
Funded by the Wayne State 
College Foundation. 
Manning et al. 
1991 
USA 
RT= 35.4 ± 2.6 yrs 
CON = 40.3 ± 5.5 
yrs 
Female 
12 weeks 
3 d per week 
Supervision not reported 
Free weights and weight 
machines 
Not reported Baseline, 4, 
8 and 12 
weeks 
Supported, in part, by grant from 
the Valley Hospital and the 
William Paterson College of New 
Jersey. 
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Sedentary obese 2-3 sets of 6-8 reps at 60-70% 
1RM 
Marcinik et al. 
1991 
USA 
RT= 29 ± 4 yrs 
CON = 30 ± 4 yrs 
Male 
Healthy sedentary 
12 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3 sets at 8-20RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Marcus et al. 
2009 
Portugal 
RT Eccentric = 56.3 
± 6.4 yrs 
CON = 53.2 ± 6.5 
yrs 
Females  
Impaired glucose 
tolerance 
12 weeks 
3 d per week 
Supervised 
Weight machine 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Supported by the Utah Building 
Interdisciplinary Research 
Careers in Women's Health 
Program (NIH grant 
5K12HD043449-04). 
Martins et al. 
2010 
Martins et al. 
2010 
USA 
Total cohort = 76 ± 
8 yrs  
Male and female 
Healthy sedentary 
 
RT= 73.2 ± 6.5 yrs 
AT = 76.2 ± 7.4 yrs 
CON = 81.2 ± 7.9 
yrs  
Males and females 
16 weeks 
3 d per week 
Supervised 
Elastic resistance bands 
1-2 weeks: 1 set of 8 reps 
3-4 weeks: 1 set of 12 reps 
5-6 weeks: 2 sets of 8 reps 
7-8 weeks: 2 sets of 10 reps 
9-10 weeks: 2 sets of 12 reps 
11-12 weeks: 2 sets of 15 reps 
13-14 weeks: 3 sets of 12 reps 
15-16 weeks: 3 sets of 15 reps 
Not reported Baseline and 
16 weeks 
 
Baseline and 
16 weeks 
Follow-up at 
32 weeks 
Supported by the Portuguese 
Foundation for Science and 
Technology and the Portuguese 
Institute of Sport. 
McDermott et 
al. 2009 
Australia 
RT = 71.7 ± 8.7 yrs 
AT = 71.7 ± 8.7 yrs  
CON = 68.5 ± 11.9 
yrs 
Male and female 
Peripheral artery 
disease 
24 weeks 
3 d per week 
Supervised 
Weight machines 
3 sets of 8 reps at 50-80% 1RM 
Education 
sessions 
Baseline and 
24 weeks 
Supported by grants R01-
HL073551 from the National 
Heart, Lung, and Blood Institute 
and by RR-00048, National 
Institutes of Health and the 
Intramural Research Program, 
National Institutes on Aging. 
McGuigan et 
al. 2001 
USA 
RT = 70 ± 6 yrs 
CON = 66 ± 6 yrs 
Male and female 
Peripheral artery 
disease 
24 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
2 sets at 8-15RM 
Continued 
with habitual 
activity 
Baseline, 12 
and 24 
weeks 
Supported by an American 
College of Sports Medicine 
Foundation Research Grant for 
doctoral students. 
Mikesky et al. 
1994 
Canada 
RT= 69.2 ± 4.0 yrs 
CON = 72.8 ± 5.7 
yrs 
Male and female 
12 weeks 
3 d per week 
Supervision for 1 session a 
week 
Body weight and elastic 
resistance bands  
Attended two 
3-h 
automobile 
driving 
Baseline and 
12 weeks 
Grant from the Indiana University 
Grant-in-Aid program. 
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Healthy elderly 1-2 weeks: 1 set of 12 reps 
3-4 weeks: 2 sets of 12 reps 
5-12 weeks: 2-3 sets of 12 reps 
safety 
classes 
during 
weeks 4 and 
8 
Millar et al. 
2008 
Japan 
RT = 66 ± 1 yrs  
CON = 67 ± 2 yrs 
Male and female 
Healthy elderly 
8 weeks 
3 d per week 
Supervision for 2 sessions a 
week 
Weight machine 
1 set of 4 reps at 30-40% MVC 
Not reported Weekly for 8 
weeks 
Supported by an Ontario 
Graduate Scholarship award and 
a Natural Sciences and 
Engineering Research Council of 
Canada Discovery grant. 
Miura et al. 
2008 
Japan 
RT 1d·week = 69 ± 
6.5 yrs 
RT 2d·week = 69.5 
± 7 yrs 
CON = 68.9 ± 7.5 
yrs 
Female 
Healthy elderly 
12 weeks 
1 or 2 d per 
week 
 
Supervised 
Free weights and elastic 
resistance bands 
3–5 sets of 15–20 reps 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Supported by a Grant-in Aid for 
Scientific Research from the 
Ministry of Education, Science, 
Sports and Culture of Japan 
(15700441). 
Miyachi et al. 
2004 
Norway 
RT = 22 ± 1 yrs 
CON = 22 ± 1 yrs 
Male 
Healthy sedentary 
16 weeks 
3 d per week  
Supervised  
Free weights, weight machines 
and body weight 
3 sets of 12 reps at 80% 1RM 
Continued 
with habitual 
activity 
Baseline and 
16 weeks 
Follow-up at 
24 weeks 
Grants from the National Institutes 
of Health (AG-020966), Japan 
Society for Promotion of Science 
(13780041 and 14208005) and 
the Meiji Yasuda Life Foundation. 
Mosti et al. 
2013 
Norway 
RT = 61.9 ± 5 yrs 
CON = 66.7 ± 7.4 
yrs 
Females  
Osteoporosis or 
osteopenia 
12 weeks 
3 d per week 
 
Supervised 
Weight machines 
4 sets of 3–5 reps at 85–90% 
1RM 
Encouraged 
to follow 
current 
exercise 
guidelines 
for 
osteoporotic 
patients 
Baseline and 
12 weeks 
Funded by the Liaison Committee 
between the Central Norway 
Regional Health Authority and the 
Norwegian University of Science 
and Technology. 
Mosti et al. 
2014 
Brazil 
RT= 22.7 ± 2.2 yrs 
CON = 21.5 ± 2.2 
yrs 
Female 
Healthy sedentary 
12 weeks 
3 d per week 
Supervised 
Weight machines 
4 sets of 3–5 reps at 85–90% 
1RM 
Encouraged 
to follow 
exercise 
advise in 
accordance 
with existing 
recommenda
tions 
Baseline and 
12 weeks 
Corresponding author funded by a 
PhD grant from the Liaison 
Committee between the Central 
Norway Regional Health Authority 
and the Norwegian University of 
Science and Technology. 
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Mota et al. 
2013 
Iran 
RT = 67.5 ± 7 yrs 
CON = 66.8 ± 5.4 
yrs 
Female 
Hypertensive 
16 weeks 
3 d per week 
Supervised 
Free weights and weight 
machines 
1-4 weeks: 3 sets of 10 reps 
5-8 weeks: 3 sets of 12 reps at 
60% 1RM 
9-12 weeks: 3 sets of 10 reps at 
70% 1RM 
13-16 weeks: 3 sets of8 reps at 
80% 1RM 
Not reported Baseline, 4, 
8, 12 and 16 
weeks 
Not reported 
Nikseresht et 
al. 2014 
 
Nikseresht et 
al. 2014 
Denmark 
RT non-linear = 
40.4 ± 5.2 yrs 
AT = 39.6 ± 3.7 yrs 
CON = 38.9 ± 4.1 
yrs 
                
RT non-linear = 
40.4 ± 5.2 yrs 
AT = 39.6 ± 3.7 yrs 
Lean = 39 ± 5.9 yrs 
CON = 38.9 ± 4.1 
yrs 
Male 
Sedentary obese 
12 weeks  
 
12 weeks 
training. 4 
weeks 
detraining 
period 
3 d per week 
Supervised 
Free weights and weight 
machines 
1-4 sets of 2-20 reps at 40-95% 
1RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
 
Baseline, 12 
weeks and 
follow-up 
None reported.                                          
Grants from the Ilam University of 
Medical Sciences, Ilam, Iran. 
Nybo et al. 
2010 
Japan 
RT = 36 ± 2 yrs 
Interval running = 
37 ± 3 yrs 
Prolonged running = 
31 ± 2 yrs 
CON = 30 ± 2 yrs 
Male 
Healthy sedentary 
12 weeks 
3 d per week 
Supervision not reported 
Free weights and weight 
machines 
1-4 weeks: 4 sets of 12-16RM 
5-12 weeks: 4 sets at 6-10RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Supported by the Danish Ministry 
of Culture (Kulturministeriets 
Udvalg for Idrætsforskning). 
O’Connor et 
al. 2017 
UK 
RT - 54.6 ± 10.6 yrs 
CON - 49.5 ± 10.6 
yrs 
Male 
Kidney transplant 
recipients 
12 weeks 
3 d per week 
Supervision for 2 sessions a 
week 
Free weights, weight machines 
and body weight 
1-3 sets of 10 reps at 80% 1RM 
Usual care 
were not 
provided with  
specific 
exercise 
guidance, 
Baseline and 
12 weeks 
Funded by the NIHR. The study 
was hosted in the KCH NIHR 
Clinical Research Facility. This 
paper presents independent 
research funded by the NIHR.  
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they received 
general 
exercise 
encourageme
nt at routine 
appointments
. 
Okamoto et al. 
2006 
Japan 
RT Eccentric = 18.9 
± 0.3 yrs 
RT Concentric 19.1 
± 0.3 yrs 
CON = 19.9 ± 1.2 
yrs 
Female 
Healthy sedentary 
8 weeks 
3 d per week 
Supervised 
Free weights 
5 sets of 8-10 reps 80-100% 
1RM 
Sedentary Baseline and 
8 weeks  
Follow-up 
(unclear 
duration) 
Not reported 
Okamoto et al. 
2009a 
Japan 
RT Eccentric = 19.6 
± 0.4 yrs 
RT Concentric = 
19.2 ± 0.3 yrs 
CON = 19.7 ± 0.3 
yrs 
Male 
Physically active 
10 weeks 
2 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
5 sets of 8-10 reps at 80% 1RM 
Sedentary Baseline and 
10 weeks 
Partially supported by the Ministry 
of Education, Science, Sports and 
Culture, Grant-in-Aid for Young 
Scientists (B), 19700539, 2007. 
Okamoto et al. 
2009b 
Japan 
RT Upper = 20.2 ± 
0.4 yrs 
RT Lower = 20 ± 
0.5 yrs 
CON =  20.1 ± 0.3 
yrs 
Male and female 
Healthy sedentary 
10 weeks 
2 d per week 
Supervised 
Free weights and weight 
machines 
5 sets of 8-10 reps at 80% 1RM
  
Sedentary Baseline and 
10 weeks 
Not reported 
Okamoto et al. 
2011 
Japan 
RT = 18.5 ± 0.5 yrs  
CON = 18.6 ± 0.5 
yrs 
Male 
Healthy sedentary 
10 weeks 
2 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
5 sets of 10 reps  
Continued 
with habitual 
activity 
Baseline and 
10 weeks 
Supported by the Grant-in-Aid for 
Scientists Research from the 
Ministry of Education, Culture, 
Sports, Science and Technology 
of Japan (21700680). 
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Okamoto et al. 
2013 
Norway 
High then low 
intensity RT = 19.1 
± 0.7 yrs 
Low then high 
intensity RT = 19.3 
± 0.7 yrs  
CON = 19.1 ± 0.6 
yrs 
Male and female 
Healthy sedentary 
10 weeks 
2 d per week 
Supervision not reported 
Free weights and weight 
machines 
3 sets of 10 reps to concentric 
failure 
Sedentary Baseline and 
10 weeks 
Not reported 
Oldervoll et al. 
2001 
Brazil 
RT = 42.2 ± 6 yrs 
AT = 42.6 ± 6 yrs  
CON = 43.9 ± 8.8 
yrs 
Female 
Musculoskeletal 
pain 
15 weeks 
2 d per week 
Supervision not reported 
2-3 sets of 12-15 reps 
Continued 
with habitual 
activity 
Baseline and 
15 weeks 
Grant no. 111222/330 from the 
Norwegian Research Council and 
the University Hospital of 
Trondheim provided financial 
support for the employment of one 
of the instructors. 
Oliveira et al. 
2013 
USA 
RT = 22 ± 3 yrs 
CON = 23 ± 4 yrs 
Male 
Physically active 
8 weeks 
3 d per week 
Supervised 
Isokinetic eccentric resistance 
exercise on weight machines 
1-2 weeks: 2 sets of 8 reps 
3-4 weeks: 4 sets of 8 reps 
5-6 weeks: 6 sets of 8 reps 
7-8 weeks: 3 sets of 8 reps 
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Supported by FAPESP and 
CNPq. 
Olson 2006 
Norway 
RT = 38 ± 1 yrs 
CON = 38 ± 2 yrs 
Female 
Sedentary 
overweight  
52 weeks 
2 d per week 
Supervised for the initial 16 
weeks 
Free weights and weight 
machines 
3 sets of 8–10 reps 
Continued 
with habitual 
activity and 
provided 
with 
education 
material 
Baseline and 
52 weeks 
Supported, in part, by the National 
Institutes of Health grant 
#:5R01DK060743-03, American 
Heart Association grant 
#:0410034Z and General Clinical 
Research Centre Program, 
NCRR/NIH #:M01-RR00400. 
Panton et al. 
1990 
South Africa 
RT = 72.2 ± 2.5 yrs 
Walk/jog = 71.8 ± 
1.9 yrs  
CON = 72.1 ± 3 yrs 
Male and female 
Healthy sedentary 
26 weeks 
3 d per week 
Supervised 
Weight machines 
1 set of 8-12 reps 
Continued 
with habitual 
activity 
Baseline and 
26 weeks 
Not reported 
Parr et al. 
2009 
Spain 
RT Upper = 66 ± 13 
yrs 
6 weeks 
3 d per week 
Supervised Continued 
with habitual 
Baseline and 
6 weeks 
Not reported 
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Conventional 
Exercise Rehab = 
57 ± 14 yrs  
CON = 62 ± 10 yrs 
Male and female 
Peripheral artery 
disease 
Free weights and weight 
machines  
15-30 reps 
activity and 
advised to 
walk at 
home 
Perez-Gomez 
et al. 2013 
Canada 
RT = 22 ± 1.2 yrs 
ET = 21.8 ± 1 yrs 
CON = 23.3 ± 2.5 
yrs 
Male 
Physically active 
10 weeks Supervised 
Free weights and weight 
machines  
50-90% of 1RM 
Not reported Baseline and 
10 weeks 
Not reported 
Plotnikoff et al. 
2010 
USA 
RT = 55 ± 12 yrs 
CON = 54 ± 12 yrs 
Male and female 
Type 2 diabetes 
16 weeks 
3 d per week 
Supervision tapered 
Free weights and weight 
machines 
Week 1: 2 sets of 10–12 reps at 
50–60% 1RM 
Week 2: 3 sets of 10-12 reps at 
50-60% 1RM 
3-8 weeks: 3 sets of 10-12 reps, 
intensity progressively increase 
to 70-80% 1RM 
Week 9: 2 sets of 10–12 reps at 
70% 1RM 
10-15 weeks: 3 sets of 8–10 
reps at 70–85% 1RM 
Week 16: 2 sets of 8–10 reps at 
80% 1RM. 
Continued 
with habitual 
activity 
Baseline and 
16 weeks 
Funded by the Canadian Institutes 
of Health Research, Strategic 
Initiative in Excellence, Innovation 
and Advancement for the Study of 
Obesity and Healthy Body Weight. 
Poehlman et 
al. 2000 
USA 
RT = 28 ± 3 yrs 
AT = 29 ± 5 yrs 
CON = 28 ± 4 yrs 
Female 
Healthy sedentary 
24 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3 sets of 10 reps 
Not reported Baseline and 
6 week 
Grant from the Department of 
Defence (DE-950226), a post-
doctoral fellowship from the 
American Heart Association,  
Maine/New Hampshire/Vermont 
affiliate, a grant from the Medical 
Research Council of Canada, and 
General Clinical Research Centre 
Grant RR-109. 
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Poehlman et 
al. 2002 
USA 
RT = 28 ± 3 yrs 
AT = 28 ± 4 yrs 
CON = 28 ± 4 yrs 
Female 
Healthy sedentary 
24 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3 sets of 10 reps 
Not reported Baseline and 
6 weeks 
Not reported 
Pollock et al. 
1991 
USA 
RT = 72.2 ± 2.5 yrs 
Walk/Jog = 71.8 ± 
1.9 yrs       
CON = 72.1 ± 3 yrs 
Male and female 
Healthy elderly 
26 weeks 
3 d per week 
Supervision not reported 
Weight machines 
1 set of 10-12 reps 
Not reported Baseline and 
26 weeks 
Not reported 
Prabhakaran 
et al. 1999 
USA 
RT = 28 ± 6 yrs 
CON = 26 ± 6 yrs 
Female 
Healthy sedentary 
14 weeks 
3 d per week 
Supervised 
Free weights and weight 
machines 
85% 1RM 
Continued 
with habitual 
activity 
Baseline and 
24 weeks 
Funded by the Yamanaka Fund. 
Rana et al. 
2008 
USA 
RT = 20.6 ± 1.9 yrs 
RT Low Velocity = 
19.4 ± 1.3 yrs 
AT = 22.3 ± 3.9 yrs 
CON = 22.9 ± 2.4  
yrs 
Female 
Healthy sedentary 
6 weeks 
week 1 - 2 
sessions  
weeks 2-6 - 
3 days a 
week 
Supervised 
Weight machines 
3 sets at 6-10RM 
Not reported Baseline and 
6 weeks 
Not reported 
Roberts et al. 
2013 
Sweden 
Only report 18-35 
yrs 
Male 
Sedentary obese 
12 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
1–2 weeks: 2 sets of 12–15 reps 
100% 12-15RM 
3–7 weeks: 3 sets of 8–12 reps 
at 100% 8–12RM 
8–12 weeks: 6–8 reps at 100% 
6–8RM 
Continued 
habitual 
activity 
Baseline and 
12 weeks 
Supported by the American Heart 
Association (BGIA # 0765139Y), 
the National Heart, Lung and 
Blood Institute (P50 HL105188), 
the National Institute of Diabetes 
and Digestive and Kidney 
Diseases (DK090406) and the 
National Centre for Advancing 
Translational Sciences through 
UCLA CTSI Grant UL1TR000124. 
Rodriguez-
Miguelez et al. 
2014 
Spain 
RT = 69.1 ± 1.1 yrs 
CON = 70 ± 0.9 yrs 
Male and female 
Healthy elderly 
8 weeks 
2 d per week 
Supervision not reported 
Weight machines 
Week 1: 3 sets of 8 reps at 60% 
1RM 
Week 2: 3 sets of 10 reps at 
60% 1RM 
Continued 
with habitual 
activity 
Baseline and 
10 weeks 
Supported by Plan Nacional I+D+I 
DEP2010-17574, Spain. 
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Week 3: 3 sets of 12 reps at 
60% 1RM 
Week 4: 3 sets of 8 reps at 70% 
1RM 
Week 5: 3 sets of 10 reps at 
70% 1RM 
Week 6: 3 sets of 12 reps at 
70% 1RM 
Week 7: 3 sets of 8 reps at 80% 
1RM 
Week 8: 3 sets of 10 reps at 
80% 1RM 
Romero-
Areanas et al. 
2007 
Finland 
High RT Circuit = 
62.1 ± 6.3 yrs 
Traditional RT = 
64.8 ± 4.5 yrs 
CON = 58 ± 5 yrs 
Male and female 
Healthy elderly 
12 weeks 
2 d per week 
Supervised 
Weight machines 
High RT Circuit: 1-3 sets 
Traditional RT: 3 sets of 6-12 
reps at 50-100% 6RM 
Not reported Baseline and 
12 weeks 
Grant 07/UPR20/10 from the 
Consejo Superior de Deportes. 
Sallinen et al. 
2007 
USA 
RT = 57.9 ± 6.6 yrs 
CON = 58.2 ± 6.1 
yrs 
Male 
Healthy elderly 
21 weeks 
1-3 d per 
week 
Supervised 
Free weights, weight machines 
and body weight 
3-6 sets of 5-10 reps at 40-80% 
1RM 
Continued 
with habitual 
activity 
Baseline, 21 
and 42 
weeks 
Not reported 
Sawyer et al. 
2014 
Germany 
Total cohort = 20.6 
± 2 yrs 
Male 
Physically active 
8 weeks 
3 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
3 sets at 8RM 
Not reported Baseline and 
8 weeks 
Not reported 
Schiffer et al. 
2011 
Denmark 
Total cohort = 22.6 
± 1.6 yrs 
Sex not reported 
Physically active 
12 weeks 
3 d per week 
Supervised 
Weight machines 
3 sets of 8-10 reps at 70-80% 
1RM 
Not reported Baseline and 
12 weeks 
Supported by the World Anti-
Doping Agency. 
Schmidt et al. 
2014 
USA 
RT = 69.1 ± 3.1 yrs 
Football = 68 ± 4 
yrs 
CON = 67.4 ± 2.7 
yrs 
Male 
Healthy elderly 
52 weeks 
2 d per week 
Supervised 
Free weights, weight machines 
and body weight 
1-4 weeks: 4 sets of 16-20RM 
5-8 weeks: 4 sets of 12RM 
9-12 weeks: 4 sets of 10RM 
13-52 weeks: 4 sets of 8RM 
Continued 
with habitual 
activity 
Baseline, 12 
and 52 
weeks 
Supported by Nordea-fonden, 
FIFA Medical Assessment and 
Research Centre, Preben and 
Anna Simondsen fonden, and The 
Danish Ministry of Culture. 
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Schmitz et al. 
2002 
USA 
RT =41 ± 6 yrs 
CON = 42 ± 6 yrs 
Female 
Healthy sedentary 
15 weeks 
2 d per week 
Supervised 
Free weights and weight 
machines 
3 sets of 8-10 reps 
Continued 
with habitual 
activity 
Baseline and 
15 weeks 
Follow up at 
39 weeks 
Supported by a Minnesota 
Obesity Centre Pilot and 
Feasibility Grant, NIH Grant 
DK50456 from the National 
Institute of Diabetes and Digestive 
and Kidney Diseases, University 
of Minnesota General Clinical 
Research Centre Grant M01- 
R00400, Tickle Family Fund for 
Breast Cancer Research, and 
Public Health Service Cancer 
Centre Support Grant P30 
CA77398. 
Schmitz et al. 
2005 
Canada 
RT = 53.3 ± 8.7 yrs  
CON = 52.8 ± 7.6 
yrs 
Female 
Breast cancer 
26 weeks 
2 d per week 
Supervised for initial 13 weeks 
Free weights and weight 
machines 
3 sets 
Usual care 
of attending 
clinic 
appointment
s and taking 
medications 
and 
continued 
with habitual 
activity 
Baseline, 24 
and 52 
weeks 
S.G. Komen Foundation grant 
BCTR0100442 and NIH grants 
M01-RR00400 and T32 CA09607-
15. 
Segal et al. 
2009 
Iran 
RT = 66.4 ± 7.6 yrs 
AT = 66.2 ± 6.8 yrs  
CON = 66.3 ± 7 yrs 
Male  
Prostate cancer 
24 weeks 
3 d per week 
Supervised 
Free weights and weight 
machines 
2 sets of 8-12 reps at 60-70% 
1RM 
Usual care 
of attending 
clinic 
appointment
s and taking 
medications 
and 
continued 
with habitual 
activity 
Baseline and 
24 weeks 
Grant 013232 from the Canadian 
Prostate Cancer Research Fund. 
Shamsoddini 
et al. 2015 
South Africa 
RT = 45.9 ± 7.3 yrs 
AT = 39.7 ± 6.3 yrs 
CON = 45.8 ± 7.3 
yrs 
Males 
8 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
1-2 weeks: 2 sets of 10 reps at 
50% 1RM 
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Supported by Exercise Physiology 
Research Centre and Research 
Centre for Gastroenterology and 
Liver Disease in Baqiyatallah 
University of Medical Sciences, 
Tehran, IR Iran. 
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Non-alcoholic fatty 
liver disease 
3-4 weeks: 2 sets of 10 reps at 
60% 1RM 
5-6 weeks: 3 sets of 10 reps at 
60% 1RM 
7-8 weeks: 3 sets of 10 reps at 
70% 1RM 
Shaw & Shaw 
2005 
India 
Mean age = 28 yrs 
Male 
Healthy sedentary 
8 weeks 
3 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
3 sets of 15 reps at 60% 1RM 
Continued 
with habitual 
activity 
Baseline and 
8 weeks 
Not reported 
Shenoy et al. 
2009 
Canada 
RT = 49.6 ± 5.2 yrs 
AT = 52.2 ± 9.3 yrs 
CON = 58.4 ± 1.8 
yrs 
Male and female  
Type 2 diabetes 
16 weeks 
2 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
3 sets of 10 reps 
Usual care 
of continuing 
with habitual 
activity and 
medications 
Baseline and 
16 weeks 
Grant from the University Grants 
Commission, New Delhi, India. 
Sigal et al. 
2009 
Finland 
RT = 54.7 ± 7.5 yrs 
AT = 53.9 ± 6.6 yrs 
Combined = 53.5 ± 
7.3 yrs 
CON = 54.8 ± 7.2 
yrs 
Male and female 
Type 2 diabetes 
22 weeks 
3 d per week 
Supervised 
Weight machines 
2-3 sets of 7-9 reps 
Continued 
with habitual 
activity 
Baseline, 12 
and 24 
weeks 
Grants from the Canadian 
Institutes of Health Research 
(grant MCT-44155), the Canadian 
Diabetes Association, a New 
Investigator Award from the 
Canadian Institutes of Health 
Research, Career Scientist Award 
from the Ontario Ministry of Health 
and Long Term Care, a 
Postgraduate Scholarship from 
the National Sciences and 
Engineering Research Council, a 
New Investigator Award from the 
Heart and Stroke Foundation, 
Doctoral Research Award from 
the Social Sciences and 
Humanities Research Council and 
an Ontario Graduate Scholarship. 
Sillanpaa et al. 
2012 
 
Sillanpaa et al. 
2009 
USA 
RT = 54.2 ± 8.1 yrs 
AT = 53.7 ± 8.2 yrs 
Combined = 53.9 ± 
8 yrs 
21 weeks 
Endurance 
and strength 
- 2 d a week; 
Supervised 
Free weights, weight machines 
and body weight 
3-4 sets 
Not reported Baseline and 
21 weeks 
Supported, in part, by a grant from 
the Ministry of Education, Finland, 
the Central Finland Health Care 
District, Jyväskylä Finland, Juho 
Vainio Foundation, Finland, Sport 
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Sillanpaa et al. 
2009 
CON = 54.5 ± 9.1 
yrs 
Male and female 
Healthy elderly 
 
RT = 54.1 ± 6 yrs 
AT = 52.6 ± 7.9 yrs 
Combined = 56.3 ± 
6.8 yrs 
CON = 53.8 ± 7.7 
yrs 
Males  
 
RT = 50.8 ± 7.9 yrs 
AT = 51.7 ± 6.9 yrs 
Combined = 48.9 ± 
6.8 yrs 
CON = 51.4 ± 7.8 
yrs 
Female 
Healthy sedentary 
Combined 4 
d a week 
1-7 weeks: 15-20 reps at 40-
60% 1RM 
8-14 weeks: 10-12 reps at 60-
80% 1RM 
15-21 weeks: 6-8 reps at 70-
80% 1RM 
Institute Foundation, Finland and 
Yrjö Jahnsson Foundation, 
Finland. 
Simons & 
Andel 2006 
Canada 
RT = 84.6 ± 4.5 yrs 
Walking = 81.6 ± 
3.3 yrs 
CON = 84 ± 3.3 yrs 
Male and female 
Healthy elderly 
16 weeks 
2 d per week 
Supervised 
Weight machines 
1 set of 10 reps at 75% 1RM 
Not reported Baseline and 
16 weeks 
Not reported 
Simpson et al. 
1992 
Korea 
RT = 73 ± 4.8 yrs  
CON = 70 ± 5.7 yrs 
Male and female 
Chronic airflow 
limitation 
8 weeks 
3 d per week 
Supervised 
Free weights and weight 
machines 
3 sets of 10 reps at 50-85% 
1RM 
Not reported Baseline and 
8 weeks 
Grants from the Medical Research 
Council of Canada, the Heart and 
Stroke Foundation of Ontario, and 
the Ontario Thoracic Society. 
Song & Sohng 
2012 
Brazil 
RT = 52.1 ± 12.4 
yrs  
CON = 54.6 ± 10.1 
yrs 
Male and female 
Haemodialysis 
12 weeks 
3 d per week 
Supervised 
Free weights and elastic 
resistance bands 
3 sets of 10-15 reps 
Not reported 
 
Baseline and 
12 weeks 
Not reported 
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Souza et al. 
2013 
UK 
RT = 25.9 ± 6.4 yrs 
Interval Training = 
24 ± 7.5 yrs 
CON = 22.5 ± 3.9 
yrs 
Male 
Physically active 
8 weeks 
2 d a week 
Supervision not reported 
Weight machines 
1–2 weeks: 3 sets at 12RM 
3–4 weeks: 4 sets at 8–10RM 
5–6 weeks: 5 sets at 6–8RM 
7–8 weeks: 3 sets at 10–12RM 
Not reported Baseline and 
8 weeks 
Grants from Fundação de Amparo 
á Pesquisa do Estado de São 
Paulo - 2007/02738-6, 
2010/51428-2, 2009/03143-1 and 
Conselho Nacional de 
Desenvolvimento Científi co e 
Tecnológico (CNPq) – 
152658/2011-4, 470207/2008-6 
and 303162/2008-2. 
Stebbings et 
al. 2013 
Belgium 
RT = 19 ± 3 yrs 
CON = 23 ± 2.4 yrs 
Male and female 
Physically active 
8 weeks (4 
weeks of 
detraining) 
3 d per week 
Supervision of 2 sessions a 
week 
Weight machines and body 
weight 
3 sets of 10 reps at 80% 1RM 
Continued 
with habitual 
activity 
Baseline, 8, 
10 and 12 
weeks 
Not reported 
Stegen et al. 
2015 
Norway 
RT = 54.8 ± 7.6 yrs 
AT = 54 ± 6.6 yrs 
CON = 54.6 ± 7.1 
yrs 
Combined = 53.6 ± 
7.2 yrs 
Male and female 
Type 2 diabetes 
24 weeks 
3 d per week 
Supervised 
Biweekly supervision after week 
4 
Weight machines 
2-3 sets if 7-9 reps 
Continued 
with habitual 
activity and 
had the 
same level 
of contact 
from the 
research 
team as  
the exercise 
group 
Baseline and 
24 weeks 
Grants from the Research 
Foundation- Flanders (FWO 
G.0243.11 and G.0352), 
Canadian Institutes of Health 
Research (Grant MCT-44155), the 
Canadian Diabetes Association, a 
Health Senior Scholar Award from 
Alberta Innovates-Health 
Solutions and a Research Chair 
from the University of Ottawa. 
Stensvold et 
al. 2010 
Norway 
RT = 50.9 ± 7.6 yrs 
AT = 49.9 ± 10.1 yrs 
Combined = 52.9 ± 
10.4 yrs 
CON = 47.3 ± 10.2 
yrs 
Male and female 
Metabolic syndrome 
12 weeks 
3 d per week 
Supervised  
Week 1: 60% 1RM 
2-13 weeks: 3 sets of 8-12 reps 
at 80% 1RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Supported by the Liaison 
Committee between the Central 
Norway Regional Health Authority 
and the Norwegian University of 
Science and Technology. 
Stensvold et 
al. 2012 
Norway 
RT = 50.9 ± 7.6 yrs 
AT = 49.9 ± 10.1 yrs 
CON = 47.3 ± 10.2 
yrs 
Male and female 
Metabolic syndrome 
13 weeks 
4 d per week 
Supervised 
Week 1: 60% 1RM 
2-13 weeks: 3 sets of 8-12 reps 
at 80% 1RM 
Not reported 1 and 12 
weeks 
Grants from Raagholts 
Foundation. 
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Strasser et al. 
2009 
Norway 
RT = 74 ± 5 yrs 
AT = 76 ± 5 yrs 
CON = 74 ± 5 yrs 
Male and female 
Healthy elderly 
24 weeks 
3 d per week 
Supervised 
Free weights, weight machines 
and body weight 
3-6 sets (per week) of 10-15 
Continued 
with habitual 
activity 
Baseline and 
24 weeks 
Not reported 
Tanimoto et al. 
2009 
Turkey 
RT Low intensity = 
19.0 ± 0.2 yrs 
RT High intensity = 
19.5 ± 0.1 yrs 
CON = 19.8 ± 0.2 
yrs 
Male 
Physically active 
13 weeks  
2 d per week 
Supervision not reported 
RT Low intensity: 3 sets at 55-
60% 1RM) 
RT High intensity: 3 sets at 85-
90% 1RM 
Continue 
with habitual 
activity 
Baseline and 
13 weeks 
Not reported 
Thabitha et al. 
2012 
India 
Chronic obstructive 
pulmonary disease 
3 d per week Supervised 
Free weights and weight 
machines 
1-3 sets of 10 reps 
 Baseline and 
endpoint 
(unknown) 
Not reported 
Tsutsumi et al. 
1997 
USA 
RT high 
intensity/low volume 
= 67.8 ± 4.9 yrs  
RT low 
intensity/high 
volume = 68.9 ± 7.5 
yrs  
CON = 69.8 ± 4.6 
yrs 
Male 
Healthy elderly 
12 weeks 
3 d per week 
Supervised 
RT high intensity/low volume: 8-
12reps at 75-85% 1RM 
RT low intensity/high volume: 
12-16 reps at 
55-65% 1RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Not reported 
Van de Rest et 
al. 2014 
Netherlands 
Placebo: 
RT = 79.2 ± 6.3 yrs 
CON = 81.2 ± 7.4 
yrs 
Protein: 
RT = 77.7 ± 8.8 yrs  
CON = 77.9 ± 8.1 
yrs 
Male and female 
Healthy elderly 
24 weeks 
2 d per week 
Supervised 
Weight machines 
3-4 sets of 8-15 reps at 50-75% 
1RM 
Not reported Baseline and 
24 weeks 
Funded by Top Institute Food and 
Nutrition and co-financed by the 
Dutch Dairy Association (NZO) 
and the European Union’s 
Seventh Framework Program 
under Grant Agreement No. 
266486. 
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Vatani et al. 
2011 
Iran 
Moderate intensity = 
20.8 ± 1.5 yrs  
High intensity = 
19.9 ± 0.7 yrs 
CON = 20.9 ± 1.1 
yrs 
Male 
Healthy sedentary 
6 weeks 
3 d per week 
Supervision not reported 
Weight machines 
MI- 45-55% 1RM in 3 sets with 
10-12 reps per set                                                                            
HI - 80-90% 1RM in 3 sets with 
4-6 reps per set 
 Baseline and 
6 weeks 
Not reported 
Venojarvi et al. 
2013 
Venojarvi et al. 
2013 
Finland 
RT = 54 ± 6.1 yrs 
Nordic walking = 55 
± 6.2 yrs 
CON = 54 ± 7.2 yrs  
 
RT = 54 ± 1.1 yrs 
Nordic walking = 55 
± 1 yrs  
CON = 54 ± 1 yrs 
Male 
Sedentary obese 
13 weeks 
4 d per week 
 
12 weeks 
3 d per week 
Supervised 
Free weights and weight 
machines 
5RM 
Continued 
with habitual 
activity 
Baseline and 
12 weeks 
Grants from the Research Council 
for Physical Education and Sports, 
the Finnish Ministry of Education, 
and Turku University of Applied 
Sciences R&D program. 
 
Grants from the Research Council 
for Physical Education and Sports, 
of the Finnish Ministry of 
Education, Turku University of 
Applied Sciences R&D program 
and the COST action CM1001. 
Vincent et al. 
2002 
 
Vincent et al. 
2003 
 
Vincent et al. 
2003 USA 
LEX = 67.6 ± 6.3 
yrs 
HEX = 66.6 ± 6.7 
yrs 
CON = 71 ± 4.7 yrs  
 
LEX = 67.4 ± 7 yrs 
HEX = 66.5 ± 7 yrs 
CON = 71.1 ± 5 yrs 
 
LEX = 67.6 ± 6 yrs  
HEX = 66.6 ± 7 yrs  
CON = 71.1 ± 5 yrs 
Male and female 
Healthy elderly 
24 weeks 
3 d per week 
Supervised 
Weight machines 
LEX – 1 set of 13 reps at 50% 
1RM 
HEX – 1 set of 8 reps at 80% 
1RM 
 
Supervision not reported 
 
Continued 
with habitual 
activity 
Baseline and 
24 weeks 
Not reported 
Vincent et al. 
2006 
USA 
Normal weight: 
RT = 68.1 ± 1.5 yrs 
24 weeks 
3 d per week 
Supervision not reported 
Weight machines 
1 set of 8-13 reps at 50-80% 
1RM 
Continued 
with habitual 
activity 
 
Baseline and 
24 weeks 
Supported, in part, by Grants T32-
AT00052 and K30-AT-00,060 
from the National Centre for 
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CON = 70.9 ± 1.4 
yrs 
Overweight/obese: 
RT = 66.5 ± 1.2 yrs 
CON =  71.2 ± 2.1 
yrs 
Male and female 
Sedentary obese 
 Complementary and Alternative 
Medicine. 
Vona et al. 
2009 
Switzerland 
RT = 57 ± 8 yrs 
AT = 56 ± 6 yrs 
Combined = 55 ± 9 
yrs 
CON = 58 ± 7 yrs 
Male and female  
Cardiac 
rehabilitation 
4 weeks 
4 d per week 
Supervision not reported 
Free weights and elastic 
resistance bands 
4 sets of 10-12 reps at 60% 
1RM 
Continued 
with habitual 
activity 
 
 
Baseline and 
4 weeks 
Not reported 
Wanderley et 
al. 2013 
Portugal 
RT = 67.3 ± 4.9 yrs 
AT = 69.9 ± 5.7 yrs 
CON = 67.8 ± 5.5 
yrs 
Male and female 
Healthy elderly 
32 weeks 
3 d per week 
Supervised 
Weight machines 
2 sets of 12-15 reps at 50-
60%1RM progressing to 80% 
1RM at week 4 
Continued 
with habitual 
activity 
Baseline and 
32 weeks 
Supported by the Portuguese 
Foundation for Science and 
Technology (grant numbers, 
PTDC/DES/108780/2008 and 
SFRH/BD/33124/2007). 
Weiser & 
Haber 2007 
Austria 
RT = 76.1 ± 2.9 yrs 
CON = not reported 
Male and female 
Healthy elderly 
12 weeks 
2 d per week 
Supervision not reported 
Free weights, weight machines 
and body weight 
1-4 weeks: 1 set of 10-15 reps 
5-8 weeks: 3 sets of 10-15 reps 
9-12 weeks: 4 sets of 10-15 reps 
Not reported Baseline and 
12 weeks 
Not reported 
Wiles et al. 
2010 UK 
18-34 years 
Male 
Physically active 
8 weeks 
3 d per week 
Supervision not reported 
Isometric exercise 
75% and 95% peak heart rate 
Not reported Baseline, 4 
and 8 weeks 
Not reported 
Yavari et al. 
2012 
Iran 
RT = 51.5 ± 6.3 yrs 
AT = 48.2 ± 9.2 yrs 
Combined = 50.9 ± 
9.8 yrs 
CON = 51.5 ± 8.5 
yrs 
Sex not reported 
Type 2 diabetes 
52 weeks 
2-3 d per 
week 
Supervised 
Weight machines 
1-4 weeks: 1-2 sets of 8-10 reps 
at 60% 1RM 
4-52 weeks: 3 sets of 8-10 reps 
at 75-80% 1RM 
Continued 
with habitual 
activity 
Baseline and 
52 weeks 
Grant from the Tabriz University of 
Medical Sciences and with a co-
operation of Endocrinology 
Reasearch Centre of Emam Reza 
haspital (Tabriz University of 
Medical Sciences). 
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Yoshizawa et 
al. 2009 
Japan 
RT = 47 ± 2 yrs 
AET = 47 ± 2 yrs  
CON = 49 ± 3 yrs 
Female 
Healthy sedentary 
12 weeks 
2 d per week 
Supervision not reported 
Weight machines 
3 sets of 10 reps at 60% 1RM.           
Not reported Baseline and 
12 weeks 
Supported by a Grant for Scientific 
Research from the Ministry of 
Education, Culture, Sports, 
Science and Technology of Japan 
(18300215, 18650186, 21970), 
and Health and Labour Sciences 
Research Grants from the Ministry 
of Health, Labour and Welfare, 
Japan. 
Zambom-
Ferraresi et al. 
2015 
Spain 
RT = 68 ± 7 yrs 
RT + AT = 68 ± 7 
yrs 
CON = 69 ± 5 yrs 
Male 
Chronic obstructive 
pulmonary disease 
6 weeks 
2 d per week 
Supervision not reported 
Weight machines 
3-4 sets of 6-12 reps at 50-70% 
1RM 
Not reported Baseline and 
6 weeks 
Support from the Spanish Ministry 
of Education and Science (Plan 
NacionalI + D + i 2004-2007 
Strategic action: “Sport and 
physical education” Ref: 
DEP2007-73220), Health 
Sciences Department of 
Government of Navarre. F and a 
pre-doctoral fellowship from the 
Public University of Navarre. 
Zavanela et al. 
2012 
Brazil 
 
 
 
Age not reported 
Male 
Healthy sedentary 
24 weeks 
3-4 d per 
week 
Supervised 
Free weights and weight 
machines 
3 sets of 10–12 reps at 10–
12RM 
Continued 
with habitual 
activity 
Baseline and 
24 weeks 
Not reported 
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Appendix 2c. Populations used in the Included Studies 
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Appendix 2d. Risk of Bias Assessment 
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Appendix 2e. Publication Bias  
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Appendix 2f. Sensitivity Analysis of the short- (ST), medium- (MT) and long-
term (LT) effects of RET on cardiometabolic outcomes. 
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Appendix 2g. Short-, Medium-, Long-term Effects of Resistance 
Exercise Training on Study Outcomes 
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Appendix 2g. Subgroup Analysis 
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Appendix 3a. Development Session Discussion Schedule 
 
Session 1 
Part 1 – Discussion 
• Introduce self and project 
• Each individual introduce themselves 
• Definitions  
o Physical activity - Physical activities are activities that get your 
body moving such as gardening, walking the dog and taking the 
stairs instead of the lift. 
o Exercise - Exercise is a form of physical activity that is planned, 
structured, and repetitive such as weight training, tai chi, or an 
aerobics class. 
• Bearing in mind the definitions I have given you , do you exercise 
regularly? 
o How do you exercise? 
▪ General activities of daily living 
▪ Aerobic 
▪ Resistance 
▪ Gym member 
• Can you tell me the differences between aerobic and resistance 
exercise? 
o How do you think each of these could benefit your health? 
o Can you tell me your opinions on resistance exercise in general? 
o If I told you that resistance exercise could bring about more 
beneficial effects to health and help alleviate some of the side 
effects of your treatment, does this change your opinion of it? 
Part 2 – Exercises 
Patients will be given a range of exercises to try under the instruction of the 
researcher. 
Part 3 – Feedback 
• Were there any exercises that you particularly liked? 
• Were there any exercises that you particularly disliked? 
• How did you find using the resistance bands? 
• Were the instructions on each exercise clear enough? 
o Could they be improved? If so, how? 
• If you were to be given a programme comprised of the exercises that 
you’ve tried today would you be happy with it? 
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o Are there any other exercises that you would like to see in a 
programme? 
o Do you think these exercises would work well in your home? 
 
 
Session2 
Part 1 – Discussion 
• Introduce self and project 
• Each individual introduce themselves 
• Do you exercise regularly? 
o How do you exercise? 
▪ General activities of daily living 
▪ Aerobic 
▪ Resistance 
▪ Gym member 
• Do you want to increase your exercise levels? 
o If not, why not? 
o What do you think would help you reach your desired level of 
exercise? 
• Do you think that exercise could benefit your recovery or help alleviate 
some of the side-effects of your treatment? 
o If so, how? 
• Were you given any exercise advice upon diagnosis or after your 
treatment? 
o If you were given advice, did you do what they advised? If not, 
why not? 
o If not, would you have liked some exercise advice? 
 
Part 2 – Exercises 
Patients will be given an exercise instruction manual and taken through the 
whole exercise programme by the researcher. Patients will wear a heart rate 
monitor and watch, have blood pressure taken after some of the exercises and 
provide ratings of perceived exertion.  
Medical professional present. 
Part 3 – Feedback 
• First of all can I get your feedback on the manual you were given? 
o Anything you would change? 
o Anything you would add in/remove? 
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o Anything that you think is particularly useful in there? 
• Please could you give me some general feedback about the 
programme? 
o Do you feel like it worked your whole body? 
o Do you like the mix of body weight and resistance band 
exercises? 
o Were there any exercises that you particularly liked? 
o Were there any exercises that you particularly disliked? 
o Is there anything extra that you would add in? 
o Do you think it would be easy to complete within your home? 
• Is this something you would have been interested in doing had you been 
offered it upon diagnosis? 
o Why? 
o What benefits do you think you can get from this programme? 
• How would you feel if I asked you to complete this programme at least 
twice a week for 12 weeks? 
o Would you stick to it? 
o Is there anything that I could do to help you stick to it? 
• So if I now told you that you would have two sessions a week supervised 
by myself for the first two weeks, the second two weeks you would 
complete one session with me and one at home and then for the next 8 
weeks you would complete all sessions at home but have regular 
contact with myself via text/email, how would you feel? 
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Appendix 3b. Exercise Manual 
 
EXERCISE 
DIARY &  
MANUAL 
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Why should you be more active? 
 
Physical health benefits of an active lifestyle: 
• Improve mobility and independence 
• Feel stronger 
• More energetic 
• Improve bone density and flexibility 
• Help maintain a healthy body weight 
• Reduce cancer-related fatigue 
 
Mental health benefits of an active lifestyle: 
• Improve sleep quality 
• Reduce stress and anxiety levels 
• Boost your self esteem 
• Increase confidence and mood 
• Improve overall mental health 
 
Social health benefits of an active lifestyle: 
• Increase social integration 
• Meet new people and create new friendships 
• Time to relax and have fun 
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How much physical activity  
is needed for health? 
 
The Department of Health recommends: 
• At least 2½ hours of moderate intensity activity in bouts of 10 
minutes or more a week 
  OR 
• 1¼ hours of vigorous intensity activity spread across the 
week 
OR 
• Combinations of both moderate and vigorous intensity 
activity 
• Adults should also undertake muscle strengthening 
exercises on at least two days a week 
• Minimise the amount of time spent being sedentary (sitting) 
for extended periods 
 
 
 
Here are some great websites that provide lots of exercise advice 
and give links to local opportunities to help you get started: 
NHS Choices: http://www.nhs.uk/pages/home.aspx 
Change4Life Local Activities: 
http://www.nhs.uk/change4life/Pages/local-change-for-life-
activities.aspx 
Macmillan Cancer Support Activities Near You: 
http://www.macmillan.org.uk/information-and-
support/coping/maintaining-a-healthy-lifestyle/keeping-
active/activities-near-you.html 
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What is moderate and  
vigorous intensity exercise? 
 
Moderate intensity physical activity refers to an activity that 
increases your heart rate to an intensity equivalent to brisk walking 
or steady cycling but you do not break into a sweat. You are just 
about able to maintain a conversation. 
Examples:  
o Mowing the lawn 
o Hoovering 
o Cycling 10-12mph 
o Golf – walking/pulling clubs 
o Carrying/moving moderate loads (< 
20kg) 
 
Vigorous intensity physical activity produces a large increase in 
breathing and heart rate to an intensity equivalent to jogging or 
cycling uphill. You won’t be able to say more than a few words 
without pausing for a breath. 
Examples: 
o Cycling 12-14mph 
o Running 
o Competitive sports and games (e.g. 
football, volleyball, hockey) 
o Carrying/moving heavy loads (> 
20kg) 
o Heavy shovelling/digging 
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How can I build muscular strength? 
 
You can build muscular strength by… 
• Lifting weights 
 
 
 
 
 
• Exercising with resistance bands 
 
 
 
• Doing exercises that use 
your body weight (e.g. 
press ups) 
 
 
 
 
• It is important that you work all major muscle groups – the 
legs, back, abdomen, chest, shoulders and arms 
 
• As exercise becomes easier, increase the weight/resistance 
or do an extra set! 
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Exercise after Prostate Cancer 
Prostate cancer is the most common form of male cancer in the 
United Kingdom. In recent years there have been marked 
improvements in early detection and innovations in treatment of 
prostate cancer. Currently treatment options are dependent on 
tumour characteristics (type, size, Gleasongrade, Prostate Specific 
Antigen (PSA; evidence of spread of disease) and patient 
characteristics and importantly preferences (including general 
health). 
Studies have provided convincing evidence that exercise reduces 
cancer-related fatigue, strengthens immune function and improves 
quality of life in prostate cancer patients who have undergone 
various treatments. Aerobic exercise (e.g. jogging and cycling) is 
reported to improve peak oxygen uptake, decrease fatigue and 
prevent a decline in physical function during treatment. Resistance 
exercise (e.g. lifting weights and using resistance bands) are also 
effective in reducing cancer-related fatigue but may bring about 
more beneficial effects compared to aerobic training in relation to 
muscle strength, quality of life and well-being, as well as reductions 
in blood pressure and waist circumference after prostate cancer 
treatments.  
 
 
 
 
 
Exercise Tips… 
• Wear comfortable clothing and suitable shoes (e.g. trainers) 
• Exercise at a time that suits you 
• Don’t exercise on an empty stomach but also leave about 2 
hours after eating a large meal before exercising 
• Stay well hydrated 
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Your home exercise plan 
 
• Remember to warm up with gentle stretching to help prevent 
injury and help increase: 
o Blood flow to muscles 
o Heart rate 
o Oxygen and nutrient supply to muscles 
 
• Use different bands for different exercises if necessary 
• Mix up the order in which you do the exercises 
• Remember to cool down. Gentle exercise and static stretching 
(hold for 10 seconds) helps to: 
o Return the body to its pre-exercise state 
o Reduce the heart rate gradually 
 
• Don’t exercise if you are injured or ill 
 
 
Your bands… 
 
 
 
 
 
 
 
 
 Yellow Red Green Blue Black 
Resistance 
Level 
Thin Medium Heavy 
Extra 
Heavy 
Special 
Heavy 
Weight at 
100% 
elongation 
1.3kgs 1.8kgs 2.3kgs 3.2kgs 4.4kgs 
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How can I make progress? 
 
1. Make it fun and personalise it! 
Try exercising with music and doing 
your exercises both inside and outside 
the house. You are more likely to keep it 
up if you enjoy it! 
 
 
2. Track your progress 
Keep a daily record in your exercise diary and reflect on the 
progress you make, this can help keep you motivated too. Set 
yourself some goals too – you can do this on the next page! 
 
 
3. Involve family and friends  
Exercising on your own can be a dull 
prospect. Exercising with a friend or 
family member can push you to work 
harder and you will have more fun. 
 
 
4. Be positive, stay positive! 
Everyone can feel low, have no motivation or feel tired before 
and during exercise. Here are some tips to staying positive: 
• Remember sessions you have performed well in or 
enjoyed the most and try to replicate them 
• Remind yourself of the benefits of exercise 
• Think about you how will feel when you make 
progress and get fitter 
• Encourage yourself with positive statements, for 
example “you can do this!” or “take a deep breath 
and go!” 
 
 
5. Discuss any issues you have with us over the phone or via 
email 
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Set yourself some goals 
 
 
My goal is to… 
 
 
 
SPECIFIC 
What precisely do I want to accomplish? 
 
 
 
 
MEASURABLE 
I will measure or track my goal as follows: 
 
 
 
 
ATTAINABLE 
Can I achieve this? Do I need to break it down into 
manageable chunks? How can I break it down? 
 
 
 
REALISTIC 
Do I have what I need to achieve my goal? 
 
 
 
 
TIME 
I will reach my goal by (target date): 
 
 
 
 
Obstacles: 
 
 
 
 
Solutions: 
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Resistance Exercise Programme 
 
You need to complete ____ sessions a week 
made up of ____ sets of ____ reps per exercise. 
 
 
Please use this scale to rate the intensity of any 
exercise over the course of the day. You just need 
to write a number in the box! 
 
 
 
 
 
 
 
 
Extremely 
easy 
Easy 
Somewhat 
easy – 
comfortable, 
slight 
difficulty 
breathing 
Somewhat 
hard – 
moderate 
sweating, 
able to 
speak 
Hard – 
Difficulty 
breathing, 
unable to 
speak 
Extremely 
hard – 
cannot 
push any 
harder 
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Exercise Diary 
 
WEEK __  Week commencing: Monday _________ 
 
 Exercise Band Day Session Intensity 
Session 
1 
  
 
 
  
  Time 
  
 
  Notes 
  Duration  
  
 
  
Session 
2 
Exercise Band Day Session Intensity 
  
 
 
  
  Time 
  
 
  Notes 
  Duration  
  
 
  
Session 
3 
Exercise Band Day Session Intensity 
  
 
 
  
  Time 
  
 
  Notes 
  Duration  
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Resistance Band Exercises 
 
Legs 
Squat 
• Place the elastic under feet (more than shoulder 
width apart), hold ends in hands and keep elbows 
straight 
• Bend knees to 90 degrees 
• Straighten knees 
• Return to the starting position 
 
 
 
 
Leg Press 
• Sit in chair 
• Loop elastic around bottom of foot as shown 
• Hold elastic in both hands 
• Push leg down straightening at knee 
• Slowly return to start position and repeat 
 
 
 
 
Quick Kicks 
• Knot and loop elastic around ankles 
• Kick leg outward and quickly repeat 
• Keep toes pointed straight ahead and 
do not bend trunk 
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Abdominals 
 
Trunk Curl-up 
• Securely attach band to the door 
anchor near floor 
• Lie on back with knees bent, 
holding ends of bands in hands, 
arms in front and elbows straight 
• Keep hands close together and 
curl trunk upward, lifting shoulder 
blades from floor 
• Hold and slowly return 
 
 
 
 
Lower Abdominal Crunch 
• Lie on back with hips and knees 
flexed. Stretch band over knees 
and cross underneath 
• Hold each end of band in hands 
and place arms at sides, with 
elbows straight 
• Lift knees upward, lifting hips off 
the floor 
• Hold and slowly return 
 
 
 
 
Side Bend 
• Stand, holding elastic in right hand, right foot securing 
other end of elastic as shown 
• Bend to left, keeping elbow straight 
• Slowly return to start position and repeat 
• Repeat sets with other side 
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Back 
Bent Over Row 
• Secure elastic under opposite foot 
• Hold elastic in involved arm 
• Slightly bend hips and knees and support upper body 
with other arm as shown 
• Pull up on elastic, raising elbow to shoulder height 
• Slowly return to start position and repeat 
 
 
 
 
 
Reverse Flies 
• Grasp elastic in hands, elbows 
straight, as shown 
• Move arms away from each other, out 
to sides 
• Slowly return to start position 
 
 
 
 
 
 
Chest 
Chest Press 
• Attach elastic using the door anchor at 
shoulder level 
• Sit or stand as shown 
• Hold elastic in hands, arms out from side, 
elbows bent, as shown 
• Push forward, straightening elbows 
• Slowly return to start position and repeat 
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Shoulders  
Upright Row 
• Stand on elastic 
• Grasp elastic in both hands in front of 
hips, elbows straight 
• Lift upward toward chin, bending 
elbows 
• Keep hands close to chest 
• Slowly lower and repeat 
 
 
 
 
 
Lateral Raise 
• Stand on elastic and hold elastic in both 
hands 
• Begin with arms at sides with palms facing 
forward 
• Keep elbows straight and lift arms to 
shoulder level 
• Slowly lower and repeat 
 
 
 
 
 
Front Raise 
• Stand on the elastic and hold at waist level as 
shown 
• Grasp elastic and pull arm backwards keeping 
elbow straight 
• Slowly return to start position 
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Arms 
Bicep Curl 
• Stand on the ends of the elastic with both feet   
• Grasp elastic in hands, palms up, arms straight 
• Pull upward, bending at elbows, keeping trunk straight 
• Slowly return to start position and repeat 
 
 
 
 
 
 
Elbow Extension 
• Attach elastic to secure object using the door 
anchor at waist level 
• Grasp elastic, thumb up, elbow bent, as shown 
• Straighten elbow, keeping elbow at side. 
• Slowly return to starting position 
 
 
 
 
 
 
Elbow Kick Back 
• Hold elastic in hand of involved arm 
• Place one end of elastic under opposite foot. 
• Slightly bend hips and support upper body with 
other arm as shown 
• Pull up on elastic, raising elbow to shoulder 
height 
• Extend elbow backward, contracting Triceps 
• Slowly return to start position and repeat 
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Appendix 3c. OMNI-RES RPE Scale (Colado et al., 2018) 
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Appendix 4a. Elements of the Senior Fitness Test used in the 
Trial 
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Appendix 4b. Questionnaire Booklet 
 
 
Questionnaire Booklet 
 
Subject ID: ______ 
 
Testing session: ________________ 
 
 
 
Included in this booklet are two quality of life 
questionnaires; one general (EQ-5D-5L) and one specific 
to prostate cancer (FACT-P). There is also an exercise 
questionnaire (Godin Leisure Time) and a tiredness or 
fatigue questionnaire (Brief Fatigue Inventory).  
 
Please note, you do not have to answer any 
questions that make you feel upset or uncomfortable. 
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EQ-5D-5L – Quality of Life 
 
Under each heading, please tick the ONE box that best describes your health 
TODAY. 
MOBILITY  
I have no problems in walking about 
❑ 
I have slight problems in walking about 
❑ 
I have moderate problems in walking about 
❑ 
I have severe problems in walking about 
❑ 
I am unable to walk about 
❑ 
SELF-CARE  
I have no problems washing or dressing myself 
❑ 
I have slight problems washing or dressing myself 
❑ 
I have moderate problems washing or dressing myself 
❑ 
I have severe problems washing or dressing myself 
❑ 
I am unable to wash or dress myself 
❑ 
USUAL ACTIVITIES (e.g. work, study, housework, family or 
leisure activities)  
I have no problems doing my usual activities 
❑ 
I have slight problems doing my usual activities 
❑ 
I have moderate problems doing my usual activities 
❑ 
I have severe problems doing my usual activities 
❑ 
I am unable to do my usual activities 
❑ 
PAIN / DISCOMFORT  
I have no pain or discomfort 
❑ 
I have slight pain or discomfort 
❑ 
I have moderate pain or discomfort 
❑ 
I have severe pain or discomfort 
❑ 
I have extreme pain or discomfort 
❑ 
ANXIETY / DEPRESSION  
I am not anxious or depressed 
❑ 
I am slightly anxious or depressed 
❑ 
I am moderately anxious or depressed 
❑ 
I am severely anxious or depressed 
❑ 
I am extremely anxious or depressed 
❑ 
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The worst health 
you can imagine 
EQ-5D-5L VAS – Quality of Life 
 
• We would like to know how good or bad your 
health is TODAY.  
• This scale is numbered from 0 to 100. 
• 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your 
health is TODAY. 
• Now, please write the number you marked on the 
scale in the box below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YOUR HEALTH TODAY = 
The best health 
you can imagine 
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FACT-P (Version 4) – Quality of Life 
 
Below is a list of statements that other people with your illness have said are 
important. Please circle or mark one number per line to indicate your 
response as it applies to the past 7 days. 
PHYSICAL WELL-BEING 
  Not 
at all 
A little 
bit 
Somewhat 
Quite 
a bit 
Very 
much 
GP1 I have a lack of energy 0 1 2 3 4 
GP2 I have nausea 0 1 2 3 4 
GP3 Because of my physical 
condition, I have trouble 
meeting the needs of my 
family 
0 1 2 3 4 
GP4 I have pain 0 1 2 3 4 
GP5 I am bothered by side 
effects of treatment 0 1 2 3 4 
GP6 I feel ill 0 1 2 3 4 
GP7 I am forced to spend time 
in bed 
0 1 2 3 4 
 
SOCIAL/FAMILY WELL-BEING 
  Not 
at all 
A little 
bit 
Somewhat 
Quite 
a bit 
Very 
much 
GP1 I feel close to my friends 0 1 2 3 4 
GP2 I get emotional support from 
my family 0 1 2 3 4 
GP3 I get support from my friends 0 1 2 3 4 
GP4 My family has accepted my 
illness 0 1 2 3 4 
GP5 I am satisfied with family 
communication about my 
illness 
0 1 2 3 4 
GP6 I feel close to my partner (or 
the person who is my main 
support 
0 1 2 3 4 
Q1 Regardless of your current level of 
sexual activity, please answer the 
following question. If you prefer not to 
answer it, please mark this box and go 
to the next section. 
    
GP7 I am satisfied with my sex life 0 1 2 3 4 
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FACT-P (Version 4) – Quality of Life 
 
Please circle or mark one number per line to indicate your response as 
it applies to the past 7 days. 
 
 
EMOTIONAL WELL-BEING  
  Not 
at all 
A little 
bit 
Somewhat 
Quite 
a bit 
Very 
much 
GP1 I feel sad 0 1 2 3 4 
GP2 I am satisfied with how I am 
coping with my illness 0 1 2 3 4 
GP3 I am losing hope in the fight 
against my illness 0 1 2 3 4 
GP4 I feel nervous 0 1 2 3 4 
GP5 I worry about dying 0 1 2 3 4 
GP6 I worry that my condition 
will get worse 0 1 2 3 4 
 
 
FUNCTIONAL WELL-BEING 
  Not 
at all 
A little 
bit 
Somewhat 
Quite 
a bit 
Very 
much 
GP1 I am able to work (include 
work at home) 0 1 2 3 4 
GP2 My work (include work at 
home) is fulfilling 0 1 2 3 4 
GP3 I am able to enjoy life 0 1 2 3 4 
GP4 I have accepted my illness 0 1 2 3 4 
GP5 I am sleeping well 0 1 2 3 4 
GP6 I am enjoying the things I 
usually do for fun 0 1 2 3 4 
GP7 I am content with the 
quality of my life right now 0 1 2 3 4 
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FACT-P (Version 4) – Quality of Life 
 
Please circle or mark one number per line to indicate your response as 
it applies to the past 7 days. 
 
ADDITIONAL CONCERNS 
  Not 
at all 
A little 
bit 
Somewhat 
Quite 
a bit 
Very 
much 
C2 I am losing weight 0 1 2 3 4 
C6 I have a good appetite 0 1 2 3 4 
P1 I have aches and pains 
that bother me 
0 1 2 3 4 
P2 I have certain parts of my 
body where I experience 
pain 
0 1 2 3 4 
P3 My pain keeps me from 
doing things I want to 
0 1 2 3 4 
P4 I am satisfied with my 
present comfort level 
0 1 2 3 4 
P5 I am able to feel like a 
man 
0 1 2 3 4 
P6 I have trouble moving my 
bowels 
0 1 2 3 4 
P7 I have difficulty urinating 0 1 2 3 4 
BL2 I urinate more frequently 
than usual 
0 1 2 3 4 
P8 My problems with 
urinating limit my activities 
0 1 2 3 4 
BL5 I am able to have and 
maintain an erection 
0 1 2 3 4 
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Godin Leisure Time Exercise Questionnaire (Modified) 
For this question, we would like you to recall your average weekly exercise during the 
past month. We will ask you separate questions about aerobic or endurance exercise 
(i.e., exercise that improves the heart and lungs such as walking or swimming) and 
strength or resistance exercise (i.e. exercise that improves muscular strength such as 
weight lifting). 
When answering these questions please remember: 
• Only count exercise sessions that lasted 10 minutes or longer in duration. 
• Only count exercise that was done during free time (i.e. not work or chores). 
• Note that the main difference between the categories ‘a,’ ‘b’, and ‘c’ is the 
intensity of the aerobic (endurance) exercise and category ‘d’ is for strength 
(resistance) exercise. 
• Please write the average frequency on the first line and the average duration 
on the second. 
• If you did not do any exercise in one of the categories, please write in “0”. 
 
 
Considering a typical week (7 days) over the PAST MONTH how many days on 
average did you do the following kinds of aerobic and strength exercise and 
what was the average duration? 
 Average 
Frequency 
(days per week) 
Average Duration 
(minutes per 
session) 
VIGOROUS INTENSITY AEROBIC 
EXERCISE (HEART BEATS 
RAPIDLY, SWEATING) 
(e.g. running, aerobics classes, 
vigorous swimming, vigorous 
cycling). 
  
MODERATE INTENSITY AEROBIC 
EXERCISE (NOT EXHAUSTING, 
LIGHT PERSPIRATION) 
(e.g. fast walking, tennis, easy 
bicycling, easy swimming, dancing). 
  
LIGHT INTENSITY AEROBIC 
EXERCISE (MINIMAL EFFORT, NO 
PERSPIRATION) 
(e.g. easy walking, yoga, bowling, 
lawn bowling). 
  
STRENGTH/RESISTANCE 
EXERCISE (MODERATE TO 
INTENSE EFFORT) 
(e.g. weight lifting, resistance bands, 
sit-ups, push-ups) 
  
246 
 
Brief Fatigue Inventory 
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Appendix 4c. Missing Data 
 
Outcome 
Baseline 
3 Month Follow-
up 
6 Month Follow-
up 
RET UC RET UC RET UC 
Flow Mediated Dilatation 
Baseline 
Diameter (mm) 
6 
(14.3%) 
11 
(26.2%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
Max Diameter 
(mm) 
6 
(14.3%) 
11 
(26.2%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
Recovery 
Diameter (mm) 
6 
(14.3%) 
12 
(28.6%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
FMD (%) 6 
(14.3%) 
11 
(26.2%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
FMDr (%) 7 
(16.7%) 
12 
(28.6%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
Shear Baseline 
(s-1) 
9 
(21.4%) 
11 
(26.2%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
Shear Max (s-1) 10 
(23.8%) 
11 
(26.2%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
Shear Area 10 
(23.8%) 
11 
(26.2%) 
12 
(28.6%) 
13 
(31.0%) 
10 
(23.8%) 
13 
(31.0%) 
Shear Area to 
Max 
10 
(23.8%) 
12 
(28.6%) 
12 
(28.6%) 
15 
(35.7%) 
10 
(23.8%) 
13 
(31.0%) 
Blood Biomarkers 
Glucose 
(mmol/L) 
3 
(7.1%) 
1 
(2.4%) 
4 
(9.5%) 
7 
(16.7%) 
3 
(7.1%) 
4 
(9.5%) 
Insulin (μU/ml) 6 
(14.3%) 
2 
(4.8%) 
4 
(9.5%) 
9 
(21.4%) 
5 
(11.9%) 
8 
(19.0%) 
HOMA-IR 6 
(14.3%) 
2 
(4.8%) 
6 
(14.3%) 
9 
(21.4%) 
6 
(14.3%) 
8 
(19.0%) 
Total Chol 
(mmol/L) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
6 
(14.3%) 
2 
(4.8%) 
3 
(7.1%) 
HDL 
Cholesterol 
(mmol/L) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
6 
(14.3%) 
2 
(4.8%) 
3 
(7.1%) 
LDL 
Chiolesterol 
(mmol/L) 
6 
(14.3%) 
7 
(16.7%) 
7 
(16.7%) 
8 
(19.0%) 
7 
(16.7%) 
7 
(16.7%) 
Non-HDL 
(mmol/L) 
4 
(9.5%) 
4 
(9.5%) 
3 
(7.1%) 
6 
(14.3%) 
2 
(4.8%) 
3 
(7.1%) 
Triglycerides 
(mmol/L) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
6 
(14.3%) 
3 
(7.1%) 
3 
(7.1%) 
Total:HDL 
(mmol/L) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
6 
(14.3%) 
2 
(4.8%) 
3 
(7.1%) 
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Cardiovascular Health 
Resting Heart 
Rate (bpm) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
Blood pressure 
(mmHg) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
QRisk-2 Score 
(%) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
Anthropometric Profile 
Body Mass 
(kg) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
BMI (kg/m2) 0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
Waist 
Circumference 
(cm) 
0 
(100%) 
3 
(7.1%) 
2 
(4.8%) 
2 
(4.8%) 
2 
(4.8%) 
3 
(7.1%) 
Waist:Hip 0 
(100%) 
3 
(7.1%) 
2 
(4.8%) 
2 
(4.8%) 
2 
(4.8%) 
3 
(7.1%) 
Skinfolds 0 
(100%) 
3 
(7.1%) 
2 
(4.8%) 
2 
(4.8%) 
2 
(4.8%) 
3 
(7.1%) 
Submaximal Aerobic Exercise 
Stage 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
4 
(9.5%) 
3 
(7.1%) 
Time (secs) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
4 
(9.5%) 
3 
(7.1%) 
Estimated 
V̇O2Peak 
(ml/kg/min) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
4 
(9.5%) 
3 
(7.1%) 
Estimated 
METs 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
4 
(9.5%) 
3 
(7.1%) 
Max HR (bpm) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
4 
(9.5%) 
3 
(7.1%) 
Strength 
Upper Body 
(reps) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
Lower Body 
(reps) 
0 
(100%) 
0 
(100%) 
2 
(4.8%) 
1 
(2.4%) 
2 
(4.8%) 
3 
(7.1%) 
Questionnaires 
EQ-5D  0 
(100%) 
0 
(100%) 
1 
(2.4%) 
3 
(7.1%) 
2 
(4.8%) 
4 
(9.5%) 
FACT-P 0 
(100%) 
0 
(100%) 
1 
(2.4%) 
3 
(7.1%) 
2 
(4.8%) 
4 
(9.5%) 
BFI 0 
(100%) 
0 
(100%) 
1 
(2.4%) 
3 
(7.1%) 
2 
(4.8%) 
4 
(9.5%) 
Godin Leisure 
Time Exercise 
Questionnaire 
(modified) 
0 
(100%) 
0 
(100%) 
1 
(2.4%) 
3 
(7.1%) 
3 
(7.1%) 
4 
(9.5%) 
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